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ABSTRACT	The	sarco/endoplasmic	reticulum	calcium	ATPase	(SERCA)	and	its	inhibitor	phospholamban	(PLB)	are	major	regulators	of	Ca2+	levels	in	the	cardiac	cell.	Deficient	calcium	handling	in	the	heart	has	been	linked	to	heart	disease,	including	heart	failure;	the	leading	cause	of	death	in	developed	countries.	As	of	today,	targeting	SERCA	and	SERCA-PLB	complex	to	enhance	cardiac	function	has	not	been	successful	due	to	lack	of	details	on	the	SERCA	regulatory	mechanisms.	Previous	molecular	dynamics	(MD)	simulations	by	my	lab	predicted	that	a	small	loop	in	SERCA	N-domain	(Nβ5-β6	loop)	regulates	SERCA	transition	from	open-to-closed	conformation	and	may	interact	with	PLB	cytosolic	domain.	Thus,	I	hypothesized	that	the	Nβ5-β6	loop	plays	a	role	in	(1)	SERCA	structural	dynamics	during	Ca2+	transport	and	(2)	SERCA	regulation	via	interaction	with	PLB	cytosolic	domain.	Two-color	SERCA	(2CS)	labeled	with	fluorescent	proteins	on	two	of	the	headpiece	domains	was	used	in	FRET	measurements,	and	open	SERCA	conformers	were	detected	during	transient	Ca2+	elevations.	I	believe	these	open	conformers	represent	a	steady-state	population	of	SERCA	in	the	sloe	step	of	the	Ca2+	cycle.	In	the	presence	of	sustained	Ca2+	elevation	the	wild-type	SERCA,	but	not	the	mutated	transporter,	acquired	a	new	slow	step	and	accumulated	in	non-physiological	high-Ca2+	affinity	closed	conformation.	Measurement	of	SERCA	function	in	vitro	showed	that	the	mutated	transporter	still	hydrolyzed	ATP	and	have	normal	Ca2+	affinity,	but	maximal	ATPase	activity	was	reduced	by	
xv		
63%.		I	attribute	this	functional	deficit	to	the	decrease	in	SERCA	headpiece	compact	assembly	as	was	detected	in	silico	and	in	live	cells.	2CS	FRET	quantifications	in	microsomes	detected	ligand-stabilized	compact	conformers	for	high-affinity	(E1)	transporter,	while	low-affinity	(E2)	states	were	characterized	by	more	open	conformations.	Additional	MD	simulations	have	shown	steady	interactions	of	Nβ5-β6	loop	with	PLB	cytoplasmic	domain	irrespective	of	loop	mutations	or	PLB	phosphorylation	status.	SERCA	ligand-stabilized	conformers	detected	with	FRET	obtained	more	closed	structure	in	the	presence	of	PLB,	and	extra	compact	assembly	upon	PLB	Ser16	phosphorylation.	Overall,	these	data	reveal	a	discrete	structural	element	that	facilitates	a	compact	conformation	during	Ca2+	transport	and	enhanced	scientific	understanding	of	ATPase	transporters	function	and	regulation.	Additionally,	I	utilized	2CS	FRET	biosensor	to	confirm	long-time	predicted	direct	interaction	with	the	indirect	SERCA	regulator	HAX-1	and	to	study	the	association	with	the	recently	identified	regulatory	micropeptide	DWORF.	Even	more,	my	lab	applied	2CS	labeling	technique	to	generate	another	2-color	ATPase	transporter	biosensor,	2-color	MRP-1,	which	was	used	in	FRET	high-throughput	screening	to	identify	novel	MRP-1	substrates.	I	further	determined	functional	effect	of	identified	ligands	on	MRP-1	function	in	live	cells	and	confirmed	the	2-color	labeling	technique	to	be	useful	for	generation	of	FRET	biosensors	in	drug	discovery.		
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CHAPTER	ONE	INTRODUCTION	AND	BACKGROUND	
The	Cardiac	Calcium	ATPase	in	the	Heart	Calcium	(Ca2+)	serves	as	a	signaling	molecule	in	the	heart	to	drive	muscle	contraction,	thus	removal	of	Ca2+	from	the	sarcoplasm	is	essential	for	myocardium	relaxation	(Bers,	2002).	In	particular,	Ca2+	binding	to	a	Ca2+	sensor	Troponin	C	induces	conformational	changes	in	myofilament	arrangement,	which	results	in	contraction.	Sarco-endoplasmic	reticulum	calcium	ATPase	(SERCA)	transports	Ca2+	from	the	cytosol	into	the	endoplasmic/	sarcoplasmic	reticulum	(ER/SR)	lumen	and	in	this	way	regulates	relaxation	of	the	heart.	Sequestering	Ca2+	from	the	cytosol	by	SERCA	also	affects	contractile	force,	as	restored	SR	Ca2+	load	determines	the	force	of	the	myofilament	contractions.	Figure	1	shows	the	Ca2+-	induced	myofilament	contraction/relaxation	cycle	in	cardiac	myocyte	(Fig.	1A)	and	changes	in	cytosolic	Ca2+	during	this	cycle	(Fig.	1B).	Depolarization	across	the	transverse	tubule	membrane	opens	L-type	calcium	channels,	causing	an	influx	of	Ca2+	into	sarcoplasm	(1).	The	influx	of	Ca2+	induces	Ca2+	release	from	the	SR	lumen	through	ryanodine	receptors	(RyR)	into	sarcoplasm,	where	Ca2+	binds	to	myofilament	force-generating	structures	and	induces	contraction	(2).	Relaxation	(3)	is	produced	when	Ca2+	is	removed	from	the	sarcoplasm	primarily	through	SERCA	(approximately	70%	of	Ca2+	removal	(Bassani	et	al.,	1994))	and	calcium	transporters	on	the	plasma	membrane	(not	shown).	During	influx	of	
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sarcoplasmic	Ca2+	(Fig.	1,	(2)),	SERCA	is	active	and	continuously	undergoes	structural	changes	in	order	to	progress	throughout	the	enzymatic	cycle	presented	in	Fig.	3.		Previous	studies	have	shown	that	SERCA	function	is	reduced	in	heart	failure	(HF)	(Gwathmey	et	al.,	1987;	Roe	et	al.,	2015).	HF	is	defined	as	the	inability	of	the	heart	to	keep	up	with	its	workload.	Normally,	the	heart	provides	adequate	blood	flow	to	supply	oxygen	and	nutrients	to	the	cells	and	remove	carbon	dioxide	and	metabolites.	In	HF,	the	body	may	not	get	the	oxygen	it	needs.	HF	is	a	chronic	and	progressive	condition	and	a	major	cause	of	morbidity	and	mortality	worldwide	(Mosterd	and	Hoes,	2007;	Mozaffarian	et	al.,	2016).	
	
Figure	1.	Schematic	representation	of	calcium	handling	in	the	cardiac	myocyte.	
(A)	Depolarization	across	the	transverse	tubule	membrane	opens	L-type	calcium	channels,	causing	an	influx	of	Ca2+	into	sarcoplasm	(1).	The	influx	of	Ca2+	induces	Ca2+	release	from	the	SR	lumen	through	RyR	into	sarcoplasm,	where	Ca2+	binds	to	myofilament	and	induces	contraction	(2).	Relaxation	(3)	is	produced	when	Ca2+	is	removed	from	the	sarcoplasm	through	primarily	SERCA	into	SR	lumen.	SERCA	can	be	inhibited	by	PLB.	
(B)	Trace	represents	cytosolic	Ca2+	change	over	time	in	response	to	Ca2+-induced	Ca2+	re-lease	from	ER	through	RyR	opening.	(1-3)	correspond	to	events	in	(A).	
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While	patients	are	treated	with	medications,	lifestyle	changes,	surgical	procedures	and	device	implantation	(Yancy	et	al.,	2017),	there	is	no	cure	for	HF	available.	HF	has	been	linked	to	deficient	Ca2+	handling	in	failing	cardiac	cells	(Bers,	2006).	More	specifically,	in	humans	failing	myocardium	SR	Ca2+	load	is	decreased	(Lindner	et	al.,	1998;	Piacentino	et	al.,	2003;	Pieske	et	al.,	1999),	while	cytosolic	calcium	levels	remain	elevated	during	the	relaxation	period	(Beuckelmann	et	al.,	1992;	Gwathmey	et	al.,	1991).	As	a	result,	the	failing	heart	has	weak	muscle	contraction	and	reduced	cardiac	output.	Since	SERCA	is	a	primary	regulator	of	calcium	handling	in	myocardium,	it	is	an	appealing	target	to	treat	cardiac	diseases.	In	particular,	increasing	SERCA	activity	in	failing	cardiac	cells	is	predicted	to	improve	heart	function	(Hayward	et	al.,	2015;	Inesi	et	al.,	2008).	Recently,	phase	2	of	gene	therapy	clinical	trials	aimed	at	upregulation	of	SERCA,	the	most	promising	heart	failure	treatment	option	(Horowitz	et	al.,	2011),	had	failed	to	significantly	improve	patient’s	cardiac	function	(Zsebo	et	al.,	2014).	This	study	was	aimed	at	increasing	SERCA	levels	in	heart	failure	patients	by	the	adeno-associated	viral	expression.	At	the	dose	tested,	increased	SERCA	levels	did	not	improve	the	clinical	outcome	of	heart	failure	patients	(Greenberg	et	al.,	2016).	One	possible	explanation	is	that	simply	increasing	SERCA	levels	is	not	sufficient	to	overcome	heart	failure	symptoms.	Instead,	enhancing	SERCA	function	is	an	alternative	approach	for	the	discovery	of	novel	therapeutic	options.	The	present	study	was	aimed	to	add	to	understanding	of	SERCA	function	by	investigation	of	SERCA	structural	dynamics	during	Ca2+	transport.	
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SERCA	in	Other	Diseases	Besides	being	a	key	component	in	heart	failure	manifestation,	various	SERCA	isoforms	have	been	implicated	in	other	pathologies.	Recently	SERCA	has	been	implicated	in	cancer	stem-like	cell	survival	by	preventing	Ca2+-induced	apoptosis	in	glucose-deprived	conditions	due	to	sequestering	Ca2+	from	cytosol	(Park	et	al.,	2017).	Other	reports	emphasize	SERCA	importance	in	skin	health,	where	somatic	mutations	in	SERCA2b	lead	to	Darier’s	disease,	characterized	by	epidermal	lesions	(Savignac	et	al.,	2011;	Takagi	et	al.,	2016).	This	disorder	results	from	a	tissue-specific	missense,	non-sense,	frameshift,	and	splicing	mutations,	which	affect	both	SERCA2b	and	SERCA2a.	Being	a	major	isoform	expressed	in	the	epidermis,	loss-of-function	SERCA2b	mutation	has	a	detrimental	effect	on	the	health	of	the	epidermis	with	variety	of	clinical	manifestations.	Germline	mutations	of	skeletal	SERCA1a	isoform	result	in	pathological	skeletal	muscle	stiffness,	called	Brody	myopathy	(Odermatt	et	al.,	1996),	while	overexpression	of	SERCA2a	rescues	dystrophic	phenotype	in	mice	(Goonasekera	et	al.,	2011).	Based	on	the	variety	of	SERCA	function	in	all	of	these	disorders,	SERCA	is	a	high	value	therapeutic	target.	Nevertheless,	the	details	of	SERCA	structural	dynamics	during	Ca2+	cycle	are	still	not	resolved	to	the	degree	that	would	allow	targeted	transporter	regulation.	This	study	was	aimed	at	discovering	the	detail	of	SERCA	structural	dynamics	during	Ca2+	cycle.		
SERCA	Structure	and	Function	SERCA	is	the	ion	transporter	that	is	responsible	for	sequestration	of	calcium	Ca2+	in	the	ER/SR.	There	are	three	isoforms	of	SERCA:	SERCA1-3	encoded	by	ATP2A1-3	respectively.	
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Sarcoplasmic	reticulum	ATPase	SERCA2	belongs	to	a	Ca2+	P-type	ATPase2	family	which	has	two	isoforms:	SERCA2a	and	SERCA2b	resulting	from	alternative	splicing	of	the	exon	20	and	only	differ	in	their	C-terminus	(SERCA2b	has	an	additional	transmembrane	helix	11).	SERCA2a	is	expressed	in	cardiac	myocytes	and	slow-twitch	skeletal	muscles.	SERCA2b	is	expressed	in	almost	all	tissues.	SERCA2	isoforms	are	found	in	ER/SR	and	involved	in	the	Ca2+	transport	from	the	cytoplasm/sarcoplasm	to	the	lumen	of	ER/SR	(Periasamy	and	Kalyanasundaram,	2007).	Orthologues	of	SERCA2	pumps	are	common	in	bacteria	and	most	likely	human	SERCA2	transporters	evolved	as	a	mechanism	to	transport	Ca2+	against	a	
	
	
Figure	2.	SERCA	structure.	SERCA	structure	showing	the	actuator	(A)	in	blue,	nucleotide-binding	(N)	in	yellow,	auto-phosphorylation	(P)	in	black,	transmembrane	(TM)	domains	in	grey,	The	Nβ5-β6	loop	is	highlighted	in	orange,	and	three	acidic	residues	Asp426,	Glu429,	and	Glu435	are	labeled	in	magnified	insert.	
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steep	gradient	(Deves	and	Brodie,	1981).	The	main	focus	of	the	current	study	is	on	the	cardiac	isoform	SERCA2a.	The	first	SERCA	to	have	the	crystal	structure	determined	was	SERCA1a	of	rabbit	muscle	(Toyoshima	et	al.,	2000).	Today,	there	is	an	abundant	collection	of	SERCA	structures	in	the	PDB	database,	including	conformers	in	various	ligand-stabilized	states.	Based	on	these	data,	a	clear	picture	of	SERCA	structure	emerged.	As	illustrated	in	Fig.	2,	SERCA2a	contains	four	distinct	domains:	three	cytoplasmic	domains	(A,	actuator;	N,	nucleotide	binding;	P,	phosphorylation)	comprise	a	cytoplasmic	headpiece,	while	10-helical	transmembrane	(TM)	domain	transports	Ca2+	(Toyoshima,	2008).	Each	of	the	domains	has	its	unique	function.	The	nucleotide	binding	N-domain	(Fig.	2,	yellow)	has	two	main	functions:	binding	of	ATP	and	phosphorylation	of	P-domain.	The	N-domain	core	structure	is	conserved	among	SERCA	isoforms	and	contains	crucial	residues	(e.g.	Phe487)	for	ATP	binding	(Sorensen	et	al.,	2004).	In	ATP	bound	state,	the	N-domain	undergoes	structural	rearrangements	and	becomes	linked	to	P-domain	via	nucleotide-mediated	interactions	which	allows	phosphorylation	of	P-domain	to	take	place	(Toyoshima,	2008).		 The	phosphorylation	P-domain	(Fig.	2,	black)	contains	the	phosphorylated	residue	Asp351	placed	in	conserved	Asp-Lys-Thr-Gly	(DKTG)	motif,	and	Mg2+-coordinating	residue	Asp703	positioned	in	conserved	Thr-Gly-Asp-Asn	(TGDN)	sequence	(Aravind	et	al.,	1998;	Picard	et	al.,	2007).	Besides	being	linked	to	the	N-domain,	P-domain’s	flat	surface	allows	docking	and	rotation	for	A-domain	(Toyoshima,	2009),	thus	potentially	mediating	A−N-domains	interaction.	
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The	actuator	A-domain	(Fig.	2,	blue)	has	a	conserved	Thr-Gly-Glu-Ser	(TGES)	motif	(Moller	et	al.,	1996)	which	plays	an	important	role	in	dephosphorylation	of	P-domain	residue	Asp351	(Clausen	et	al.,	2004),	thus	serving	a	protein	phosphatase	function.	A-domain	connects	to	TM-domain	via	a	long	linker	that	allows	A-domain	to	be	flexible	and	serve	as	a	gating	mechanism	(actuator)	for	Ca2+	binding	and	release	(Toyoshima	et	al.,	2007).	SERCA	transports	two	Ca2+	ions	from	cytosol	to	the	ER/SR	lumen	for	every	ATP	hydrolyzed	(Inesi	et	al.,	1980).	In	addition,	SERCA	counter-transports	2	or	3	H+	ions	(Stokes	and	Green,	2003;	Yu	et	al.,	1993).	According	to	classical	theory	for	ion	transport,	when	P-domain	gets	phosphorylated	via	ATP	hydrolysis,	the	ATP-mediated	interaction	between	N-	and	P-domains	breaks,	and	P-domain	shifts	and	pulls	along	the	A-domain,	which	in	turn	tugs	the	A-domain	linker	connected	to	TM-domain.	These	complex	structural	rearrangements	of	cytoplasmic	headpiece	result	in	TM	reorganization	suitable	for	Ca2+	transport	(Toyoshima,	2008).	There	are	two	Ca2+	transport	sites	in	the	center	of	the	TM-domain,	which	can	be	in	high	or	low	affinity	states,	and	sequential	Ca2+	binding	is	cooperative	(Inesi	et	al.,	1980).	Ca2+	binding	to	the	site	I	is	maintained	by	oxygen	side	chains	and	one	water	molecule	on	cytosolic	side	of	helixes	M5,	M6,	and	M8.	Only	after	the	first	Ca2+	binds,	can	the	second	Ca2+	bind	to	site	II	on	nearby	helix	M4	which	provides	3	main	chain	carbonyl	groups	for	ion	coordination	(Toyoshima	et	al.,	2000).		If	Ca2+	binding	sites	are	exposed	to	the	cytoplasmic	site,	then	the	ATPase	is	in	a	high-affinity	(E1)	conformation.	On	the	other	hand,	if	Ca2+	binding	sites	are	exposed	to	the	luminal	side	of	ER	membrane,	the	transporter	is	in	a	low-
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affinity	state	(E2)	(Moller	et	al.,	2010).	Transition	of	the	transporter	from	E1	to	E2	conformation	has	been	proposed	to	be	induced	by	phosphorylation	event.	Specifically,	P-domain	phosphorylation	results	in	distortion	of	the	high-affinity	binding	sites	and	opens	an	ion	exiting	channel	on	the	other	side	of	the	membrane,	while	repositioning	the	dephosphorylation	TGES	motif	of	A-domain	closer	to	the	phosphorylation	site	on	P-domain	(Moller	et	al.,	2010;	Toyoshima	and	Mizutani,	2004).	The	consequent	repositioning	of	A-domain	during	hydrolysis	of	aspartylphosphate	of	P-domain	(dephosphorylation	event)	results	in	transition	of	the	pump	from	the	E1	to	E2	conformation,	which	is	predicted	to	be	the	slowest	step	of	the	Ca2+	catalytic	cycle	(Fig.	2,	(c))	(Champeil	et	al.,	1986;	Hanel	and	Jencks,	1990;	Petithory	and	Jencks,	1986).	Fig.	3	presents	a	simplified	schematic	overview	of	SERCA	Ca2+	transport	cycle	steps,	including	Ca2+	binding	(a),	phosphorylation	(b),	Ca2+	release	(c),	dephosphorylation	(d),	and	reset	of	cycle	by	ATP	binding	(e).	All	of	these	steps	of	the	enzymatic	cycle	are	intrinsically	regulated	by	means	of	the	transporter	structural	determinants’	responses	to	the	ligand	(Ca2+,	ATP,	Mg2+)	binding	and	their	or	their	metabolites	release	events.	For	example,	SERCA	structural	rearrangement	during	transition	from	open	to	close	conformation	upon	Ca2+	binding	(Toyoshima	and	Mizutani,	2004)	was	proposed	to	result	in	the	restriction	of	ATP	delivery	to	phosphorylation	site,	and	thus	prevent	the	sequence	of	events	that	would	lead	to	TM-domain	rearrangement	and	backflow	of	Ca2+	ions	from	the	SR	luminal	side	(Toyoshima,	2008;	Toyoshima,	2009).	This	idea	of	internal	structural	determinants	regulating	the	pump	catalytic	cycle	is	a	powerful	approach	to	understanding	SERCA	functional	mechanisms.	Identification	of	the	structural	determinants	that	regulate	SERCA	catalytic	cycle	would	be	beneficial	in	rational	design	of	
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SERCA	targeted	modulators.	Up	to	this	point,	only	few	SERCA	specific	activators	have	been	identified,	and	their	potency	is	still	under	investigation	(Cornea	et	al.,	2013;	Dahl,	2017;	Kang	et	al.,	2016).	One	of	the	goals	of	this	work	was	to	contribute	to	understanding	of	SERCA	function	via	thorough	investigation	of	SERCA	structural	dynamics	during	Ca2+	transport.		
Nβ5-β6	Loop	is	Predicted	to	Regulate	SERCA	Compact	Conformation	The	advances	in	crystallography	and	electron	microscopy	techniques	allowed	science	to	capture	SERCA	short-lived	transitional	structures	in	biochemically-stabilized	
	
Figure	3.	Simplified	schematic	overview	of	SERCA	kinetic	cycle.		E1	state	are	yellow	and	E2	states	are	green.	(a)	ATP	binding	induces	conformational	changes	that	facilitate	Ca2+	binding	at	the	cytosolic	membrane	side.	(b)		P-domain	phos-phorylation	and	ATP	hydrolysis.	(c)	Ca2+	release	at	the	other	side	of	membrane.	(d)	Dephosphorylation.	(e)	ATP	binding.	Steps	(c-d)	are	predicted	to	be	the	slowest.	
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environments.	Nevertheless,	the	structural	dynamics	of	SERCA	during	Ca2+	cycling	have	not	been	fully	discovered	and	alternative	approaches	are	needed	to	investigate	transitional	conformations.	A	recent	computational	study	by	Smolin	et	al.	(Smolin	and	Robia,	2015a)	has	identified	a	β-loop	in	SERCA	N-domain	as	a	potential	regulator	of	SERCA	transition	from	open-to-closed	conformation.	This	short	(10	amino	acids)	Nβ5-β6	loop	has	three	negatively	charged	residues	(Asp426,	Glu429,	and	Glu435)	which	are	predicted	to	interact	with	positive	cluster	on	the	A-domain	surface.	Formation	of	H-bonds/salt	bridges	between	the	Nβ5-β6	loop	and	polar/basic	residues	of	A-domain	is	predicted	to	penetrate	the	poorly	diffusible	water	cushion	separating	A-	and	N-domains	and	facilitate	the	closure	of	the	SERCA	cytoplasmic	headpiece	during	Ca2+	transport	cycle.	The	N-domain	Nβ5-β6	loop	is	highly	conserved	among	SERCA	isoforms	and	multiple	species	(Smolin	and	Robia,	2015a).	Analysis	of	two	major	human	genome	variance	databases	(OMIM	and	COSMIC)	revealed	that	Nβ5-β6	loop	carries	no	reported	mutations	(Amberger	et	al.,	2015;	Forbes	et	al.,	2015).	High	preservation	and	absence	of	variance	in	this	discrete	structure	suggest	that	SERCA	Nβ5-β6	loop	residues	may	play	an	important	role	in	transporter	assembly/function.	One	of	the	goals	of	the	current	study	is	to	investigate	in	detail	the	predicted	role	of	Nβ5-β6	loop	in	SERCA	structural	regulation	and	function.		
SERCA	Regulation	by	PLB	The	SERCA’s	main	inhibitor	is	phospholamban	(PLB),	a	52-amino-acid	residue	polypeptide	(Fig.	1,	PLB	in	red)	(Kirchberber	et	al.,	1975;	Tada	and	Inui,	1983;	Toyoshima	et	al.,	2003).	PLB	is	composed	of	amino-terminal	cytosolic	α-helix,	connected	via	an	unstructured	hinge	
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to	a	carboxyl	hydrophobic	transmembrane	single-spin	α-helix	(Simmerman	et	al.,	1986).	PLB	binds	to	SERCA	at	the	TM	groove	composed	of	helixes	M2	(residues	89-119),	M4	(residues	313-330),	M6	(residues	789-809),	and	M9	(residues	932-950)	and	stabilizes	SERCA	conformation	in	reduced	affinity	for	Ca2+,	and	thus	reduces	maximal	Ca2+	transport	rate	(Vmax)	(Chen	et	al.,	2006;	Morita	et	al.,	2008).	SERCA	inhibition	by	PLB	is	relieved	when	PLB	cytosolic	domain	is	phosphorylated	by	protein	kinase	A	(PKA)	on	Ser16	or	calcium/calmodium-dependent	protein	kinase	II	(CaMKII)	on	Thr17	(Simmerman	et	al.,	1986;	Tada	and	Inui,	1983).	Several	studies	suggest	that	PLB	phosphorylation	increases	SERCA	maximal	rate	of	Ca2+	transport	beyond	of	SERCA	Vmax	alone	(Antipenko	et	al.,	1997;	Reddy	et	al.,	2003),	suggesting	that	PLB	binding	even	‘primes’	SERCA	for	more	efficient	enzymatic	cycling.		In	the	SR	membrane	PLB	forms	homo-pentamers,	and	upon	de-oligomerization	into	active	monomers	is	able	to	bind	and	inhibit	SERCA	(Simmerman	and	Jones,	1998).	PLB	mutations	that	prevent	homo-pentamer	formation	and	thus	enhance	a	monomeric	form	of	PLB	have	been	shown	to	improve	PLB	ability	to	inhibit	SERCA	(Kimura	et	al.,	1997).	It	is	assumed	that	PLB	monomers	bind	to	SERCA,	while	PLB	homo-pentamers	serve	as	a	non-inhibitory	reserve	pool	(Simmerman	and	Jones,	1998).	PLB	monomeric	to	pentameric	equilibrium	is	highly	dynamic	(Robia	et	al.,	2007)	with	different	affinities	of	PLB	monomers	to	different	SERCA	conformational	states	(Bidwell	et	al.,	2011).	The	interaction	between	PLB	subunits	and	SERCA	conformers	are	still	under	investigation.	Currently,	there	are	two	models	how	PLB	phosphorylation	causes	relief	of	SERCA	inhibition.	The	dissociation	model	suggests	that	PLB	phosphorylation	results	in	PLB	
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dissociation	from	SERCA,	which	allows	SERCA	to	return	into	a	high	Ca2+	affinity	conformational	state	(Chen	et	al.,	2006;	James	et	al.,	1989;	Kimura	et	al.,	1997).	Nevertheless,	this	model	does	not	explain	why	phosphorylation	of	PLB	results	in	SERCA	maximal	rate	of	Ca2+	transport	increase	beyond	Vmax	of	SERCA	alone	(Antipenko	et	al.,	1997;	Reddy	et	al.,	2003).	The	alternative	model,	the	so	called	‘subunit’	model,	predicts	that	PLB	remains	bound	to	SERCA	after	phosphorylation	(Bidwell	et	al.,	2011;	Negash	et	al.,	2000).	This	model	predicts	that	PLB	binding	serves	as	a	SERCA	“shortcut”	to	efficient	Ca2+	transport	by	shifting	ATPase	conformation	to	an	ordered,	compact	and	high	Ca2+	affinity	(high-efficiency)	structural	state	(Pallikkuth	et	al.,	2013).	Additionally,	the	significant	structural	changes	in	SERCA-PLB	complex	toward	more	compact	conformation	upon	PLB	phosphorylation	have	been	supported	by	the	decrease	in	SERCA-to	PLB	FRET	(Hou	et	al.,	2008).	Thus,	this	model	of	PLB	shift	becomes	more	and	more	predominant	over	dissociation	model.		 Unfortunately,	the	crystal	structure	of	SERCA-PLB	regulatory	complex	has	been	determined	without	the	PLB	cytosolic	domain	(residues	1-23	not	resolved)	due	to	its	highly	dynamic	structure	(Akin	et	al.,	2013).	To	date,	it	remains	unclear	how	PLB	cytosolic	domain	phosphorylation	can	induce	SERCA-PLB	compact	conformation	and	increased	Ca2+	transport	rate.	My	lab’s	recent	MD	simulations	of	SERCA	spontaneous	motions	have	shown	that	SERCA	Nβ5-β6	loop	was	in	position	to	interact	with	PLB	cytosolic	domain	(Smolin	and	Robia,	2015a);	thus,	it	is	reasonable	to	hypothesize	that	Nβ5-β6	loop	could	be	an	intrinsic	regulator	of	SERCA	function	via	interaction	with	PLB.	Specifically,	Nβ5-β6	loop	has	three	negatively	charged	residues,	Asp426,	Glu429,	and	Glu435,	which	are	potential	candidates	
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for	interaction	with	multiple	positive	residues	on	PLB	cytosolic	domain.	Negative	charges	introduced	to	Ser16	and	Thr17	with	addition	of	phosphoryl	groups	upon	phosphorylation	may	cause	repulsion	of	PLB	cytosolic	domain	from	negative	loop	residues	and	in	this	way	become	that	force	that	shifts	SERCA-PLB	complex	and	relieves	it	from	inhibition.	One	of	the	goals	of	current	study	is	to	examine	the	regulatory	complex	in	more	detail	and	investigate	the	possible	role	of	Nβ5-β6	loop	in	structural	regulations	in	SERCA-PLB	regulatory	complex.		
SERCA	in	Regulatory	Complexes:	HAX-1	and	DWORF	SERCA	regulation	is	a	plausible	target	to	improve	cardiac	function	in	heart	related	disorders.	Even	though	PLB	remains	a	major	SERCA	regulator,	recently	other	molecules	were	predicted	to	regulate	pump	activity.	Two	of	them,	HAX-1	and	DWORF,	were	included	in	the	scope	of	current	study	and	are	described	below.	HS-1-Associated-protein-X-1	(HAX-1)	is	a	ubiquitously	expressed	protein	that	has	been	shown	to	play	an	anti-apoptotic	role	in	striated	muscles	via	interaction	with	the	mitochondrial	enzyme	caspase-9	(Han	et	al.,	2006).	In	failing	heart,	Hax-1	has	been	shown	to	interact	with	SERCA	inhibitor	phospholamban	residues	16-22,	which	overlaps	with	phosphorylation	sites	(Vafiadaki	et	al.,	2007).	The	HAX-1	pull-down	experiments	detected	SERCA	in	complex	with	HAX-1	and	PLB,	which	suggests	that	PLB	can	interact	with	both	HAX-1	and	SERCA	simultaneously,	or	alternatively,	HAX-1	can	interact	with	both	SERCA	and	PLB	at	the	same	time	(Kimura	and	Inui,	2002).	HAX-1	binding	to	SERCA	has	been	confined	to	residues	575-594	on	N-domain	by	additional	in	vitro	pull-down	experiment	
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(Vafiadaki	et	al.,	2009).	Recently,	Hax-1	has	been	reported	to	promote	cell	survival	via	positive	regulation	of	SERCA	levels	(Bidwell	et	al.,	2017;	Vafiadaki	et	al.,	2009)	and	mediate	PLB	inhibitory	activity	on	SERCA	(Bidwell	et	al.,	2018),	which	suggests	that	SERCA	is	under	HAX-1	regulation.	Nevertheless,	direct	binding	of	HAX-1	to	SERCA	in	live	cells	that	is	not	mediated	by	simultaneous	association	with	PLB	is	still	under	investigation	(Vandecaetsbeek	et	al.,	2011).	I	examined	the	direct	effect	of	Hax-1	on	SERCA	headpiece	closure.		Long	noncoding	RNAs	(lncRNA)	were	long	viewed	as	junk	nucleic	acids	that	are	not	translated	into	proteins.	Nevertheless,	over	the	last	decade,	lncRNAs	have	been	demonstrated	to	carry	out	transcriptional	regulation,	serve	as	scaffold,	and	to	functionally	regulate	proteins	and	RNA	molecules	(Ulitsky	and	Bartel,	2013).	Even	more	strikingly,	some	lncRNAs	were	identified	as	transcripts	that	encode	short	peptides	(Anderson	et	al.,	2015;	Matsumoto	et	al.,	2017;	Nelson	et	al.,	2016).		The	Dworf	RNA	transcript	encodes	the	muscle-specific	short	peptide	named	DWORF	(Nelson	et	al.,	2016).	DWORF	has	been	shown	to	localize	in	SR	with	SERCA	and	has	been	predicted	to	physically	interact	with	SERCA	at	the	same	groove	and	with	similar	affinity	as	PLB.	Moreover,	DWORF	enhances	SR	Ca2+	uptake	by	SERCA	through	displacement	of	the	inhibitory	PLB,	and	is	proposed	to	be	a	promising	therapeutic	target	to	enhance	cardiac	contractility.		I	examined	the	detail	of	DWORF	interaction	with	and	regulation	of	SERCA	in	this	study,	which	is	discussed	further.		
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2-color	ATPase	Transporters:	SERCA	and	MRP-1		My	laboratory	developed	a	2-color	SERCA	FRET	biosensor	for	a	high-throughput	screening	strategy	that	allowed	identification	of	molecule’s	effectors	with	high	precision	and	speed	in	live	cells.	This	technique	is	used	for	drug	discovery	and	has	a	potential	for	rapid	and	precise	identification	of	small-molecule	regulators	of	transporter	activity	(Cornea	et	al.,	2013).	The	transport	ATPases	include	not	only	Ca2+	pumps	like	SERCA,	but	a	wide	variety	of	proteins	that	move	different	types	of	ions	or	molecules	across	the	biological	membranes	(Pedersen,	2005).	All	ATPase	transporters	hydrolyze	ATP	in	order	to	move	substrates	across	membranes	and	are	involved	in	variety	of	physiological	processes.	Mutations	observed	in	ATPases	result	in	a	large	number	of	diseases.	While	SERCA	belongs	to	P-type	ATPase	class,	there	are	three	more	major	classes:	V,	F,	and	ABC	types.		Multidrug	resistance	protein	1	(MRP-1)	is	an	ABC	(ATP-binding	cassette)	family	plasma	membrane	transporter	that	exports	a	wide	variety	of	drugs	from	the	cell	(Deeley	et	al.,	2006).	As	a	result,	MRP-1	is	a	major	contributor	to	the	failure	of	chemotherapy	in	cancer	patients.	It	is	only	recently	a	high	resolution	MRP-1	structure	was	resolved	with	electron	cryomicroscopy	(Johnson	and	Chen,	2017),	and	before	that,	homologous	ABC-family	transporters	were	used	to	predict	MRP-1	structure.		MRP-1	has	been	expected	to	be	composed	of	two	membrane	spanning	domains	and	two	cytoplasmic	nucleotide-binding	domains	(Dean	and	Allikmets,	2001).	Two	structural	conformers	of	MRP-1	were	predicted	to	exist.	The	first	one	is	a	low	substrate-affinity	conformation	with	nucleotide-binding	domains	locked	together	and	ligand-binding	site	exposed	to	the	extracellular	environment	(Fig.	36A,	bottom	panel),	while	a	second	one	is	a	high	substrate-affinity	conformation	with	
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binding	site	exposed	to	cytoplasm	and	nucleotide-binding	domains	separated	(Fig.	36A,	top	panel)	(Aller	et	al.,	2009).	Without	the	MRP-1	structure	resolved,	the	real	conformational	dynamics	of	this	important	transporter	were	not	defined,	and	an	alternative	approach	was	needed	to	investigate	the	MRP-1	structural	determinants.	My	lab	used	similar	to	2CS	labeling	strategy	(Hou	et	al.,	2012;	Pallikkuth	et	al.,	2013)	in	generating	2-color	MRP-1	biosensor.	Fluorescent	MRP-1	sensor	was	used	for	identification	of	transporter’s	structural	dynamics	and	to	monitor	the	conformational	changes	of	MRP-1	nucleotide	binding	domains	in	the	presence	of	small	molecules.	As	a	result,	several	substrates	that	induced	MRP-1	conformational	changes	were	identified	as	candidates	into	MRP-1	allosteric	modulators	(Iram	et	al.,	2015).	This	study	describes	advanced	investigation	of	functional	significance	of	identified	compounds	in	MRP-1	activity	as	a	part	of	present	project.			 Overall,	this	dissertation	work	concentrates	on	structural	dynamics	and	regulation	of	several	ATPases,	predominantly	SERCA.	Specifically,	I	investigate	SERCA	headpiece	structural	transitions	during	the	enzymatic	cycle	and	a	role	of	Nβ5-β6	loop	during	these	transitions.	I	examine	SERCA’s	regulatory	interactions,	mostly	with	PLB	and	in	a	smaller	scale	with	DWORF	and	HAX-1.	In	my	investigations,	I	utilize	FRET	biosensor	labeling	strategy	to	carry	out	SERCA	structural	measurements.	I	successfully	apply	this	strategy	to	generating	MRP-1	FRET	sensor	and	showed	that	this	approach	can	be	used	as	a	wide-ranging	tool	in	structural	biology	and	drug	discovery.		
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CHAPTER	TWO	MATERIALS	AND	METHODS	
Molecular	Biology	and	Cell	Culture	The	engineering	and	functional	characterization	of	2CS	has	been	previously	described	in	detail	by	Hou	et	al	(Hou	et	al.,	2012).	I	used	a	canine	SERCA2a	construct	labeled	with	Cer	on	the	N-terminus	and	a	YFP	intra-sequence	tag	inserted	before	residue	509	in	the	N-domain.	In	some	experiments,	like	ATPase	assay,	I	used	an	analogous	construct,	with	Tag-RFP	on	the	N-terminus	and	an	EGFP	tag	inserted	before	residue	509	in	the	N-domain.	The	Cer-YFP	pair	has	a	Förster	distance	(R0)	of	49.8	Å	and	the	EGFP-TagRFP	pair	has	an	R0	of	58.3	Å	(Gadella,	2011).	Ala	mutations	in	Nβ5-β6	loop	residues	Asp426,	Glu429,	Glu435	were	introduced	with	QuickChange	Lightning	Site-Directed	Mutagenesis	Kit	(Agilent	Technologies,	Stratagine,	La	Jolla,	CA)	according	to	the	manufacture’s	protocol.	Single	mutations	and	a	triple	mutation	were	made:	Asp426Ala,	Glu429Ala,	Glu435Ala,	and	Asp426Ala/Glu429Ala/Glu435Ala	(AAA).	Adenoviral	vectors	of	TagRFP-EGFP-SERCA	(WT	and	AAA)	were	obtained	from	the	Loyola	Cardiovascular	Research	Institute	virus	production	facility.	All	constructs	were	validated	with	nucleotide	sequencing	and	in	fluorescent	signal	in	cell	expression.	AAV-293	cells	were	cultured	and	transiently	transfected	using	MBS	mammalian	transfection	kit	(Agilent	Technologies,	Stratagine,	La	Jolla,	CA)	as	described	previously	(Hou	et	al.,	2012).	Briefly,	the	transfected	cells	were	trypsinized	for	1	min	and	plated	onto	
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poly-D-	and	allowed	to	adhere	for	1−2	hr	prior	to	imaging.		
Fluorescence	Microscopy	and	FRET	Quantification	Acceptor-sensitized	emission	FRET	was	used	to	measure	intermolecular	protein-protein	or	intramolecular	protein	interactions.	This	technique	allows	excited-state	energy	to	be	transferred	directly	from	excited	fluorophore	(donor)	to	a	proximate	molecule	(acceptor)	and	thus	provides	evidence	of	molecule	interactions	(Day	and	Davidson,	2012;	Gordon	et	al.,	1998).	FRET	was	calculated	from	fluorescence	intensities	of	donor	(Cer)	and	acceptor	
	
Figure	4.	Acceptor-sensitized	FRET.	
(A)	AAV293	cells	expressing	Cer-YFP	2-color	SERCA.	(B)	2-color	SERCA	intramolecular	FRET	was	measured	between	donor	and	acceptor	fluorophores	attached	to	A-	and	N-do-mains	respectively.	As	a	control,	thapsigargin	(TG)	addition	results	in	SERCA	population	to	obtain	open	headpiece	conformation	(low	FRET).	The	addition	of	Ca2+	activates	and	shifts	SERCA	population	to	more	compact,	closed	headpiece	state	(high	FRET).	
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(YFP)	images,	as	well	as	an	image	that	captures	the	acceptor	emission	with	donor	excitation.	Wide-field	fluorescent	microscopy	was	done	as	described	previously	(Hou	et	al.,	2008).	Briefly,	cells	expressing	2-color	SERCA	(Fig.	4A)	were	imaged	with	an	inverted	microscope	(Nikon	Eclipse	TE2000-U)	equipped	with	a	metal	halide	lamp	and	a	back-thinned	CCD	camera	(iXon	887:	Andor	Technology,	Belfast,	Northern	Ireland).	For	each	sample,	acquisition	of	the	field	was	performed	with	a	60×1.49	N.A.	objective	with	100	or	150−ms	exposure	for	each	channel:	Cer,	YFP,	and	FRET.	Fluorescence	intensity	was	automatically	quantified	with	a	multiwavelength	cell	scoring	application	in	MetaMorph	software	(Molecular	Devices,	Sunnyvale,	CA).	The	background	threshold	was	set	to	100	counts.	Cell	size	criteria	were	limited	to	30-80	μm	diameter	or	manually	defined	by	drawing	a	cell	contour.	FRET	efficiency	E	was	calculated	according	to	E=Fem/(Fem+G×FCer)	where	Fem=FFRET−a×FYFP−d×FCer	(Bidwell	et	al.,	2011;	Hou	et	al.,	2008),	FFRET,	FYFP,	and	FCer	are	the	matching	fluorescence	intensity	from	FRET,	YFP,	and	Cer	images,	respectively,	and	
G	represents	FRET	intensity	corrected	for	the	bleed-through	of	the	channels	calculated	as	in	photobleaching-correction	method	described	by	Zal	and	Gascoigne	(Zal	and	Gascoigne,	2004).	G	was	calculated	as	
𝐺 = (𝐹%&) − )𝐹%&*+,-.𝐹/012 − 𝐹3%4 	where	𝐹%&	calculated	before	and	𝐹%&*+,-calculated	after	photobleaching,	and	G	determined	to	be	3.20	for	experimental	set	up.	The	acceptor	photobleaching	technique	details	are	descried	below.	The	parameters	a	and	d	are	bleed-through	constants	calculated	as	a=	
FFRET/FCer	for	a	control	sample	transfected	with	only	YFP-SERCA,	and	d=	FFRET/FCer	for	a	
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control	sample	transfected	with	only	Cer-SERCA.	These	calibrations	indicated	a=0.074	and	
d=0.70	in	my	experimental	setup.		 Each	cell	that	expressed	CFP	and	YFP	above	background	threshold	was	plotted	as	percent	FRET	over	a	range	of	expressed	protein	as	determined	by	YFP	intensity	(in	arbi-trary	units,	A.U.).	The	plotted	data	were	fit	by	equation:	FRET=(FRETmax	x	IYFP)/(Kd+IYFP),	where	IYFP	is	YFP	intensity,	FRETmax	is	maximum	FRET,	and	Kd	is	the	apparent	dissociation	constant	of	the	donor-	and	acceptor-labeled	proteins	for	each	other.	Another	FRET	technique	used	in	investigation	of	protein-protein	interactions	is	progressive	acceptor	photobleaching.	This	method	utilizes	irreversible	selective	destruction	of	the	acceptor	fluorophore	through	prolonged	excitation.	Once	destroyed,	the	acceptor	fluorophore	no	longer	can	quench	the	donor	emission	(assuming	FRET	pair	was	in	
	
Figure	5.	Acceptor	photobleaching	FRET.	
(A)	Representative	images	of	AAV293	cells	expressing	PLB	labeled	with	Cer	and	PLB	la-beled	with	YFP	before	and	after	photobleaching.	PLB	was	used	as	control	in	photobleaching	experiments,	as	it	is	known	to	form	dimers	and	pentamers.	(B)	Acceptor	(YFP)	fluorophore	intensity	decreasing,	while	donor	(CFP)	fluorescence	intensity	is	increasing	during	10	min	of	photobleaching	experiment.	The	first	2	min	are	used	to	establish	a	baseline	by	imaging	YFP	and	Cer	at	30	sec	interval.	
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distance	suitable	for	FRET),	and	donor	fluorescence	intensity	increases	(Patel	et	al.,	2002).	Acceptor	photobleaching	experiments	were	performed	on	a	similar	set	up	as	described	for	acceptor-sensitized	emission	FRET,	except	that	YFP	was	selectively	photobleached	by	exposure	to	YFP	excitation	(504/12nm	bandpass	filter)	for	10	s,	and	then	YFP	and	CFP	were	imaged.	The	first	10	images	were	acquired	in	10	s	intervals	without	photobleaching	to	obtain	fluorescence	intensities	baseline	values.	Images	were	analyzed	with	ImageJ	software	(Schindelin	et	al.,	2012)	by	manually	selecting	cells.	The	fluorescence	intensity	values	were	plotted	over	time	either	as	arbitrary	units	(A.U.)	or	average	intensity	was	normalized	to	baseline	intensity	using	the	equation:	F/F0=(F−Fbg)/(F0−F0bg),	where	F	is	the	fluorescence	intensity	after	photobleaching,	F0	is	last	baseline	fluorescence	intensity	recorded,	and	Fbg	and	F0bg	are	background	fluorescence	signals.	Figure	5	shows	a	representative	field	of	cells	expressing	Cer-PLB	and	YFP-PLB	and	changes	in	their	corresponding	fluorescence	intensities	before	and	after	YFP	photobleaching.		
Live	Cell	Ca2+	Uptake	Activity	Assay	To	evaluate	Ca2+	transport	activity	of	SERCA,	I	transfected	AAV-293	cells	with	Cer-SERCA	and	YFP-PLB	DNA	constructs	and	performed	Ca2+	uptake	activity	assay	as	described	previously	(Bidwell	et	al.,	2011).	24	hrs	post-transfection,	cells	were	labeled	with	the	cell-permeant	Ca2+	indicator	dye	X-Rhod-1	(AM)	(ThermoScientific,	Waltham,	MA).	Transfected	and	untransfected	cells	were	distinguished	based	on	the	intensity	of	Cer	and	YFP	fluorescence	emissions.	Release	of	Ca2+	from	ER	stores	was	accomplished	by	stimulating	purinergic	receptors	with	extracellular	application	of	200	μM	ATP,	which	activated	inositol	1,4,5-trisphosphate		receptors	on	ER	membrane	(Dubyak	and	el-Moatassim,	1993).		Accumulation	of	Ca2+	in	the	cytosol	was	quantified	as	an	increase	in	X-Rhod-1	fluorescence.	
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SERCA	Ca2+	transport	activity	was	detected	as	decrease	in	ATP-stimulated	cytosolic	Ca2+	accumulation	relative	to	untransfected	cells.	4	min	after	application	of	extracellular	ATP,	cells	were	treated	with	50	μM	TG	to	determine	the	size	of	the	Ca2+	store	remaining	in	the	ER.		
Measuring	Calcium	Oscillations	by	Confocal	Microscopy	in	Live	Cells		AAV-293	cells	were	transiently	co-transfected	with	three	plasmids	containing	genes	of	human	GFP-Ryanodine	receptor-2	(RyR),	low	affinity	ER	calcium	sensor	R-CEPIA1er,	and	2-color	canine	SERCA2a	wild	type	(WT)	or	triple	loop	mutant	AAA	(ratio	of	DNA	constructs	was	3	unites	of	RyR	to	1	unit	of	R-Cepia1er,	and	10	unites	of	SERCA).	Transfected	cells	were	cultured	for	24	hrs	and	seeded	into	poly-D-lysine	coated	glass	bottom	chamber	slides	in	MDM.	24	hrs	after	seeding,	media	was	changed	with	PBS	with	Ca2+/Mg2+	and	experiments	were	conducted	with	a	Leica	SP5	laser	scanning	confocal	microscope	equipped	with	a	63×	water	objective.	R-CEPIA1er	was	excited	with	the	543	nm	line	of	a	He-Ne	laser,	and	emitted	fluorescence	was	measured	at	wavelength	≥580	nm.	2CS	fluorophores	Cer	and	YFP	were	excited	with	the	430	and	514	nm	lines	of	an	Argon	laser,	respectively,	and	emitted	fluorescence	was	measured	at	wavelength	≥485±15	nm	and	≥537±15	nm,	respectively.	Images	were	acquired	in	line-scan	mode	for	up	to	8−12	min	with	addition	of	10	mM	caffeine	or	100	μM	ionomycin	(Iono)	at	2	min.	Fluorescence	image	analysis	was	performed	with	Fiji	(ImageJ)	software	(Schindelin	et	al.,	2012).	To	load	cells	with	the	low-affinity	Ca	indicator	X-Rhod-1/AM	(X-Rhod)	(Lock	et	al.,	2015)	cells	were	incubated	with	10	μM	X-Rhod	(ThermoScientific,	Waltham,	MA)	for	15	min	in	PBS	with	Ca2+/Mg2+.	Before	conducting	experiments,	cells	were	washed	twice	with	PBS	with	Ca2+/Mg2+.	
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	 MRP-1	functional	measurements	were	accomplished	with	Argon	laser	illumination	at	488	nm	for	GFP	and	DOX,	and	detection	of	emission	bands	of	496-522	and	565-650	nm	respectively.			
All-atoms	Molecular	Dynamics	Simulations	All-atoms	MD	simulations	were	performed	with	the	GROMACS	software	package	(Hess	et	al.,	2008;	Pronk	et	al.,	2013)	with	CHARMM	27	force	field	(MacKerell	et	al.,	2000).	TIP3P	water	model	(Jorgensen	W.	L.	and	L.,	1983)	was	used	to	carry	out	MD	simulations	with	an	integration	time	of	2	fs.	The	reference	1SU4	crystal	structure	of	SERCA	(Toyoshima	et	al.,	2000)	was	used	to	introduce	Nβ5-β6	loop	mutations	and	perform	energy	minimization	with	the	steepest	descent	method	for	1000	steps.	Then	the	structures	were	embedded	into	a	POPC	lipid	bilayer	and	solvated	into	triangular	water	box	with	dimension	sizes	130 ´	130	
´	160	Å.	Na+	and	Cl−	ions	were	added	to	the	solution	to	concentration	of	150	mM.	The	Berendesen	method	(Berendsen	H.	J.	C.,	1984)	with	relaxation	time	of	0.1	ps	was	used	to	increase	the	temperature	of	the	system	to	300	K	and	to	increase	the	pressure	to	1	bar.	After	1	ns	equilibration,	the	production	run	was	performed	in	the	NPT	assemble	using	the	Nose-Hoover	thermostat	(Hoover,	1985;	Nose,	1984)	and	the	Parrinello-Rahman	barostat	(Parrinello,	1981)	with	relaxation	time	of	1	ps.	Six	independent	production	runs	for	each	wild-type	or	mutant	models	were	started	with	different	sets	of	assigned	velocities	at	300	K.	The	atoms	coordinates	were	saved	every	1	ps.	The	production	runs	were	carried	out	for	100	ns.		
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Structural	Analysis	and	Visualization	The	VMD	program	(Humphrey	et	al.,	1996)	was	used	for	visualization	and	rendering	structures.	The	GROMACS	(Hess	et	al.,	2008;	Pronk	et	al.,	2013)	program	was	used	for	the	computational	analysis	of	secondary	structures	of	AAMD	run	productions.	The	A-N	domains	distance	was	computed	as	minimum	distance	between	atoms	of	domain	A-	(residues	number	1−40	and	128−241)	and	atoms	of	N-domain	(residues	360−603).	The	number	of	contacts	was	calculated	within	4	Å	between	atoms	of	A-	and	N-domains.	A	contact	of	an	N-domain	atom	with	multiple	atoms	of	A-domain	was	counted	as	one	contact	(i.e.,	instead	of	multiple	contacts).	The	first	10	ns	of	MD	runs	were	considered	as	equilibration	time	and	not	included	into	calculations	(except	for	SERCA-PLB	complex,	where	whole	trajectories	were	included	into	quantification).		
Principal	Component	Analysis	To	identify	the	major	motions	of	the	SERCA	headpiece	during	MD	trajectories,	I	aligned	SERCA	structures	using	the	10-helix	TM-domain	as	a	reference	and	used	principle	component	analysis	(PCA)	(Amadei	et	al.,	1993;	Kitao	et	al.,	1998;	Tournier	and	Smith,	2003).	In	order	to	compare	structural	ensembles	with	respect	to	the	same	eigenvectors,	I	combined	three	SERCA	reference	X-ray	crystal	structures	(1SU4	(Toyoshima	et	al.,	2000),	3W5B	(Toyoshima	et	al.,	2013)	and	1VFP	(Toyoshima	and	Mizutani,	2004)),	six	MD	trajectories	of	WT-SERCA,	and	six	MD	trajectories	of	AAA-SERCA	into	a	single	trajectory.	To	obtain	sets	of	eigenvectors	and	eigenvalues	corresponding	to	principle	components	I	built	covariance	matrixes	of	the	atomic	fluctuations	in	GROMACS	(Hess	et	al.,	2008;	Pronk	et	al.,	2013).	The	diagonalization	of	matrixes	yielded	the	eigenvectors	(which	are	principle	components)	and	their	associated	eigenvalues.	
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Domain	Orientation	Calculation	The	GROMACS	program	was	used	for	the	computational	analysis	of	SERCA	structures	from	AAMD	productions.	To	perform	correlation	analysis	of	domains	orientation,	I	quantified	the	orientation	of	the	vector	which	connects	the	domain	hinge	and	domain	center	of	mass.	I	computed	the	hinge	disorder	function	defined	as	
𝜃6(𝑡) = 8cos<= > 𝑞6@@@@⃗ (𝑡) ∙ 𝑞6@@@@⃗ (𝑡)|𝑞6@@@@⃗ (𝑡)| ∙ |𝑞6@@@@⃗ (𝑡)|DE	where	𝑥	is	N,	A,	or	P	domain.	Thus,	𝜃6(𝑡)	defines	the	time-dependent	orientation	of	each	domain	relative	to	the	starting	orientation	(Fig.	6).		
	
Figure	6.	The	diagram	of	the	SERCA	domains	angular	autocorrelation	vectors	
sampling.	The	domain	hinge	was	used	as	a	starting	point	of	the	vector,	while	the	domain	center	of	mass-	its	end,	and	vector	displacement	was	calculated	over	time.	Hand-drawn	cones	represent	approximate	sampling	of	vectors	angular	displacement.		
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Root	Mean	Square	Fluctuations	Calculations	(RMSF)	RMSF	was	calculated	in	GROMACS	(Hess	et	al.,	2008;	Pronk	et	al.,	2013)	as	the	root	mean	square	fluctuations	(i.e.	standard	deviation)	of	atomic	positions	in	the	trajectory	after	fitting	to	TM-domain	with	a	reference	to	structure	at	10	ns.		
Root	Mean	Square	Deviation	Calculations	(RMSD)	RMSD	was	calculated	in	GROMACS	(Hess	et	al.,	2008;	Pronk	et	al.,	2013).	SERCA	structures	of	production	runs	were	aligned	using	10-helix	TM-domain	as	a	reference.	RMSD	was	calculated	for	Cα	positions	with	reference	to	starting	structure	at	10	ns.		
AAV-293	Cell	Microsomal	Membranes	Preparations	Microsomal	membrane	containing	SERCA	were	isolated	from	AAV-293	cells	infected	(for	ATPase	assay)	or	transfected	(FRET	measurement)	with	two-color	SERCA	constructs	as	described	(Clifford	and	Kaplan,	2009).	Cells	were	grown	to	confluency	on	7−10	x	150	mm2	dishes	for	2	days,	washed	twice	with	PBS,	harvested	by	scraping,	and	pelleted	at	4°C	for	10	min	at	1000	×	g.	To	prepare	cell	homogenate,	the	cell	pellets	were	(1)	resuspended	in	cold	homogenizing	solution	(0.5	mM	MgCl2,	10	mM	Tris-HCl	pH	7.5,	EDTA-free	complete	protease	inhibitor	cocktail	(Santa	Cruz	Biotechnology,	Inc.,	Dallas,	TX)),	(2)	disrupted	in	Potter-Elvehjem	homogenizer,	(3)	supplemented	with	equal	volume	of	sucrose	solution	(100	mM	MOPS	pH	7.0,	500	mM	sucrose,	EDTA-free	complete	protease	inhibitor	cocktail),	and	(4)	passed	through	a	27-gauge	needle.	To	prepare	microsomal	membranes,	(1)	cell	homogenates	were	centrifuged	for	10	min	at	1000	×	g	at	4°C,	(2)	the	low-speed	supernatants	were	centrifuged	at	30	min	at	55000	rpm	(Beckman	Coulter	Optima	Ultracentrifuge,	rotor	TLA-110,	~	average	130000	×	g),	(3)	the	high-speed	membrane	
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pellets	were	resuspended	in	a	1:1	mix	of	homogenizing	and	sucrose	solutions,	and	(4)	the	membrane	suspensions	were	passed	through	a	27-gauge	needle.	The	protein	concentration	of	microsomal	membranes	was	determined	with	Pierce	BCA	assay	kit	(ThermoScientific,	Waltham,	MA).	ATPase	assay	was	performed	the	same	day;	otherwise,	microsomal	membranes	were	aliquoted,	snap-frozen	in	liquid	nitrogen,	and	stored	at	−80°C.	Light	SR	(LSR)	microsomal	samples	enriched	in	SERCA	(approximately	90%	of	proteins	in	the	LSR	is	SERCA)	were	a	gift	from	Dr.	David	D.	Thomas	at	the	University	of	Minnesota.		
Ca2+-ATPase	Functional	Measurements	Two-color	SERCA	enzymatic	activity	was	measured	and	quantified	in	microsomes	by	spectrophotometric	measurement	of	the	rate	of	NADH	consumption	as	a	function	of	Ca	concentration	in	an	enzyme-coupled	activity	assay	in	a	96-well	plate	(Lockamy	et	al.,	2011;	Reddy	et	al.,	2003).	Figure	7	shows	the	schematic	of	the	enzyme-linked	ATPase	assay.	The	
	
Figure	7.	Schematic	representation	of	the	enzyme-linked	ATPase	assay.	SERCA	specific	ATPase	activity	measured	as	a	function	of	the	rate	at	which	NADH	absorbance	at	340	nm	is	decreased.	SERCA	consumes	ATP	generated	in	pyruvate	production	reaction	by	phosphoenolpyruvate	and	pyruvate	kinase.	Pyruvate	is	used	in	lactic	acid	generation	by	lactate	dehydrogenase,	which	oxidizes	NADH	in	the	process.	NADH	depletion	serves	as	an	indirect	measurement	of	SERCA	ATPase	activity.		
ADP NADHATP NAD+
PEP Pyruvate Lactic Acid
Pyruvate Kinase Lactate Dehydrogenase
SERCA
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time-dependent	change	of	NADH	absorbance	was	measured	at	25°C	in	a	PHERAstar	FSX	microplate	reader	(BMG	Labtech,	Cary,	NC)	at	340	nm.	Each	well	contained	3−4	μg	of	microsomal	membranes,	50	mM	MOPS	at	pH	7.0,	0.1	M	KCl,	5.0	mM	MgCl2,	1.0	mM	EGTA,	2.5	mM	ATP,	0.2	mM	NADH,	5	IU	of	pyruvate	kinase,	5	IU	of	lactate	dehydrogenase,	and	0.7	μg	of	Ca2+	ionophore	(A23187)	(chemicals	were	obtained	from	SigmaAldrich,	St.	Louis,	MO).	Free	Ca2+	concentrations	were	calculated	using	Ca2+/Mg2+/ATP/EGTA	Calculator	from	Theo	Schoenmakers’	Chelator	(Schoenmakers	et	al.,	1992).	Data	were	fitted	using	a	Hill	function:	V=Vmax/[1+10−n(pKCa−pCa)],	where	V	is	the	initial	ATPase	rate,	n	is	the	Hill	coefficient,	and	KCa	is	the	apparent	Ca2+	dissociation	constant	and	Vmax	was	obtained	from	the	fit	of	the	Hill	equation	at	saturated	Ca2+	concentrations.		
Western	Blotting	The	protein	concentrations	were	determined	with	a	bicinchoninic	acid	protein	assay	(BCA)	(ThermoScientific,	Waltham,	MA)	according	to	the	manufacture’s	instructions.	Microsomal	membrane	preparations	were	diluted	in	2-fold	SDS	buffer	(BioRad,	Hercules,	CA),	heated	at	55°C	for	10	min	and	loaded	on	a	4−15%	polyacrylamide	precast	gel	(BioRad,	Hercules,	CA).	The	proteins	were	separated	at	110V	for	1	hr	and	transferred	to	polyvinylidene	difluoride	membrane	at	4°C	for	one	hr	at	100	V.	The	membrane	was	blocked	in	Odyssey	PBS	blocking	buffer	(LI-COR,	Lincoln,	NE)	for	one	hr	at	room	temperature	followed	by	incubation	with	primary	antibody:	mouse	anti-SERCA2	(IID8,	1:1,000;	Abcam,	Cambridge,	UK)	or	mouse	anti-PLB	(2D12,	1:1,000;	Abcam,	Cambridge,	UK)	overnight	at	4°C.	Blots	were	incubated	with	anti-mouse	secondary	antibodies	IRDye680RD	or	IRDye800CW	(1:10,000,	LI-COR,	Lincoln,	NE)	for	1hr	at	room	temperature.	The	blots	were	imaged	using	LI-COR	Odyssey	
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biomolecular	imager	and	intensities	were	analyzed	with	Image	Studio	Lite	Version	5.2	software	(LI-COR,	Lincoln,	NE).		
Ligand-induced	Stabilization	of	SERCA	Biochemical	Intermediates	To	fix	SERCA	in	substrate-stabilized	biochemical	intermediates,	various	substrate	solutions	were	prepared	by	addition	of	corresponding	substrates	to	the	calcium-free	base	solution	which	included	KCl	100	mM,	Imidazole	10	mM,	MgCl2	5	mM,	EGTA	2	mM,	pH	7.0	(KOH).	The	following	ligands	were	used	to	prepare	specific	solutions	corresponding	to	SERCA	biochemical	state	(in	parenthesis):	100μM	thapsigargin	(E2-TG),	3mM	ATP	(E1-ATP),	2.1	mM	CaCl2	(E1-2Ca)	with	free	[Ca2+]i=100	μM);	2.1	mM	CaCl2	and	3	mM	ATP	(E1-2Ca+ATP);	2.1	mM	CaCl2	and	3	mM	ATP	non-hydrolysable	analog	AMP-PCP	(E1-2Ca+AMMPPCP);	2.1	mM	CaCl2,	3	mM	ADP,	3mM	KF	and	50	μM	AlCl3	(E1P-2Ca+AlF−+ADP);	0.1	mM	orthovanadate	(E2-Vi);	50	μM	AlCl3	and	3	mM	KF	(E2-AlF4−).	Chemicals	were	obtained	from	SigmaAldrich,	St.	Louis,	MO.		To	measure	SERCA	intramolecular	FRET	in	ligand-stabilized	biochemical	intermediates,	1μl	of	membrane	preparations	(7−10	μg	total	protein	concentration)	was	thawed	on	ice	and	mixed	with	9	μl	of	substrate	solutions	and	immediately	imaged	using	fluorescent	microscopy,	as	described	above.		
MRP-1	Functional	Measurements	I	measured	doxorubicin	(DOX)	extrusion	from	GFP-MRP-1	expressing	cells	to	determine	function	of	MRP-1	in	the	presence	of	candidate	modulators.	Transiently	transfected	cells	plated	on	glass-bottom	coverslip	were	pre-incubated	with	10	μM	each	candidate	compound	for	15	min,	and	then	2	μM	DOX	was	added	for	1	hour.	Cells	were	imaged	by	
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confocal	microscopy,	and	the	intensity	of	the	red	fluorescence	was	used	as	an	index	of	DOX	accumulated	in	the	cell	nucleus.	Cells	expressing	MRP-1	were	identified	by	the	presence	of	GFP	fluorescence	and	compared	to	cells	in	the	same	field.		
Statistical	Analysis	Data	are	presented	as	the	mean	±	S.E.M.	of	≥	3	experiments	unless	specified	in	figure	legend.	All	statistical	tests	were	done	using	OriginPro	9.1	(OriginLab	Corporation,	Northampton,	MA).	Student's	t	test	(unpaired	two-tailed)	was	used	to	compare	the	difference	between	two	groups,	one-way	analysis	of	variance	(ANOVA)	was	used	to	compare	the	difference	between	three	or	more	groups,	and	two-way	ANOVA	was	used	to	compare	the	difference	between	different	groups	under	different	treatment	conditions.	ANOVA	was	followed	by	Tukey's	post	hoc	test.	A	probability	(p)	value	of	<0.05	was	considered	significant.			
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CHAPTER	THREE	SERCA	STRUCTURAL	DYNAMICS	DURING	CALCIUM	TRANSPORT	
All-atom	Molecular	Dynamics	Simulations	of	SERCA	Point	Mutants	Previous	MD	simulations	of	SERCA	spontaneous	movements	indicated	that	a	SERCA	headpiece	open-to-closed	transition	was	initiated	by	an	interaction	between	the	A-domain	and	the	Nβ5-β6	loop	of	the	N-domain	via	electrostatic/H-bond	interactions	(Smolin	and	Robia,	2015a).	The	Nβ5-β6	loop	(426-DYNEAKGVYEK-436)	was	predicted	to	help	in	piercing	the	poorly-diffusible	water	layer	and	to	support	a	stable,	ordered	arrangement	of	the	N-	and	A-domains	during	Ca2+	cycling.	When	this	loop	was	mutated	in	silico	to	remove	the	three	negative	charges	(D426A/E429A/E435A,	or	AAA),	SERCA	was	not	able	to	obtain	closed	conformations.	To	further	investigate	the	role	of	Nβ5-β6	loop	in	SERCA	headpiece	dynamics,	I	extended	these	simulations	for	WT-	and	AAA-SERCA	from	40	ns	up	to	100	ns	as	a	more	physiologically	relevant	time	point,	and	performed	additional	simulations	of	SERCA	Nβ5-β6	loop	single-point	mutants.	Fig.	2	shows	the	starting	structure	of	SERCA	used	for	MD	simulations	(PDB	accession	code	1SU4	(Toyoshima	et	al.,	2000)),	highlighting	the	A-,	N-,	P-,	and	TM-domains,	plus	the	Nβ5-β6	loop.	First,	I	examined	SERCA	global	structural	dynamics	to	confirm	that	the	gross	structure	and	motions	of	SERCA	were	not	disrupted	by	the	introduction	of	loop	mutations.	
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I	observed	comparable	domain	RMSD	for	WT-,	AAA-	and	SERCA	point	mutants,	indicative	of	similar	domain	dynamics	(Fig.	8A).	Although	the	N-domain	was	the	most	dynamic,	no	substantial	differences	in	its	motions	were	observed	between	SERCA	starting	structures	(Fig.	8B-C).	SERCA	Cα	atoms	RMSF,	that	present	residue-by-residue	motions,	showed	higher	RMSF	values	for	N-domain	(Fig	8D).	This	observation	also	confirms	that	N-domain	is	the	most	dynamic	for	all	SERCA	structures.	Nevertheless,	all	of	the	SERCA	
	
Figure	8.	RMSD	and	RMSF	of	SERCA	structural	dynamics	calculated	from	MD	
simulations.	
(A)	SERCA	N-	(orange),	A-	(blue),	P-	(grey)	and	TM-	(black)	domains	showed	similar	Cα	RMSD	fluctuations	for	SERCA	WT	and	all	mutants.	(B)	Global	Cα	RMSD	fluctuations	of	the	most	dynamic	SERCA	N-domain	revealed	similar	motions.	(C)	Quantification	of	B.	(D)	Quantification	of	RMSF	of	Cα	atoms	revealed	that	nucleotide-binding	domain	was	the	most	mobile	domain	with	similar	relative	structural	dynamics	for	all	SERCA	structures.	Highly-mobile	cytosolic	regions	and	stable	TM	regions	are	labeled	by	letters	and	arrows	(bottom):	WT-SERCA	(black),	AAA	(red),	D426A	(blue),	E429A	(green),	and	E435A	(magenta).	Data	represent	the	average	of	6	MD	run	productions	for	each	SERCA	construct.	
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structures	had	dynamics	comparable	to	WT	as	shown	in	Fig.	8D	by	overlapping	plots.	Small	RMSF	increases	(like	for	the	A-domain’s	and	TM-helix’s	residues	for	point	mutants	in	Fig.	8D)	was	regarded	as	non-significant	changes	compared	to	RMSF	changes	reported	for	SERCA	different	structures	1SU4,	1WPG,	and	2ZBD	(Smolin	and	Robia,	2015a).	To	inspect	SERCA	dynamics	in	more	detail,	I	calculated	angular	autocorrelation	of	cytoplasmic	domains	for	all	SERCA	structures,	and	compared	the	relative	motions	of	the	cytoplasmic	domains	to	the	starting	orientation.	This	analysis	allowed	sampling	of	domains’	redistribution	in	the	space	and	detected	larger	dynamics	for	N-domain	as	represented	by	larger	angle	values	(Fig.	9A	top	panel).	A-domain	had	the	intermediate	rotational	dynamics	(Fig.	9A	center	panel),	while	P-domain	presented	with	smallest	angular	correlation	values	(Fig.	9A	bottom	panel).	Similar	angular	autocorrelation	values	were	observed	for	the	WT	and	mutant	SERCA	structures	for	all	of	the	domains	(Fig.	9A),	indicating	the	preservation	of	the	cytosolic	domains’	dynamics	upon	mutations.	Fig.	9B	shows	representative	covariance	matrices	for	WT-SERCA	(upper	left)	and	AAA-SERCA	(lower	right)	as	a	residue-by-residue	correlation	of	transporter	motions.	If	residues	move	in	the	same	direction	(follow	each	other),	they	are	considered	to	be	positively	correlated	and	presented	in	red	color,	while	negative	correlations	represent	motions	in	the	opposing	directions	(toward	or	away	from	each	other)	and	colored	in	blue.	I	observed	a	positive	self-correlation	within	N-domain	(residues	369-603)	for	all	structures	(Fig.	9B,	red).	This	observation	was	expected,	as	generally	the	domain	residues	move	in	the	same	direction	as	a	part	of	the	whole	domain.	On	the	contrary,	the	correlation	between	the	N-	and	A-domains	was	negative	for	WT-SERCA	due	to	independent	motions	of	these	domains	in	opposing	directions.	Interestingly,	motions	of	AAA-SERCA	A-	and	N-domains	
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had	null	correlation	(Fig.	9B,	white),	indicative	of	reduction	of	dependent	motions	of	these	domains.	This	observation	that	AAA-SERCA	has	reduced	correlation	between	A-	and	N-domains	motions	signify	that	Nβ5-β6	loop	mutations	decrease	domain-to-domain	dependent	dynamics.	Besides	that	element,	the	rest	of	the	WT-and	AAA-SERCA	structural	motions	were	similar.	Even	though	the	primary	SERCA	structural	dynamics	were	conserved,	the	quantitative	analysis	of	MD	trajectories	proved	a	very	specific	structural	effect	of	Nβ5-β6	
	
Figure	9.	The	relative	motions	of	SERCA	domains	are	preserved	upon	Nβ5-β6	loop	
mutations.	
(A)	Angular	autocorrelation	of	the	cytoplasmic	domains	during	100	ns	production	runs.	Data	represent	the	average	of	6	MD	runs.		(B)	Representative	covariance	matrices	Cα	atoms	for	WT-SERCA	(upper	left)	and	AAA-SERCA	(lower	right).	Covariance	analysis	of	WT-SERCA	residue	dynamics	as	measured	from	Cα	revealed	positively	(red)	and	negatively	(blue)	correlated	motions.	For	AAA-SERCA,	covariance	analysis	indicated	similar	global	dynamics	yet	reduced	anti-correlated	A-domain	motions	compared	to	WT-SERCA.		
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loop	mutations	on	the	separation	of	the	SERCA	headpiece	domains.	In	particular,	substitution	of	three	negative	Nβ5-β6	loop	residues	to	alanine	decreased	the	N-	and	A-domains	contacts	(Fig.	10A)	and	increased	minimal	distance	(Fig	10C).	Figures	10B	and	10D	show	distribution	of	sampled	trajectories.	When	means	of	six	trajectories	for	each	of	the	number	of	contacts	and	distance	between	A-	and	N-domains	were	plotted	against	each	other,	the	domains	minimal	distance	and	the	number	of	contacts	showed	a	negative	correlation	(r	=	−1)	for	WT-SERCA	structure	(Fig.	10E,	black).	This	observation	means	that	a	short	distance	between	domains	was	maintained	by	a	large	number	of	contacts.	On	the	contrary,	AAA-SERCA	structure	showed	an	opposing	negative	correlation	presented	by	a	
	
Figure	10.	SERCA	loop	mutations	increase	A-	and	N-domains	separation	in	silico.	WT-SERCA	(black),	AAA	(red),	D426A	(blue),	E429A	(green),	E435A	(pink).	Data	represent	average	of	6	MD	run	productions.	(A)	Number	of	contacts	between	the	N-	and	A-domains	during	MD	trajectories.	(B)	Distribution	of	data	in	(A).	(C)	AAA-SERCA	shows	an	increase	in	N–A-domains	separation	distance	compared	to	WT-SERCA.	(D)	Distribution	of	data	in	(C).	
(E)	Negative	correlation	of	separation	distance	on	domain–domain	contacts,	from	results	in	(A)	and	(C).	Pearson	correlation	r	=	−0.99,	p=0.002,	*	p=0.037	for	number	of	contacts.	
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large	domain	separation	and	significantly	fewer	contacts	(Fig.	10E,	red).	The	single-point	mutants	were	well-tolerated	and	resulted	in	intermediate	phenotypes	between	AAA	and	WT	values	for	domain-domain	separations	(Fig.	10E.	blue,	green,	and	magenta).	This	result	supports	the	importance	of	Asp426,	Glu429	and	Glu435	residues	in	SERCA	structural	assembly.	Interestingly,	single	point	mutant	Glu429A	had	shown	number	of	contacts	between	A-	and	N-domains	comparable	to	WT,	but	increased	domains	separation	(Fig.	10E,	green).	This	observation	suggests	that	one	or	both	of	the	remaining	residues,	Asp426	and/or	Glu435,	are	redistributed	in	space	to	form	a	large	number	of	contacts,	while	keeping	domains	apart.	Considering	the	fact	that	Glu429	is	at	the	very	tip	of	the	SERCA	Nβ5-β6	loop	(Fig.	1),	it	is	likely	that	residue	Glu429	is	the	first	residue	of	the	N-domain	to	interact	with	the	A-domain,	and	this	residue	may	be	defining	for	the	decrease	in	the	distance	between	cytosolic	domains.	In	conclusion,	my	in	silico	analysis	of	SERCA	spontaneous	motions	detected	preserved	gross	dynamics	of	SERCA	mutants	compared	to	WT	(Fig.	8-9),	suggesting	maintenance	of	structural	assembly	upon	introduction	of	mutations.	On	the	other	hand,	SERCA	A-	and	N-domains	separation	was	significantly	increased	by	removal	of	the	Nβ5-β6	loop	negative	charges	(mutation	of	Asp426,	Glu429	and	Glu435	to	Alanine),	which	was	aimed	to	prevention	of	the	salt	bridges/H-bonds	between	the	Nβ5-β6	loop	and	the	A-domain	basic/positive	residues.	Thus,	my	all-atoms	MD	simulations	implicated	the	Nβ5-β6	loop	as	a	discrete	structure	that	regulates	SERCA	headpiece	closure	(Fig.	10).	Next,	I	set	up	to	determine	what	effect	this	structural	deficit	in	the	cytosolic	headpiece	closure	has	on	the	transporter	structural	dynamics.	
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Comparison	between	Structural	Dynamics	of	WT-	and	AAA-SERCA	To	examine	in	detail	SERCA	motions	and	the	effect	of	Nβ5-β6	loop	mutations	on	SERCA	structural	dynamics,	I	performed	a	principal	component	analysis	(PCA)	of	the	ensembles	of	WT-and	AAA-SERCA	trajectories.	PCA	analysis	determines	how	each	trajectory	sampled	the	major	motions	compared	to	the	starting	structure.	Here	I	present	two	most	dominant	motions,	PC1	(48%	of	all	motions)	and	PC2	(15%	of	all	motions).	The	principal	motion	PC1	was	SERCA	headpiece	opening/closing,	while	the	second	major	motion	PC2	was	twisting	of	the	cytoplasmic	domains.	Fig.	11A	summarizes	positive	and	negative	motions	of	the	A-	and	N-domains	along	each	component.	To	visualize	the	distribution	of	PC1	and	2,	I	plotted	them	against	each	other	for	each	structure	sampled	every	10	ns	in	all	of	the	trajectories	(Fig.	11B).	As	a	result,	6	different	WT-SERCA	trajectories	sampled	values	ranging	from	-36	Å	(closed)	to	+25	Å	(open)	(Fig.	11B9G,	black),	while	6	different	AAA-SERCA	trajectories	(Fig.	11B,	red)	showed	more	population	of	open	structures	at	the	expense	of	closed	
	
Figure	11.	First	and	second	principal	components	of	SERCA	structural	dynamics.	
(A)	Black	arrows	represent	first	and	second	principal	components	of	SERCA	domain	motions.	Plus	and	minus	signs	correspond	to	coordinates	labels	in	(B).	(B)	Relative	sampling	of	the	top	two	principal	components	by	WT-SERCA	(black)	and	AAA-SERCA	(red)	trajectories.	Each	point	represents	a	conformation	extracted	from	the	MD	trajectories	at	an	interval	of	0.1	ns.	For	comparison,	grey	dots	represent	X-ray	structures	with	open	(1SU4),	closed	(1VFP),	and	intermediate	(3W5B)	headpiece	conformations.	
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conformations	(minimum	of	-30	Å,	maximum	of	+31	Å).	This	result	is	consistent	with	the	observed	increased	separation	between	N-	and	A-domains	upon	Nβ5-β6	loop	mutations	(Fig.	10).	Along	the	second	dominant	motion	PC2	axis	(twisting	of	the	cytoplasmic	domains),	WT	showed	several	trajectories	ranging	from	-27	to	+23	Å,	which	was	56%	greater	than	the	range	of	AAA-SERCA	along	PC2	(from	-14	to	+18	Å)	(Fig.	11B).	Individual	trajectories	for	WT-	and	AAA-SERCA	are	highlighted	in	different	colors	in	Fig.	12B	and	C	respectively	and	show	a	wider	distribution	of	individual	WT	trajectories.	The	representative	structures	were	extracted	at	the	representative	point	of	trajectory	in	each	of	
	
Figure	12.	Principal	component	analysis	for	WT-	and	AAA-SERCA.	
(A)	Sampling	of	the	first	and	second	principal	components	for	six	WT-SERCA	(black)	trajectories	and	six	AAA-SERCA	(red)	trajectories.	Each	graphical	point	(black	and	red)	represents	a	structure	extracted	from	trajectories	at	a	time	interval	of	0.1	ns	over	the	time	course	of	100	ns	simulations.	Turquoise	dots	indicate	selected	structures	(shown	in	inset)	from	each	structural	quadrant.	The	arrows	represent	specific	motions	of	the	N-domain	(yellow)	and	A-domain	(blue).	(B,	C)	Individual	PC	analysis	for	WT-SERCA	(B)	and	AAA-SERCA	(C),	where	the	six	different	colors	represent	each	of	six	individual	MD	simulations.		
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the	quadrants	as	in	figure	12A	(green	dots)	and	represent	the	conformational	extremes.	Overall,	PCA	indicates	that	the	AAA-loop	mutations	decrease	the	range	of	motions	of	SERCA	cytosolic	domains	along	the	first	two	principal	components	and	shifts	the	population	of	structures	toward	a	more	open	ensemble.		 Additionally,	I	looked	into	SERCA	headpiece	ensemble	in	more	detail	by	examining	separation	of	cytosolic	domains	(Fig.	13).	Minimal	distance	between	A−N-domains	was	increasing	over	time,	while	distances	between	P-	and	A-domains	or	P-and	N-domains	were	not	changed	(Fig.	13A).	This	result	suggests	that	while	A-	and	N-domains	are	separate	from	each	other,	it	is	the	P-domain	that	retains	contacts	with	both	A-	and	N-domains	constantly.	Separation	of	A−N	domains	was	expected	due	to	high	RMSD	of	these	domains,	especially	N-domain	(Fig.	8A).	Consistent	with	the	preceding	observation	(Fig	13A),	numbers	of	contacts	between	P−N	or	P−A-domains	were	the	highest,	and	I	observed	their	matching	changes	along	the	trajectories	(Fig.	13B).	This	result	indicates	that	the	P-domain	may	serve	as	an	anchoring	structure	for	cytosolic	domains,	while	A-	and	N-domains	separate	from	each	other	in	distance	(Fig.	13A)	but	still	retain	a	minimal	number	of	contacts	(Fig.	13B).		This	deduction	may	be	an	alternative	hypothesis	to	my	earlier	observation	that	residue	Glu429	is	critical	for	A-	and	N-domains	minimal	distance	decrease	(Fig.	10E).		Analysis	of	distance	between	each	domain’s	center	of	mass	shows	redistribution	of	domains	in	space.	Specifically,	I	observed	the	same	pattern	for	A−N	and	P−N-domains	separation,	while	the	P−A-domains	position	remained	unchanged,	which	suggests	that	the	P-domain	is	moving	together	with	the	A-domain,	and	they	both	follow	more	dynamic	N-
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domain	motions.	Overall,	this	analysis	gives	more	insight	on	SERCA	cytoplasmic	dynamics:	the	P-domain	serves	as	an	anchoring	structure	for	A-	and	N-domains,	and	dynamic	motions	of	N-domain	are	principal	for	structural	changes	in	remaining	cytosolic	domains.	Overall,	my	MD	simulations	detected	a	decrease	in	SERCA	structural	dynamics	for	the	Nβ5-β6	loop	triple	mutation.	Specifically,	PC1	analysis	sampled	more	open	conformations	in	the	expense	of	the	closed	ensembles,	while	PC2	had	overall	decreased	distribution	(Fig.	11-12).	I	believe	that	the	direct	consequence	of	the	AAA-SERCA	reduced	dynamics	is	the	observed	deficit	in	AAA-SERCA	headpiece	closure	(Fig.	10)	and	the	Nβ5-β6	loop	serves	as	SERCA	structural	determinant.	Additionally,	analysis	of	SERCA	cytosolic	domains’	spatial	distribution	suggested	that	P-domain	serves	as	a	coordinating	domain	between	highly	dynamic	A−N-domains	(Fig.	13).	These	insights	into	SERCA	structural	dynamics	and	identification	of	the	Nβ5-β6	loop	as	SERCA	structural	determinant	are	important	for	understanding	transporter	function,	which	will	be	examined	next.				
	
Figure	13.	SERCA	headpiece	domains	structural	dynamics.		Separation	between	domains:	black	traces	for	A−N	and	P−N	domains,	while	P−A	is	in	grey.	
(A)	Minimal	distance	between	A−N-domains	is	increased	compared	to	P−A	and	P−N-domains.		(B)		Number	of	contacts	between	the	domains	during	MD	trajectories	are	very	stable.	(C)	Distance	between	A−N	and	P−N-domains	change	simultaneously,	while	distance	between	P−A-domains	does	not	change.	Data	present	average	of	6	MD	run	productions.		
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The	Role	of	the	Nβ5-β6	Loop	in	SERCA	ATPase	Activity	To	determine	the	possible	functional	significance	of	the	Nβ5-β6	loop,	I	prepared	microsomal	vesicles	from	AAV-293	cells	expressing	2-color	WT-SERCA	or	AAA-SERCA	and	measured	Ca2+-dependent	ATPase	activity.	Fig.	14A	shows	a	representative	example	of	n	=	4	independent	experiments	and	demonstrates	that	the	maximal	activity	of	AAA-SERCA	was	decreased.	Quantification	of	all	4	experiments	yielded	a	63±5%	difference	in	ATPase	maximal	rate	between	WT	and	AAA	transporter	(p	=	0.015)	(Fig.	14C).	This	result	is	consistent	with	the	previous	finding	by	Inesi	lab	that	mutation	of	Asp426	to	Ala	decreased	SERCA	ATPase	activity	by	61%	(Inesi	et	al.,	1988).	Based	on	KCa	values	of	7.2±0.2	(WT)	and	7.1±0.3	(AAA),	the	apparent	Ca2+	affinity	of	AAA-SERCA	was	not	significantly	different	from	
	
Figure	14.	N-domain	β5-β6	loop	triple	mutation	decreases	SERCA	function.	
(A)	Ca2+-ATPase	assay	of	microsomes	from	cells	expressing	WT-	or	AAA-SERCA.		(B)		Ca2+	sensitivity	of	ATPase	activity	(KCa),	as	in	(A).	(C)	Maximal	Ca2+-dependent	ATPase	rate	(Vmax),	as	in	(A).	*	p<0.015.	(D)	Western	blotting	confirms	SERCA	viral	expression	in	microsomes	used	for	ATPase	assay.	(E)	Ca2+-ATPase	assay	of	preparations	of	control	light	sarcoplasmic	reticulum	(LSR,	blue)	or	microsomes	from	cells	expressing	GFP	(pink).		
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that	of	WT-SERCA	(p	=	0.61)	(Fig.	14B).	I	detected	2-color	SERCA	viral	expression	in	microsomal	preparations	by	the	Western	blotting	analysis	(Fig	14D).	Since	I	observed	a	band	for	endogenous	SERCA,	I	confirmed	that	endogenous	SERCA	activity	was	not	significant	and	thus	negligible	by	measuring	Ca2+-dependent	ATPase	activity	in	microsomes	from	AAV-293	cells	transduced	with	control	GFP	vector	(Fig.	14E,	pink).	Overall,	the	data	indicate	that	SERCA	ATPase	activity	is	decreased	by	mutations	of	negatively	charged	loop	residues;	nevertheless,	the	mutated	transporter	is	still	able	to	perform	a	complete	enzymatic	cycle.	This	functional	ATPase	assay	confirmed	the	significance	of	the	Nβ5-β6	loop	in	SERCA	ATPase	activity	in	vitro.	To	further	investigate	SERCA	structural	intermediates	during	the	ATPase	enzymatic	cycle,	I	performed	in	vitro	structural	measurements	of	SERCA	transitional	states	in	the	substrate-stabilized	environment.		
Quantification	of	FRET	of	2-color	SERCA	Expressed	in	Microsomal	Membranes	It	has	been	previously	demonstrated	that	2-color	SERCA	FRET	is	increased	with	increasing	Ca2+	(Hou	et	al.,	2012).	I	performed	2-color	FRET	measurements	in	microsomal	membranes	prepared	from	AAV-293	cells	expressing	WT-SERCA	with	controlled	Ca2+	concentrations.	Fig.	15A	shows	that	increasing	Ca2+	resulted	in	a	progressive	shift	toward	a	higher	FRET	values.	The	WT	2-color	SERCA	FRET	response	to	Ca2+	had	a	KCa	of	1.25±0.22	μM,	which	was	different	from	0.1	μM	value	obtained	for	the	ATPase	assay.	I	attribute	this	nearly	12-fold	difference	in	KCa	to	the	different	composition	of	buffers	for	different	assays.	Even	though	I	calculated	free	Ca2+	concentration	using	the	Ca2+/Mg2+/ATP/EGTA	Calculator	from	Theo	Schoenmakers’	Chelator	(Schoenmakers	et	al.,	1992),	it	is	not	uncommon	to	observe	a	10-fold	discrepancy	in	KCa	between	published	reports	(Hou	et	al.,	2012;	Hughes	
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and	Middleton,	2014;	Sahoo	et	al.,	2015;	Sahoo	et	al.,	2013;	Shaikh	et	al.,	2016).	The	observed	Hill	coefficient	of	0.76	suggests	the	apparent	lack	of	cooperativity,	which	is	consistent	with	the	proposition	that	the	structural	transition	from	low-	to	high-affinity	states	is	complete	after	binding	of	the	first	Ca2+	to	the	transport	site	I	(Cantilina	et	al.,	1993;	Chen	et	al.,	2006;	Henderson	et	al.,	1994a;	Henderson	et	al.,	1994b;	Inesi	et	al.,	1988;	
	
Figure	15.	SERCA	structural	dynamics	measured	by	FRET	in	microsomes.	
(A)	WT	2-color	SERCA	showed	an	increase	in	FRET	with	Ca2+	increase.	(B)	FRET	of	2-color	SERCA	stabilized	in	key	enzymatic	states.	(C)	FRET	values	for	SERCA	E1	and	E2	conformers.	Yellow	highlights	E1	states,	while	green	highlights	E2	states.	Data	represent	at	least	5	independent	experiments.	(D)	Real-time	measurements	of	SERCA	FRET	upon	addition	of	Ca2+	with	ATP	solution	shows	SERCA	FRET	decrease	and	eventually	gradual	recovery.	Red	line	represents	exponential	FRET	recovery	by	Hill1	fit.	Data	represent	12	cells	from	2	independent	experiments.		
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Trieber	et	al.,	2009).	Overall,	the	data	are	compatible	with	my	previous	observation	that	upon	increase	in	Ca2+	concentration	with	ionophore	treatment,	2-color	SERCA	exhibit	a	high	FRET	compact	state	(Hou	et	al.,	2012).		 To	investigate	SERCA	intermediates	in	the	ATPase	enzymatic	cycle,	I	stabilized	Ca2+	transporter	conformers	with	biochemical	substrates	(MacLennan	et	al.,	1997).	I	observed	low	FRET	in	the	presence	of	ligands	for	the	E2	(low	Ca2+	affinity)	intermediates	and	high	FRET	in	the	presence	of	ligands	for	E1	(high	Ca2+	affinity)	states.	Specifically,	E2-H+	(protonated	SERCA)	showed	9.9±0.6%	FRET,	and	E2-TG,	which	locks	SERCA	in	the	Ca2+-free	E2	state	(Sagara	et	al.,	1992a;	Sagara	et	al.,	1992b)	resulted	in	10.3±0.5%	FRET.	E2P,	
	
Figure	16.	Modified	Post-Albers	reaction	cycle.	Blue	boxes	enclose	states	with	similar	intramolecular	FRET	efficiencies.	E1	state	are	yellow	and	E2	states	are	green.	Major	transitional	states	are	shown	in	black,	while	grey	represent	non-physiological	state	(TG-bound.	E2-TG)	and	alternative	pathway	(Ca2+	binding	prior	to	ATP	binding,	E1-2Ca).	(a)	ATP	binding	induces	conformational	changes	that	facilitate	Ca2+	binding	at	the	cytosolic	membrane	side.	(b)		P-domain	phosphorylation	and	ATP	hydrolysis.	(c)	Ca2+	release	at	the	other	side	of	membrane.	(d)	Dephosphorylation.	(e)	ATP	binding.	Steps	(c-d)	are	predicted	to	be	the	slowest	steps.			
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phosphoenzyme	intermediates,	(E2-AlF4–	and	E2-Vi)	showed	even	lower	~8%	FRET.	In	contrast,	I	observed	higher	FRET	(above	15%)	for	microsomes	in	E1	states:	E1-ATP,	E1-2Ca,	E1-2Ca+ATP,	2Ca+AMP-PCP,	and	E1-2Ca+ADP+AlF4–.	The	FRET	values	for	each	state	are	summarized	in	Table	1	(Fig.	15C).	Overall,	these	data	indicate	that	SERCA	E1	conformers	are	more	compact,	while	E2	conformers	are	more	open	headpiece	conformations.			 SERCA	progression	through	the	Ca2+	transport	cycle	is	powered	by	ATP	hydrolysis.	In	my	FRET	detection	of	biochemically-stabilized	conformers	in	SERCA-rich	microsomal	membranes	I	used	3	mM	ATP,	which	is	on	the	higher	side	of	the	physiological	ATP	concentration.	Nevertheless,	I	wanted	to	confirm	that	ATP	remains	non-depleted	and	I	detect	true	FRET	values	for	the	E1-ATP	and	E1-2Ca+ATP	states.	As	an	alternative	to	ATP,	I	used	non-hydrolysable	ATP	analog-	AMP-PCP,	which	showed	FRET	similar	to	E1-ATP	state	(~15%)	(Fig.	15B).	Additionally,	I	monitored	FRET	changes	after	ATP	addition	in	real-time	and	observed	an	initial	decrease	with	following	recovery	in	2-color	SERCA	FRET	(Fig.	15D).	I	interpreted	this	result	as	a	demonstration	of	several	cycling	SERCA	phases:	entering	in	active	cycling	(decrease),	build-up	of	luminal	Ca2+	(increase),	and	steady-state	cycling	with	inhibition	by	high	luminal	Ca2+	or	build-up	of	ADP	(plateau)	(Inesi	and	de	Meis,	1989).	Based	on	these	findings,	it	is	most	likely	that	in	Fig.	15B	for	E1-2Ca+ATP	state	I	was	measuring	a	plateau	steady-state	cycling	phase	when	SERCA	is	continuously	cycling	following	addition	of	activated	solution	(2Ca+ATP)	as	in	Fig.	15,	and	while	ATP	is	not	depleted,	but	rather	significant	ADP	build-up	results	in	SERCA	accumulation	in	this	compact	conformation.	
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	 SERCA	FRET	measurements	in	a	substrates-stabilized	environment	allowed	identification	of	SERCA	headpiece	structural	conformers	for	several	intermediate	states	during	Ca2+	transport	(Fig.	15).	As	a	result,	in	Fig.	16	I	present	a	Post-Alberts	reaction	cycle	supplemented	with	my	data.	I	highlighted	states	with	similar	intramolecular	FRET	efficiencies	in	blue	boxes:	E1	states	(yellow)	have	high	FRET	(~15%),	while	E2	states	(green)	have	predominantly	low	FRET	(~8-10%).	My	data	demonstrates	compact	SERCA	E1	conformers,	while	E2	conformers	have	more	open	headpiece	conformation	and	indicate	a	shift	in	SERCA	conformers	depending	on	ligand	presence	during	specific	cycle	steps.	To	provide	complementary	details	for	SERCA	structural	dynamics	in	physiological	conditions,	I	next	detected	FRET	responses	to	regulated	Ca2+	levels	in	live	cells.			
SERCA	Structural	Dynamics	in	AAV-293	Cells		To	determine	if	SERCA	headpiece	structural	differences	observed	in	MD	simulations	and	in	
vitro	were	present	in	the	cells,	I	used	widefield	microscopy	and	acceptor-sensitized	FRET	to	measure	SERCA	headpiece	dynamics	in	AAV-293	cells	in	response	to	Ca2+	elevations.	The	average	basal	FRET	for	2-color	SERCA	was	significantly	lower	for	AAA-	and	all	point	mutant	SERCA	structures	compared	to	WT-SERCA	(Fig.	17A),	which	is	indicative	of	a	more	open	headpiece	conformation	upon	N5β-6β	loop	mutations	and	supports	my	MD	calculations	(Fig.	10).	It	is	remarkable	that	single	point	mutants	D426A,	E429A,	and	E435A	showed	decreased	basal	FRET	intermediate	between	WT-	and	AAA-SERCA,	which	is	consistent	with	intermediary	opened	headpiece	phenotype	I	observed	for	these	mutants	in	MD	simulations	(Fig10E).	Thus,	2-color	SERCA	intramolecular	FRET	measurements	in	cells	show	the	same	specific	structural	effect	of	Nβ5-β6	loop	mutations	on	separation	of	the	SERCA	headpiece	domains	as	in	my	MD	data.	
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Our	lab	had	previously	shown	that	2-color	SERCA	FRET	is	markedly	decreased	with	binding	to	TG	(Hou	et	al.,	2012).	In	accordance	with	this	result,	the	average	FRET	observed	for	WT-,	AAA-SERCA	and	all	point	mutants	decreased	momentarily	with	addition	of	50	μM	of	TG	(Fig.	17B).	This	decrease	in	average	FRET	indicates	that	TG	binding	at	TM-domain	induced	structural	changes	in	SERCA	cytosolic	headpiece.	Thus,	I	believe	the	protein	structure	is	intact	and	preserved	after	loop	mutation.	Notably,	addition	of	DMSO	vehicle	did	not	result	in	FRET	change	(Fig	17B,	navy).	
	
Figure	17.	SERCA	headpiece	structural	dynamics	measured	by	FRET	in	AAV-293	cells.	
(A)Basal	FRET	of	live	cells	expressing	2-color	SERCA,	*	p≤0.005.	(B)	TG	addition	reduced	FRET	for	WT	and	all	mutants,	but	vehicle	control	(Ctrl,	dark	blue)	had	a	minimal	effect.	(C)	Addition	of	the	Ca	ionophore	ionomycin	(Iono)	resulted	in	a	biphasic	FRET	response	for	WT	and	single-point	mutants,	as	detected	using	epifluorescence	microscopy.	AAA-SERCA	(red)	showed	only	the	first	phase:	a	decrease	in	FRET.	Data	represent	6-25	cells	for	each	condition.	(D)	Tau	determined	for	phase	2	FRET	recovery	for	data	presented	in	(C),	while	for	AAA-SERCA	lacking	phase	2,	tau	was	not	determined	(n/d).				
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	Application	of	the	Ca2+	ionophore	ionomycin	(Iono)	allowed	influx	of	Ca2+	into	the	cells	expressing	2-color	WT-SERCA	and	resulted	at	first	in	the	immediate	FRET	decrease	(phase	1	in	Fig.	17C,	black)	and	secondly,	in	the	slow	FRET	recovery	to	around	the	starting	FRET	value	(phase	2	in	Fig.	17C,	black).	This	observation	indicates	that	rapid	Ca2+	increase	allows	reorganization	of	SERCA	population	into	a	very	open	conformation,	followed	by	emerging	of	closed	SERCA	conformers	until	reaching	an	equilibrium	of	mixed	SERCA	ensembles	within	a	few	minutes.	All	point	mutants	behaved	similar	to	the	WT-SERCA	population	in	response	to	Iono	(Fig17C,	blue,	green	and	pink)	with	similar	kinetics	of	phase	2	FRET	recovery	(Fig.17D).	In	contrast,	AAA-SERCA	only	exhibited	phase	1	FRET	change	and	was	lacking	recovery	phase	2	(Fig17C,	red).	This	result	indicates	that	the	mutation	of	just	one	of	the	negative	residues	of	N5β-6β	loop	is	not	enough	to	abolish	SERCA	headpiece	closure,	while	removal	of	all	three	negative	H-bonding	residues	from	the	N5β-6β	loop	has	a	detrimental	effect	on	SERCA	obtaining	compact	state.	Since	AAA-SERCA	responded	normally	to	TG,	I	believe	that	the	deficit	in	phase	2	of	FRET	change	in	response	to	Ca2+	influx	was	not	due	to	a	global	structural	defect,	but	instead	due	to	lack	of	H-bonding	N5β-6β	loop	residues	that	are	regulate	SERCA	headpiece	closure.	One	of	the	future	directions	for	this	study	is	the	detection	of	FRET	during	real-time	structural	changes	that	SERCA	undergoes	with	addition	of	Ca2+	(or	other	substrates)	in	a	fast-flow	set	up	(Schaaf	et	al.,	2017).	These	measurements	will	allow	the	detection	of	SERCA	intermediate	states	in	real-time	with	the	variety	of	substrates	and	will	significantly	enhance	the	scientific	understanding	of	SERCA	structural	dynamics	during	Ca2+	transport.	Overall,	the	in-cells	FRET	data	(Fig.	17)	are	compatible	with	the	MD	simulation	analysis	that	detected	a	significant	defect	in	SERCA	headpiece	closure	for	AAA-SERCA,	
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while	the	point	mutants	exhibited	intermediate	between	WT	and	AAA,	or	similar	to	WT-SERCA	phenotype	(Fig.	10).	In	discussion	chapter	I	will	further	elaborate	on	the	observed	SERCA	phase	1	and	2	FRET	changes	in	response	to	sustained	Ca2+	influx.	To	advance	scientific	understanding	of	structural	rearrangement	that	SERCA	has	to	undergo	during	Ca2+	cycling,	I	simultaneously	monitored	real-time	changes	in	SERCA	intramolecular	FRET	and	spontaneous	Ca2+	oscillations	in	the	cytosol	or	ER	in	live	cells.		
SERCA	Conformational	Changes	in	Response	to	Intracellular	Ca2+	Dynamics	To	monitor	simultaneous	real-time	changes	in	SERCA	intramolecular	FRET	and	spontaneous	Ca2+	fluctuations,	I	utilized	the	muscle-like	system	as	described	previously	(Bovo	et	al.,	2016).	Briefly,	I	reconstituted	elements	of	muscle	cell	Ca2+	handling	in	AAV-293	cells	by	co-expression	of	GFP-RyR	and	2CS.	Ca2+	was	monitored	in	the	cytosol	with	X-rhod-1	Ca2+	indicator	or	in	the	ER	with	low-affinity	Ca2+	sensor	R-CEPIA1er	by	confocal	microscopy.	SERCA	conformational	changes	were	detected	as	anti-correlated	changes	in	Cer	and	YFP	fluorescence	(Fig.	18A)	and	intramolecular	FRET	was	quantified	as	the	YFP/Cer	fluorescence	ratio	(Fig.	18B).	In	preceding	experiments	I	observed	high	intramolecular	FRET	measured	in	microsomal	membranes	in	the	presence	of	high	Ca2+	and	for	all	E2-2Ca	states	(Fig.	15A-B),	as	well	as	accumulation	of	SERCA	in	high	FRET	state	after	Iono	treatment	(Fig.	17C).	Thus,	I	expected	to	detect	high	intramolecular	FRET	correlated	to	elevation	of	cytosolic	Ca2+	during	spontaneous	Ca2+	release	events.	Surprisingly,	Ca2+	elevations	in	the	cytosol	corresponded	to	decreases	in	FRET	(Fig.	18B),	suggesting	that	SERCA	population	shifted	to	an	open	conformation.	Similarly,	SERCA	intramolecular	FRET	dropped	at	the	same	time	when	ER	Ca2+	store	was	at	the	lowest	(release	event)	(Fig.	18C),	indicating	that	SERCA	cytosolic	headpiece	shifted	towards	open	conformation	during	Ca2+	
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elevation	in	the	cytosol.	I	noticed	that	while	SERCA	intramolecular	FRET	decrease	was	instantaneous	at	the	moment	of	spontaneous	Ca2+	release	events	(Fig.	18B-C),	FRET	increase	happened	in	the	middle	of	the	gradual	increase	in	ER	Ca2+	before	the	full	restoration	of	ER	Ca2+	stores	(Fig.	18C).	This	observation	indicates	that	the	ER	continues	to	fill	even	after	SERCA	FRET	is	reverted	to	baseline	and	cytosolic	Ca2+	is	returned	to	its	lowest	(Fig.	18B).	I	believe	that	this	phenomenon	is	due	to	the	activity	of	store-operated	Ca2+	entry	mechanisms	that	function	irrespective	of	cytosolic	Ca2+	levels	to	fill	ER	Ca2+	store	(Hogan	and	Rao,	2015).	Nevertheless,	the	biggest	paradox	was	the	observation	of	SERCA	
	
Figure	18.	SERCA	structural	dynamics	in	response	to	spontaneous	Ca2+	events	
measured	by	FRET	in	AAV-293	cells.	
(A)	Anti-correlated	changes	in	Cer	and	YFP	fluorescence	intensity	indicate	rhythmic	FRET	fluctuations	in	intact	cells.	(B)	The	ratio	of	YFP/Cer,	as	in	(A)	was	used	as	an	index	of	FRET	(top	panel,	grey).	FRET	was	inversely	correlated	to	cytosolic	Ca2+,	as	measured	by	X-Rhod-1	fluorescence	(black,	bottom	panel).	(C)	A	decrease	in	2-color	SERCA	intramolecular	FRET	(top	trace)	occurs	simultaneously	with	depletion	of	ER	Ca2+	stores	(bottom	trace).	(D)	AAA-SERCA	FRET	decreased	during	spontaneous	cytosolic	Ca2+	elevations.			
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intramolecular	FRET	decrease	upon	cytosolic	Ca2+	increase,	as	I	expected	the	complete	opposite.		In	addition	to	observed	anti-correlated	FRET/Ca2+	oscillations	paradox	during	transient	Ca2+	elevations,	AAA-SERCA	showed	similar	to	WT	anti-correlated	intramolecular	FRET/	intracellular	Ca2+	oscillations	(Fig.	18D).	This	observation	was	the	opposite	from	what	I	expected	based	on	my	previous	results	when	I	observed	that	AAA-SERCA	has	a	deficit	in	obtaining	high	FRET	compact	conformation	in	response	to	persistent	Ca2+	influx	upon	Iono	treatment	(Fig.	17C,	red).	
	
Figure	19.	SERCA	structural	dynamics	in	response	to	transient	and	sustained	Ca2+	
elevation	measured	by	FRET	in	AAV-293	cells.	
(A)	After	addition	of	Iono,	both	cytosolic	Ca2+	and	WT-SERCA	FRET	increased.	(B)	Addition	of	caffeine	(Caf)	transiently	increased	cytosolic	Ca2+	and	decreased	WT-SERCA	FRET.	(C)	In	contrast	to	WT-SERCA	FRET,	AAA-SERCA	FRET	decreased	with	addition	of	Iono.	(D)	AAA-SERCA	FRET	increased	in	response	to	caffeine,	similar	to	WT-SERCA	FRET	(F).			
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I	detected	the	same	unexpected	anti-correlated	FRET	and	Ca2+	fluctuations	during	a	different	experimental	set	which	was	aimed	to	induce	a	transient	cytosolic	Ca2+	increase.		The	transient	cytosolic	Ca2+	elevation	was	triggered	by	treating	cells	expressing	GFP-RyR	and	2-color	SERCA	with	caffeine	(Caf),	a	RyR	activator,	which	resulted	in	an	immediate	increase	in	cytosolic	Ca2+	and	its	rapid	decrease	to	a	low	level	of	cytosolic	Ca2+	(Fig.	19B)	due	to	activation	of	plasma	membrane	Ca2+	extruders.	As	expected	for	transient	Ca2+	elevation,	this	event	was	mirrored	by	anti-correlated	FRET	changes	(rapid	decrease,	then	sustained	increase).	Again,	opposing	my	previous	observations	that	Nβ5-β6	loop	triple	mutant	was	not	able	to	obtain	high	FRET	compact	conformation	(Fig.	17C),	AAA-SERCA	reacted	similarly	to	WT-SERCA	to	Caf-induced	transient	increase	in	cytosolic	Ca2+,	presenting	an	initial	FRET	decrease	which	was	followed	for	FRET	increase	(Fig.	19D).	To	further	investigate	these	unexpected	observations,	I	measured	SERCA	response	to	Iono	immediately	after	detecting	unexpected	anti-correlated	FRET	and	cytosolic	Ca2+	fluctuations.	First,	I	monitored	the	puzzling	negative	correlation	in	SERCA	intramolecular	FRET	and	cytosolic	Ca2+	levels	for	both	WT-	and	AAA-SERCA	before	the	addition	of	Iono	(Fig.	19A,	C).	Then,	immediately	after	Iono	addition,	WT-SERCA	intramolecular	FRET	exhibited	a	biphasic	response	(rapid	decrease	and	slow	increase)	(Fig.	19A),	and	AAA-SERCA	intramolecular	FRET	only	presented	phase	1	(rapid	decrease)	and	was	lacking	phase	2	of	FRET	recovery	(Fig.	19C),	as	observed	earlier	(Fig.	17C).	Combining	FRET	measurements	during	transient	and	then	sustained	Ca2+	elevations	in	one	experiment	showed	that	both	of	the	opposing	FRET	changes	indeed	take	place.	Since	the	major	difference	that	was	determining	the	FRET	change	directions	in	response	to	Ca2+	elevations	was	the	level	of	Ca2+	influx,	I	concluded	that	the	anti-correlated	FRET	and	cytosolic	Ca2+	
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oscillations	are	characteristic	for	transient	Ca2+	elevations,	while	correlation	between	FRET	and	cytosolic	Ca2+	levels	is	a	distinctive	response	to	sustained	cytosolic	Ca2+	increase.	Thus,	the	anti-correlated	simultaneous	FRET	and	cytosolic	Ca2+	fluctuations	are	observed	during	transient	intramolecular	Ca2+	dynamics.	It	is	noteworthy,	that	intracellular	spontaneous	Ca2+	oscillations	were	hard	to	detect	in	cells	expressing	AAA-SERCA	compared	to	cells	transfected	with	WT-SERCA.	Additionally,	in	those	AAA-SERCA	cells	that	displayed	intracellular	spontaneous	Ca2+	fluctuations,	the	frequency	of	Ca2+	release	events	was	lower	compared	to	cells	transfected	with	WT-SERCA	(compare	Fig.	18B	vs.	18D).	These	observations	demonstrate	that	in	AAA-SERCA	cells,	ER	Ca2+	stores	are	not	sufficient	to	activate	RyR	for	spontaneous	Ca2+	release,	and/or	AAA-SERCA	has	slower	Ca2+	transport	kinetics	and	requires	longer	time	to	fill	in	the	ER	lumen	than	WT-SERCA.	I	propose	that	these	functional	deficiencies	arise	from	the	AAA-SERCA	defective	headpiece	closure	mechanism.	It	has	been	reported	that	SERCA	forms	dimers	which	enhances	SERCA	activity	(Blackwell	et	al.,	2016)	and	potentially	SERCA	headpiece	dynamics.	I	tested	if	observed	
	
Figure	20.	SERCA	FRET	changes	in	response	to	intracellular	Ca2+	dynamics	is	not	due	
to	intermolecular	FRET		(A)	Quantification	of			intermolecular	FRET	between	Cer-SERCA	and	YFP-SERCA	molecules	using	progressive	photobleaching	(started	at	black	arrow).	Data	presented	are	the	mean	of	F/F0	of	Cer	and	YFP	fluorescence	in	6	cells.	(B-C)	SERCA	intermolecular	FRET	did	not	change	with	spontaneous	Ca2+	release	events	(bottom	trace)	(J)	or	in	response	to	Iono	addition	(K).			
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FRET	fluctuations	were	due	to	changes	in	intermolecular	FRET	between	two	SERCA	molecules	rather	than	representing	SERCA	headpiece	dynamics.	As	expected,	I	detected	
intermolecular	FRET	between	Cer-SERCA	and	YFP-SERCA	in	muscle	reconstituted	experimental	conditions	(Fig.	20A).	Nevertheless,	intermolecular	FRET	did	not	change	in	response	to	spontaneous	Ca2+	releases	(Fig.	20B)	or	Iono	addition	(Fig.	20C).	Thus,	I	concluded	that	observed	FRET	changes	in	response	to	cytosolic	Ca2+	elevation	were	a	result	of	genuine	intramolecular	structural	rearrangements	and	not	induced	by	SERCA	oligomerization	events.	More	elaborate	explanation	on	the	cause	of	the	FRET	differences	in	response	to	Ca2+	levels	are	provided	in	the	discussion	section.	It	has	been	previously	proposed	that	SERCA	saturation	in	E2-2Ca	state	can	occur	as	a	result	of	the	inhibition	by	increased	luminal	Ca2+	(Inesi	and	de	Meis,	1989).	To	test	if	observed	slow	FRET	recovery	phase	2	(Fig.	16C)	was	due	to	saturation	of	SERCA	in	the	E2-2Ca	state,	I	monitored	SERCA	intramolecular	FRET	simultaneously	with	ER	Ca2+	buildup	(Fig.	21A).	After	I	detected	correlated	FRET	decrease	upon	ER	Ca2+	store	release	events,	I	saturated	cytosol	with	Ca2+	by	means	of	Iono	treatment,	and	observed	expected	biphasic	
	
Figure	21.	SERCA	structural	dynamics	in	correlation	with	ER	Ca2+	changes		(A)	Addition	of	Iono	causes	an	increase	in	ER	Ca2+	content,	but	this	increase	occurs	more	slowly	than	the	second	phase	of	the	observed	FRET	response	of	2-color	SERCA.	(B)	2CS	FRET	does	not	change	with	addition	of	PBS.	Data	represent	representative	traces.			
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FRET	response	along	with	a	slow	accumulation	of	Ca2+	in	the	ER.	Ca2+	build-up	in	ER	occurred	much	more	slowly	that	the	phase	2	FRET	change,	which	suggests	that	the	phase	2	FRET	change	in	Fig.	16C	is	not	due	to	saturation	of	SERCA	by	luminal	Ca2+	binding.	I	also	confirmed	that	the	observed	change	in	the	FRET	ratio	or	ER	Ca2+	fluctuations	was	not	triggered	by	the	addition	of	control	PBS	solution,	which	indicate	that	my	technique	does	not	introduce	motion	artifacts	that	could	interfere	with	fluorescence	quantification	(Fig.	21B).	Overall,	monitoring	of	simultaneous	real-time	changes	in	SERCA	intramolecular	FRET	and	spontaneous	Ca2+	fluctuations	detected	SERCA	population	accumulated	in	low	FRET	state	(open	headpiece	architecture)	with	increased	cytosolic	Ca2+	levels,	while	a	decrease	in	the	cytosolic	Ca2+	resulted	in	the	redistribution	of	SERCA	population	into	high	FRET	state	(closed	headpiece	conformation)	(Fig.	18B).	This	observation	was	the	opposite	from	what	I	expected	based	on	my	in	cells	Iono	experiments,	where	I	observed	a	FRET	increase	in	response	to	Ca2+	elevations	(Fig.	17C).	Another	unexpected	observation	was	that	the	defective	in	headpiece	closure	AAA-SERCA	population	had	displayed	similar	to	WT	anti-correlated	FRET	response	to	cytosolic	Ca2+	oscillations.	I	propose	that	both	of	these	paradoxical	to	my	previous	observations	are	due	SERCA	accumulation	in	the	specific	slow	steps	of	Ca2+	transport	cycle.	I	will	elaborate	in	the	substantial	detail	on	both	the	anti-correlated	FRET	and	Ca2+	changes	and	the	normal	AAA-SERCA	FRET	response	to	transient	Ca2+	elevation	in	discussion	chapter.
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CHAPTER	FOUR	SERCA	STRUCTURAL	DYNAMICS	IN	COMPLEX	WITH	PLB	
All-atoms	MD	Simulations	of	WT-	or	AAA-SERCA	in	the	Complex	with	PLB	Previous	MD	simulations	of	SERCA	structural	dynamics	predicted	that	the	Nβ5-β6	loop	was	pointing	toward	PLB	binding	cleft	and	in	acidic	loop	residues	Asp426,	Glu429,	and	Glu435	were	in	the	position	to	interact	with	various	positive	residues	of	PLB	cytosolic	domain	(Smolin	and	Robia,	2015a).	Here,	I	investigated	this	possibility	by	performing	runs	and	analysis	of	100	ns	MD	simulations	of	structural	dynamics	of	WT-	or	AAA-SERCA	complexes	with	non-phosphorylated	PLB	or	with	PLB	phosphorylated	on	Ser16	(PLBpS16).	Fig.		22A	shows	the	starting	x-ray	crystal	structure	of	SERCA-PLB	complex	that	was	used	for	MD	simulations:	PDB	accession	code	4KYT	(Akin	et	al.,	2013).	Since	PLB	cytosolic	domain	was	not	resolved	due	to	its	dynamic	structure,	the	cytoplasmic	part	of	PLB	from	crystal	structure	PDB	access	code	1ZLL	was	added	(by	former	research	assistant	Dr.	Nikolai	Smolin).	The	A-domain	is	highlighted	in	blue,	N-domain	is	in	yellow,	P-domain	is	in	black,	TM-domain	is	in	grey,	Nβ5-β6	loop	is	in	orange,	and	PLB	is	in	red.	For	each	complex,	three	independent	production	runs	were	executed.	Previously,	my	lab’s	MD	simulations	of	SERCA	spontaneous	motions	detected	an	increase	in	SERCA	A-N	domains	separation	when	the	triple	Nβ5-β6	loop	mutation	was	introduced	(Fig.	10).	PLB	association	with	SERCA	was	not	able	to	interfere	with	this	specific	effect	of	
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loop	mutations,	and	I	observed	a	2	Å	increase	in	distance	between	centers	of	A-	and	N-domains’	masses	for	AAA-SERCA	compared	to	WT-SERCA	complexes	(Fig.	22C-D).	Additionally,	I	observed	a	greater	deviation	in	distances	between	A-	and	N-domains	of	individual	trajectories	upon	triple	loop	mutation	as	detected	by	greater	distribution	of	trajectories	from	the	starting	separation	distance	of	approximately	40	Å	(Fig.	22B,	red	line).	This	observation	indicates	that	triple	Nβ5-β6	loop	mutation	interferes	with	SERCA	cytosolic	headpiece	closure,	and	also	destabilizes	A-	and	N-domain	interactions.	
	
Figure	22.	WT-SERCA	and	AAA-SERCA	complex	structural	dynamics	in	complex	with	
non-phosphorylated	PLB	or	PLB	phosphorylated	on	Ser16	
(A)	SERCA-PLB	starting	structure	4KYT	with	added	PLB	cytosolic	domain	from	structure	1ZLL.		(B)	Each	panel	represents	distances	calculated	between	A-	and	N-	domains	center	of	mass	for	3	independent	trajectories	for	SERCA-PLB	complexes.	AAA-SERCA	shows	an	in-crease	in	trajectories	distribution	from	a	starting	point	(red	line).		(C)	AAA-SERCA	shows	an	increase	in	A-N	domains	separation	compared	to	WT-SERCA	independent	of	PLB	phos-phorylation.	(D)	Quantification	of	C.	(E)	Ser16	phosphorylation	increases	interaction	with	A-domain.	(F)	Interaction	of	Nβ5-β6	loop	with	PLB	is	stable	and	not	affected	by	Nβ5-β6	loop	mutations	or	Ser16	phosphorylation.	Error	bars	present	S.D.,	n=3		
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Nevertheless,	phosphorylation	of	Ser16	did	not	facilitate	detectable	differences	in	distance	between	A-	and	N-domain	for	either	WT-	or	AAA-SERCA	structures	(Fig.	22B-D).	Considering	that	phosphorylation	introduces	negative	charges	to	the	residue	with	phosphoryl	group	addition,	and	according	to	my	structural	analysis	A-domain	has	a	cluster	of	positive	residues	(133-139)	accessible	for	PLB	binding,	I	hypothesized	that	Ser16	interaction	with	A-domain	would	be	enhanced	by	PLB	phosphorylation.	As	predicted,	phosphorylation	increased	Ser16	interaction	with	A-domain	from	4.7±3	to	7.6±1.6	for	WT-SERCA	and	from	1.2±1.5	to	6.9±1.3	for	AAA-SERCA	(Fig.	22E).	These	results	indicate	that	PLB	interaction	with	A-domain	is	enhanced	by	Ser16	phosphorylation.	Additionally,	I	observed	a	similar	number	of	contacts	between	the	Nβ5-β6	loop	and	PLB	independent	of	PLB	phosphorylation	on	Ser16	or	Nβ5-β6	loop	mutations	which	indicated	a	stable	interaction	between	the	Nβ5-β6	loop	and	PLB	(Fig.	22F).	Based	on	the	observations	that	PLB	stably	interacts	with	SERCA	Nβ5-β6	loop	and	that	phosphorylated	Ser16	has	an	increased	interaction	with	A-domain,	I	further	hypothesized	that	PLB	serves	as	a	connecting	structure	between	N-	and	A-domains	via	interaction	with	Nβ5-β6	loop,	while	Ser16	phosphorylation	allows	more	effective	‘bridging’	of	A−N-domains.	To	further	investigate	this	hypothesis,	I	extended	MD	simulations	for	WT-SERCA	in	complex	with	non-phosphorylated	PLB	or	phosphorylated	on	Ser16	PLBpS16	from	100	ns	up	to	200	ns.		
Extended	MD	Simulations	of	SERCA	and	PLB/PLBpS16	Complexes	I	started	with	analysis	of	the	effect	of	Ser16	phosphorylation	on	the	global	structure	and	dynamics	of	SERCA-PLB	complex.	I	
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	observed	comparable	global	structural	dynamics	for	SERCA	in	complex	with	PLB	and	PLBpS16	by	detecting	similar	RMSD	trajectories	in	SERCA-domains	motions	(Fig.	23A)	and	relatively	comparable	residue-specific	RMSF	for	both	complex	structures,	SERCA	(Fig.	23B)	and	PLB	(Fig.	23C).	It	may	be	worth	noticing	that	PLB	Ser16	phosphorylation	induced	a	slight	increase	in	motion	(~1Å)	for	unstructured	linker	between	cytosolic	and	TM-domains	(Fig.	23C,	residues	20-26).	This	result	suggests	that	Ser16	phosphorylation	changes	PLB	structural	dynamics,	which	will	be	investigated	in	more	detail	below	(Fig.	27,	28).	Interestingly,	the	amplitude	of	SERCA	N-domain	motions	was	reduced	from	the	maximal	of	~11	Å	for	SERCA	alone	(Fig.	8D)	to	a	maximal	of	~5	Å	in	complex	with	PLB	(Fig.	23B).	This	result	indicates	that	PLB	binding	results	in	more	compact	conformation	of	SERCA	headpiece.	
	
Figure	23.	RMSD	and	RMSF	of	SERCA-PLB	complex	structural	dynamics	calculated	
from	MD	simulations	
(A)	Individual	SERCA	domains	(orange	N-domain,	blue	A-domain,	grey	P-domain,	and	black	TM-domain)	show	similar	global	Cα	RMSD	fluctuations	by	WT-SERCA	in	complex	with	PLB	and	Ser16	phosphorylated	PLB.		(B)	RMSF	analysis	of	SERCA	Cα	atoms	revealed	that	the	A-	and	N-domains	are	the	most	mobile,	while	with	similar	relative	structural	dynamics.	(C)	RMSF	analysis	of	PLB	Cα	atoms	shows	similar	residue-specific	fluctuations	for	non-phosphorylated	(black)	and	phosphorylated	on	Ser16	PLB	(red).	Data	represent	mean	±S.D.	of	n=3.	
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Next,	I	confirmed	that	SERCA	Nβ5-β6	loop	interaction	with	PLB	was	still	preserved	on	the	extended	time-scale.	The	number	of	contacts	between	PLB	and	Nβ5-β6	loop	was	similar	with	a	slight	increase	from	17.7±6.4	to	21.3±14.3	upon	Ser16	phosphorylation	(Fig.	24	A-B),	suggesting	that	PLB	phosphorylation	could	increase	interaction	with	Nβ5-β6	loop	on	extended	time-scale.	I	also	tested	to	determine	if	my	previous	observation	that	PLB	Ser16	phosphorylation	increases	the	number	of	contacts	with	the	A-domain	for	the	extended	time-scale.	Fig.	24C	shows	a	red	trace	that	presents	an	average	of	three	independent	trajectories	for	SERCA-PLBpS16	complexes	above	the	black	trace	(SERCA-PLB)	for	most	of	the	interval	of	0-100	ns.	Nevertheless,	at	the	interval	of	100-200	ns	
	
Figure	24.	SERCA-PLB	structural	dynamics	in	response	to	PLB	phosphorylation	on	
Ser16.		
(A)	Number	of	contacts	between	Nβ5-β6	loop	(N-loop)	and	PLB	calculated	for	SERCA-PLB	(black)	and	SERCA-PLBpS16	(red)	complexes.	(B)	Quantification	of	D.	(C)	Number	of	con-tacts	between	SERCA	A-domain	and	PLB	Ser16	residue	calculated	for	SERCA-PLB	(black)	and	SERCA-PLBpS16	(red)	complexes.	(D)	Quantification	of	C.	(E)	Number	of	contacts	be-tween	SERCA	Arg139	and	PLB	Ser16	residue	calculated	for	SERCA-PLB	(black)	and	SERCA-PLBpS16	(red)	complexes.	(F)	Number	of	contacts	between	SERCA	Arg134	and	PLB	Ser16	residue	calculated	for	SERCA-PLB	(black)	and	SERCA-PLBpS16	(red)	complexes.	(G)	Dis-tance	between	SERCA	A-	and	N-domains	centers	of	masses	calculated	for	SERCA-PLB	(black)	and	SERCA-PLBpS16	(red)	complexes.	(H)	Quantification	of	G.	Data	represent	mean	±S.D.	of	3	trajectories.	
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SERCA-PLBpS16	is	characterized	by	the	decreased	number	of	contacts	compared	to	SERCA-PLB	(Fig.	24C),	indicating	an	alteration	of	the	PLB	cytosolic	domain	position	in	regard	to	the	A-domain.	This	result	is	unexpected	but	not	surprising,	as	PLB	cytosolic	domain	is	known	to	be	very	dynamic,	and	extending	my	MD	simulations	is	necessary	to	provide	more	details	on	the	PLB	cytosolic	domain	dynamics.		Since	my	preceding	hypothesis	implied	that	negative	charges	introduced	to	Ser16	by	phosphorylation	strengthen	the	interaction	with	SERCA	A-domain	positively	charged	cluster	(residue	133-139),	I	tested	if	the	number	of	contacts	between	Ser16	and	two	positive	residues	on	A-domain	surface,	Arg139	and	Arg134,	was	affected	by	phosphorylated	Ser16	separation	from	A-domain.	I	observed	a	reduction	in	the	number	of	contacts	between	SERCA	Arg139	and	PLB	Ser16	from	5.8±7.6	to	0.9±1.5	upon	phosphorylation	(Fig.	24E),	while	for	Arg134	the	number	of	contacts	was	below	0.2	(Fig.	24F)	independent	of	Ser16	phosphorylation,	meaning	that	this	interaction	is	not	likely	to	occur.	In	Figure	24E-F	I	observed	a	large	deviation	in	the	SERCA-PLB	number	of	contacts	measured	between	PLB	Ser16	and	Arg134	and	139.	This	result	was	most	likely	due	to	the	fact	that	PLB	cytoplasmic	domain	(residues	1-23,	including	Ser16),	is	extremely	dynamic	and	briefly	samples	variety	of	sites	on	A-domain,	including	analyzed	residues	Arg134	and	Arg139,	and	in	this	way	displays	a	great	variation	in	the	numbers	of	contacts	it	forms.	These	data	indicate	that	phosphorylation	of	PLB	on	Ser16	does	not	just	reduce	interaction	between	PLB	Ser16	and	SERCA	A-domain,	but	specifically	with	the	positive	cluster	on	the	A-domain	surface.	I	tested	to	determine	if	an	extension	of	SERCA-PLB	complex	MD	simulations	resolved	the	effect	of	PLB	Ser16	phosphorylation	on	SERCA	headpiece	dynamics	and	
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calculated	the	number	of	contacts	between	N−A-domains	for	the	200	ns	production	runs.	I	detected	no	difference	between	SERCA-PLB	and	SERCA-PLBpS16	complexes	in	A-	and	N-domains	separation	(Fig.	24G-H).	Interestingly,	SERCA	headpiece	closure	was	observed	as	the	distance	between	centers	of	masses	of	A-	and	N-domains	decreased	by	over	5	Å	during	MD	trajectories	(Fig.	24G).	This	observation	indicates	SERCA	spontaneous	headpiece	closure	in	the	presence	of	PLB,	and	is	complementary	to	induction	of	compact	headpiece	conformation	which	I	observed	as	a	decrease	in	RMSF	of	the	most	dynamic	N-domain	in	the	presence	of	PLB	(Fig.	8D	and	23B).	Since	I	was	not	able	to	resolve	specific	effects	of	PLB	Ser16	phosphorylation	on	SERCA	structural	dynamics	during	the	simulated	time,	I	decided	to	test	if	I	could	identify	differences	in	the	relative	motions	within	the	SERCA-PLB	complexes	by	covariance	
	
Figure	25.	PLB	cytosolic	domain	motions	are	positively	correlated	with	SERCA	
headpiece	structural	dynamics.		Representative	of	n=3	covariance	matrices	Cα	atoms	for	SERCA-PLB	(A)	and	SERCA-PLBpS16	(B).	Covariance	analysis	of	residue	dynamics	as	measured	from	Cα	revealed	positively	(red)	and	negatively	(blue)	correlated	motions.	PLB	residues	are	plotted	after	SERCA	as	residues	995-1046.		
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analysis.		Fig.	25	shows	representative	covariance	matrices	for	the	SERCA-PLB	(A)	and	the	SERCA-PLBpS16	(B)	complexes	as	a	residue-by-residue	correlation	of	motions.	If	residues	move	in	the	same	directions,	they	are	considered	to	be	positively	correlated	(red),	while	negative	correlations	represent	motions	in	the	opposing	directions	(blue).	As	for	SERCA	alone	(Fig	9D),	I	detected	a	positive	self-correlation	within	the	N-domain	(residues	369-603).	In	contrast	to	SERCA	structure	alone,	the	correlations	within	the	A-	and	N-domains	and	between	A−N-domains	were	positive	for	both	SERCA-PLB	complexes,	suggesting	that	PLB	association	with	SERCA	increases	dependent	motions	of	these	domains.	Overall,	the	covariance	matrixes	for	SERCA	in	complex	with	PLB	were	presented	by	more	red	colors	(positively	correlated	motions)	(Fig.	25)	compared	to	SERCA	alone	matrix	(Fig.	9D),	which	indicates	that	PLB	binding	induces	coordinated	motions	within	SERCA	intramolecular	interactions.	Another	interesting	observation	was	the	occurrence	of	mostly	positive	correlation	between	the	motions	of	PLB	cytoplasmic	domain	(residues	1-23)	and	SERCA	A-	and	N-domains	for	both	non-phosphorylated	and	phosphorylated	Ser16	complexes	(Fig.	25),	which	indicates	that	dynamics	of	PLB	cytoplasmic	helix	are	coordinated	with	SERCA	headpiece	dynamics.	This	conclusion	is	consistent	with	the	preceding	MD	observation	that	PLB	cytosolic	domain	interaction	with	SERCA	headpiece	is	persistent	(Fig.	24B).	To	summarize,	my	all-atom	MD	simulations	of	SERCA-PLB/PLBpS16	complexes	identified	more	ordered	SERCA	conformation	induced	by	PLB	binding	as	detected	by	the	reduction	in	the	N-domain	dynamics	(Fig.	8D	and	23B)	and	more	coordinated	motions	of	SERCA	cytoplasmic	domains	(Fig.	9	and	25).	Additionally,	I	observed	a	stable	interaction	of	PLB	cytosolic	domain	with	the	SERCA	N5β-6β	loop	irrespective	of	Ser16	phosphorylation	(Fig.	24A-B).	These	data	suggest	that	the	induction	of	SERCA	ordered	conformation	is	due	
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to	the	PLB	coordination	via	SERCA	N5β-6β	loop.	Thus,	it	is	the	PLB	binding	itself,	not	the	Ser16	phosphorylation,	which	regulates	SERCA	compact	conformation	and	ordered	structural	dynamics.	I	further	performed	MD	simulations	analysis	targeted	to	resolve	effects	of	Ser16	on	SERCA-PLB	structural	dynamics.		
Effect	of	Ser16	Phosphorylation	on	SERCA-PLB	Structural	Dynamics		 	According	to	the	subunit	model,	when	SERCA	inhibition	by	PLB	is	relieved	by	PLB	phosphorylation,	PLB	shifts	to	a	new	position	on	SERCA	TM-domain	(Bidwell	et	al.,	2011;	Negash	et	al.,	2000).	Nevertheless,	the	precise	position	of	phosphorylated	PLB	on	SERCA	TM-domain	after	the	shift	is	not	yet	determined.		Therefore,	I	examined	the	change	in	interaction	between	TM-domain	of	PLB	and	SERCA	TM-domain.	I	calculated	the	number	of	contacts	between	PLB	TM-helix	(Fig.	26A,	red	licorice	structure,	residues	23-52)	and	SERCA	M-helices	that	comprise	the	PLB	docking	groove	(Fig.	26A,	M2-helix,	residues	89-119,	pink;	M4-helix,	residues	313-330,	blue;	M6-helix,	residues	789-809,	violet;	M9-helix,	residues	932-950,	green).	I	detected	a	slight	reduction	in	the	number	of	contacts	between	PLB	TM-helix	and	SERCA	M2-helix	from	99.2±10.8	to	88.9±8.4	upon	PLB	Ser16	phosphorylation.	At	the	same	time	I	detected	an	increase	in	the	number	of	contacts	from	52.4±5.0	to	56.8±6.6	between	PLB	TM-helix	and	SERCA	M9-helix,	and	no	change	for	M4-	and	M6-helices.	These	data	correspond	to	a	displacement	of	PLB	TM-domain	from	SERCA	M2-helix	onto	M9-helix.	Nevertheless,	the	detected	changes	in	the	number	of	contacts	are	relatively	low	(~10%	for	M2-helix	and	~3%	for	M9-helix),	and	further	investigations	are	required	to	determine	if	the	PLB	TM-domain	shift	from	the	SERCA	M2-	to	the	M9-helix	is	a	considerable	event.		
65		
	 	
The	SERCA	acidic	residues	Glu309,	Glu770,	Asp779,	and	Glu908	have	been	identified	as	the	Ca2+	transport	site	II	with	Glu309	being	the	‘gating’	residue	(Clarke	et	al.,	1989).	A	recent	publication	by	Autry	et	al	(Autry	et	al.,	2016)	described	structural	
	
Figure	26.	PLB	phosphorylation	on	Ser16	effect	on	SERCA	TM-domain	structural	dy-
namics.		Data	represent	mean	±S.D.	of	3	trajectories.	(A)	SERCA-PLB	complex	structure.	PLB	resi-dues	used	for	calculations	in	(B)	are	in	licorice	presentation.	M2-helix	is	pink,	M4-helix	is	blue,	M6-helix	is	violet,	M9-helix	is	green.	(B)	Number	of	contacts	calculated	between	PLB	residues	highlighted	in	licorice	presentation	in	(A)	and	SERCA	M-helices	show	a	~10%	de-crease	in	PLB	interaction	with	M2-helix	and	a	~3%	increase	in	contacts	with	M9-helix	upon	PLB	phosphorylation.	(C)	SERCA	TM-domain	shows	gating	residue	Glu309	and	other	resi-dues	of	Ca2+	transport	site	II	in	green.	(D)	Minimal	distance	between	Glu309	and	Ca2+	transport	site	II	has	increased	upon	PLB	Ser16	phosphorylation	by	1.14	Å.		
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rearrangements	in	the	Ca2+	transport	site	II	induced	by	sarcolipin,	an	inhibitory	peptide,	specifically	emphasizing	displacement	of	the	gating	residue	Glu309.	Since	sarcolipin	binds	to	the	same	SERCA	helixes	as	PLB,	I	tested	to	determine	if	PLB	phosphorylation	induced	a	change	in	the	transport	site	II	gating	mechanism	by	comparing	minimal	distances	between	SERCA	Glu309	and	remaining	residues	of	Ca2+	transport	site	II	(residues	799,	770,	and	908).	I	detected	an	increase	in	distance	between	Glu309	and	transport	site	II	from	12.6±1.0	Å	to	13.3±0.2	Å	upon	PLB	S16	phosphorylation	(Fig.	26C-D),	confirming	distortion	of	the	Glu309	gating	mechanism	for	Ca2+	transport	site	II	upon	PLB	Ser16	phosphorylation.	Since	the	size	of	a	Ca2+	ion	is	only	1.14	Å,	the	0.7	Å	increase	in	transport	site	may	translate	into	considerable	structural	rearrangements	for	Ca2+	accommodation	or	displacement.	I	detected	displacement	of	PLB	TM-domain	from	SERCA	M2-helix	onto	M9-helix	and	distortion	of	the	Glu309	gating	mechanism	for	Ca2+	transport	site	II	upon	PLB	Ser16	phosphorylation.	These	specific	changes	induced	by	PLB	Ser16	phosphorylation	indicate	that	phosphorylation	of	PLB	cytosolic	domain	on	Ser16	has	an	effect	on	SERCA-PLB	transmembrane	interactions	which	allow	transport	of	Ca2+	ions.	This	counter-intuitive	conclusion	has	been	suggested	by	several	reports	(Autry	et	al.,	2016;	Espinoza-Fonseca	et	al.,	2015a;	Espinoza-Fonseca	et	al.,	2015b;	Espinoza-Fonseca	and	Ramirez-Salinas,	2015)	and	required	further	investigation.			
SERCA-PLB	Structural	Dynamics	Compared	to	FRET	in	Live	Cells		 	Previously,	my	lab	had	reported	a	decrease	in	FRET	efficiency	between	the	SERCA	N-terminus	and	the	N-terminus	of	PLB	from	25±1.2%	for	non-phosphorylatable	PLB-Ser16Ala	to	14±1.3%	for	phosphomimetic	PLB-Ser16Glu	(Hou	et	al.,	2008),	which	indicated	a	decrease	in	distance	between	the	SERCA	N-terminus	and	the	N-terminus	of	PLB	upon	PLB	
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phosphorylation.	I	calculated	the	minimal	distance	between	the	SERCA	N-terminus	and	the	PLB	N-terminus	(Fig.	27A)	from	MD	simulations	and	were	able	to	detect	an	average	of	a	4.5	Å	decrease	in	minimal	distances	upon	PLB	phosphorylation	(Fig.	27B-C).	This	result	suggests	that	while	MD	simulations	and	FRET	measurements	are	different,	these	techniques	can	be	used	to	complement	each	other.	
	
Figure	27.	200	ns	MD	simulations	of	SERCA-PLB	structural	dynamics	compared	to	
FRET	experiments	in	cells.	For	B-C	and	E-F	data	represent	mean	±S.D.	of	3	trajectories.	(A)	SERCA-PLB	complex	structure	with	SERCA	N-terminus	and	residue	509	highlighted	in	red.	(B)	Minimal	distance	between	SERCA	N-terminus	and	residue	509.	(C)	Quantification	of	C.	(D)	SERCA-PLB	complex	structure	with	SERCA	N-terminus	and	PLB	N-terminus	highlighted	in	red.	(E)	Minimal	distance	calculated	for	SERCA-PLB	complexes.	(F)	Quantification	of	(E)	shows	a	decrease	between	SERCA	and	PLB	upon	PLB	phosphorylation	on	Ser16.	
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I	used	fluorescently	labeled	2-color	SERCA	in	acceptor	sensitization	FRET	experiments	in	live	cells	to	investigate	SERCA	cytosolic	headpiece	structural	dynamics	(Gruber	et	al.,	2014;	Hou	et	al.,	2012;	Pallikkuth	et	al.,	2013).	The	Cer	fluorophore	is	attached	to	N-terminus	(before	residue	1)	while	YFP	is	inserted	before	residue	509	within	A-domain	(Fig.	27D).	I	hypothesized	that	I	can	predict	in	silico	the	structural	dynamics	of	SERCA	headpiece	upon	PLB	Ser16	phosphorylation,	as	would	be	detected	by	FRET	in	live	cells.	I	used	MD	generated	trajectories	to	calculate	the	minimal	distance	between	SERCA	N-terminus	and	residue	509.	Analysis	of	MD	production	runs	showed	no	significant	separation	of	SERCA	N-terminus	and	residue	509	upon	PLB	phosphorylation	on	Ser16	(Fig.	27E-F).	This	observation	suggests	that	the	PLBpS16	effect	on	SERCA	structure	in	live	cells	could	be	hard	to	resolve.	On	the	other	hand,	the	structural	changes	observed	in	real-time	in	live	cells	are	happening	on	the	scale	of	μs	and	higher,	and	most	likely	further	extension	of	my	MD	runs	is	necessary	to	observe	substantial	SERCA	structural	changes	in	complex	with	PLB	that	will	correspond	to	in-cells	observations.		
PLB	Structural	Dynamics	in	Complex	with	SERCA	It	has	been	shown	that	PLB	phosphorylation	affects	PLB	structure	and	intramolecular	interactions	(Li	et	al.,	2003;	Petithory	and	Jencks,	1986;	Sayadi	and	Feig,	2013;	Sugita	et	al.,	2006).	It	is	plausible	to	propose	that	PLB	intramolecular	changes	induced	by	Ser16	phosphorylation	could	regulate	SERCA	structural	dynamics	to	increase	SERCA	activity,	especially	with	my	preceding	observations	that	PLB	phosphorylation	increased	SERCA	N-domain	order	(Fig.	9B	vs.	23B)	and	that	relative	motions	of	A−N-domains	and	PLB	are	correlated	(Fig.	25).	Thus,	I	set	to	examine	some	potential	changes	in	PLB	structure	and	intramolecular	interactions	that	has	been	proposed	by	numerous	studies.		
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PLB	Ser16	phosphorylation	has	been	reported	to	decrease	the	distance	between	TM-domain	residue	Cys24	and	cytosolic	domain	residue	Tyr6	by	3	Å,	as	well	as	stabilize	the	hinge	region	between	PLB	TM-	and	cytosolic	domains	(Li	et	al.,	2003).	Calculated	minimal	distance	for	these	residues	(Fig.	28A)	from	my	MD	production	runs	showed	5.9	Å	increase	in	distance	between	Cys24	and	Tyr6	upon	Ser16	phosphorylation	(Fig.	28B-C).	This	contradiction	may	arise	from	the	differences	in	physiological	solutions	used	for	FRET	experiments	and	current	MD	simulation	system	set-up,	and	stresses	an	importance	of	complementary	techniques.	Nevertheless,	these	results	implicated	a	separation	of	PLB	cytosolic	domain	from	TM-domain	upon	Ser16	phosphorylation.	
	
Figure	28.	PLB	intramolecular	interactions	upon	Ser16	phosphorylation.		For	B-C	and	E-G	data	represent	the	mean	±S.D.	of	3	trajectories.	(A)	SERCA-PLB	complex	structure	with	PLB	Cys24	and	Tyr6	residues	highlighted	in	violet	licorice	representation.	
(B)	Minimal	distances	calculated	between	PLB	Cys24	and	Tyr6	show	an	increase	in	separation	between	these	residues	upon	Ser16	phosphorylation	(red).	(C)	Quantification	of	B.	(D)	SERCA-PLB	complex	structure	with	PLB	Ser16,	Arg9,	Arg13	and	Arg14	highlighted	in	violet	licorice	representation.	(E-F)	Minimal	distance	between	PLB	Ser16	and	Arg14	(E)	and	Ser16	and	Arg13	(F)	is	reduced	upon	Ser16	phosphorylation	(red).	(G)	Minimal	distance	between	PLB	Ser16	and	Arg14	is	not	affected	by	Ser16	phosphorylation	(red).	
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	 The	phosphoryl	group	on	Ser16	has	been	shown	to	interact	with	PLB	cytosolic	residues	Arg9,	Arg13	and	Arg14	(Fig.	28D)	to	unwind	the	cytosolic	helix	and	affect	PLB’s	inhibitory	interactions	with	SERCA	(Sugita	et	al.,	2006).	I	tested	to	determine	if	Ser16	interaction	with	the	positive	arginine	cluster	on	PLB	cytosolic	domain	was	increased	with	phosphorylation	by	calculating	minimal	distances	between	Ser16	and	each	of	Arg9,	Arg13,	and	Arg14.	I	observed	a	decrease	in	separation	between	Ser16	and	neighboring	Arg14	by	2.2	Å,	between	Ser16	and	Arg13	by	0.8	Å,	and	no	detectable	changes	between	Ser16	and	furthermost	Arg9	(Fig.	28E-G).	These	data	confirm	that	the	Ser16	interacts	with	the	cytosolic	arginine	cluster	upon	Ser16	phosphorylation,	supposedly	via	H-bonding	formed	
	
Figure	29.	PLB	conformational	changes	upon	Ser16	phosphorylation.		Data	represent	mean	±S.D.	of	3	trajectories.	Non-phosphorylated	PLB	is	in	black,	while	SER16	phosphorylation	is	in	red.	(A)	Overall	PLB	conformation	becomes	more	structured	upon	Ser16	phosphorylation.	(B-D)	α-helicity	of	PLB	is	increased	(B),	while	unstructured	coil	(B)	and	bent	(C)	arrangements	are	decreased	upon	Ser16	phosphorylation.	(E)	PLB	cytosolic	domain	α-helicity	is	induced	by	Ser16	phosphorylation.	(F)	Stricture	of	PLB	and	residues	used	for	assignment	of	vectors	(represented	by	blue	errors)	are	highlighted	in	blue	licorice	presentation.	θ	represents	angle	between	cytoplasmic	and	TM-domains.	(G)	Angle	between	PLB	cytoplasmic	and	TM-domains	is	increased	upon	Ser16	phosphorylation.	
(H)	Quantification	of	(G).	
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by	the	negative	phosphoryl	group.	Importantly,	such	interaction	of	neighboring	residues	will	most	likely	introduce	a	natural	kink	in	PLB	structure	and	result	in	more	compact	and	stabilized	structural	composition	of	PLB.	I	next	examined	PLB	structural	composition.		 In	order	to	investigate	changes	in	PLB	structure	upon	Ser16	phosphorylation,	I	calculated	the	percentage	of	structured	and	unstructured	elements.	I	detected	an	increase	from	60.0±4.5%	to	65.0±4.6%	in	PLB	overall	structure	as	a	result	of	Ser16	phosphorylation	(Fig.	29A).	Further	investigation	revealed	that	α-helical	organization	was	increased	by	from	52.0±4.0%	to	56.0±3.6%	(Fig.	29B),	while	more	unstructured	configurations,	such	as	coil	and	bend,	were	decreased	by	from	26.3±5.0%	to	23.3±4.9%	and	from	10.7±1.5%	to	9.3±1.5%	respectively	(Fig.	29C-D).	Specifically,	α-helicity	of	the	cytosolic	domain	was	increased	by	from	60.9±13.1%	to	77.3±6.0%	upon	PLB	phosphorylation	(Fig.	29E).	Thus,	my	data	suggest	that	PLB	phosphorylation	on	Ser16	induces	more	structure	and	order	in	PLB	conformation.	With	PLB	Ser16	phosphorylation	I	detected	an	increased	separation	of	PLB	cytosolic	and	TM	domains	while	predicating	a	kink	in	PLB	domains’	linker	due	to	phosphorylated	Ser16	increased	interaction	with	Arg13/Arg14	cluster	(Fig.	28).	Such	interesting	structural	PLB	arrangement	would	be	possible	if	the	kink	results	in	twisting	of	PLB	cytosolic	domain	upward.	To	investigate	PLB	structural	arrangement	in	more	detail,	I	calculated	the	angle	between	PLB	cytoplasmic	and	TM-domains	by	assigning	vector	generated	between	Cα	of	residues	12	and	Cα	of	residues	4	as	the	cytoplasmic	domain	vector,	while	the	vector	of	Cα	of	residues	23	and	Cα	of	residues	52	as	TM-domain	vector	(Fig.	29F)	(Sayadi	and	Feig,	2013).	I	detected	a	31.6°	increase	in	PLB	intra-domain	angle	(Fig.	28G-H),	suggesting	that	PLB	cytosolic	domain	unfolds/twists	from	TM-domain	and	obtains	more	upward	
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conformation	upon	Ser16	phosphorylation.	This	result	complements	a	detected	increase	in	minimal	distance	between	TM	residue	Cys24	and	cytoplasmic	domain	Tyr6	(Fig.	28B-C)	and	confirms	the	presents	of	the	kink	in	the	Ser16	region	introduced	by	increased	interaction	between	Ser16	and	cytosolic	Arginine	cluster	(Fig.	87E-F).	One	possible	explanation	for	such	strange	structural	arrangement	when	the	PLB	cytosolic	domain	is	directed	upwards	with	a	kink	in	Ser16	region	could	be	the	preceding	observation	that	the	PLB	cytoplasmic	domain	strongly	interacts	with	the	SERCA	Nβ5-β6	loop	(Fig.	24A-B)	and	thus	oriented	upward,	toward	SERCA	headpiece	domain.	Overall,	PLB	Ser16	phosphorylation	has	a	pronounced	effect	on	PLB	structure.	I	detected	a	separation	of	PLB	cytosolic	domain	from	the	TM-domain	by	an	increase	in	distance	(Fig.	28)	and	an	angle	(Fig.	29G-H)	between	these	two	domains.	Additionally,	I	observed	an	increase	in	PLB	structural	organization	with	detecting	more	structured	and	less	unstructured	PLB	intramolecular	assemblies	with	Ser16	phosphorylation	(Fig.	29A-E).	These	results	provide	an	alternative	explanation	to	the	question	how	the	phosphorylation	of	PLB	cytosolic	domain	results	in	SERCA	TM	domain	rearrangement	to	accommodate	Ca2+	ions	transport:	detected	reorganizations	of	PLB	structural	composition	result	in	adjusted	PLB-SERCA	TM	interactions,	which	may	lead	to	PLB	shift	to	a	distinct	binding	groove	and	rearrange	Ca2+	transport	sites.	I	extended	my	studies	of	PLB-SERCA	structural	dynamics	upon	PLB	binding	and	PLB	Ser16	phosphorylation	in	vitro.		
SERCA	Conformational	Changes	in	Complex	with	PLB	measured	by	FRET	To	further	investigate	the	SERCA-PLB	regulatory	complex,	I	performed	an	analysis	of	SERCA	structural	conformers	in	vitro.	Acceptor-sensitized	FRET	was	used	to	examine	conformation	of	the	SERCA	cytosolic	headpiece	in	the	presence	of	non-phosphorylatable	or	
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phosphomimetic	PLB.	I	prepared	microsomal	membranes	from	cells	co-expressing	WT	2-color	SERCA	alone,	SERCA	with	phosphomimetic	PLB-Ser16Glu,	and	SERCA	with	non-phosphorylatable	PLB-Ser16Ala.	Fig.	30A	shows	FRET	increase	with	Ca2+	concentration	for	SERCA	alone	or	in	complex	with	PLB.	The	apparent	Ca2+	affinity	was	not	changed	by	PLB	binding	as	KCa	was	not	significantly	changed	in	PLB	presence	(Fig.	30B).	Overall,	I	detected	an	increase	in	2-color	SERCA	FRET	with	Ca2+	concentration,	and	SERCA	intramolecular	FRET	increase	was	observed	in	complex	with	PLB,	especially	in	complex	with	phosphomimetic	PLB-Ser16Glu.	This	observation	indicates	that	phosphorylated	PLB	stabilizes	SERCA	in	the	compact	conformation.		 SERCA	conformational	states	were	stabilized	with	substrates	to	characterize	the	intermediates	of	the	Ca2+	transport	cycle	(Fig.	30C-D)	(MacLennan	et	al.,	1997).	As	for	SERCA	alone	(Fig.	15B),	I	observed	low	FRET	for	SERCA	conditions	under	which	E2	conformers	are	expected	to	be	predominant:	protonated	SERCA	(H+),	TG-bound,	and	E2P	phosphoenzyme	intermediates	(AlF4–	and	Vi).	Higher	FRET	was	observed	for	microsomes	in	E1	states:	ATP-bound,	Ca2+-bound	(2Ca),	and	both	ATP	and	Ca2+-bound	(2Ca+ATP)	intermediates.	The	FRET	values	for	each	intermediate	are	presented	in	Fig.	31.	In	agreement	with	my	previous	observations	(Fig.	30A),	I	detected	higher	FRET	for	SERCA	in	complex	with	PLB,	with	the	highest	values	attained	in	the	presence	of	phosphomimetic	PLB-Ser16Glu.	These	data	confirm	that	SERCA	headpiece	obtains	very	compact	conformations	during	high-affinity	E1	states	of	enzymatic	cycle,	and,	overall,	the	SERCA	headpiece	structure	obtains	even	more	compact	conformations	upon	PLB	phosphorylation.		 It	has	been	shown	that	overexpression	of	SERCA	in	AAV-293	cells	dramatically	enhances	SERCA	ability	to	transport	Ca2+	from	the	cytosol,	while	PLB	decreases	SERCA	
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mediated	Ca2+	sequestering	into	ER	(Bidwell	et	al.,	2011).	To	determine	the	differences	in	SERCA	Ca2+	transport	in	complex	with	phosphomimetic	or	wild-type	PLB,	I	performed	Ca2+	uptake	in	live	cells	which	enabled	the	monitoring	of	SERCA	function	as	Ca2+	transient	in	the	presence	of	PLB	(1	nM	SERCA	to	5	nM	PLB	transfection	ratio	of	DNA	constructs).	Since	PLB	phosphorylation	has	been	shown	to	relieve	SERCA	inhibition	(Simmerman	et	al.,	1986;	Tada	and	Inui,	1983),	I	predicted	that	phosphomimetic	PLB	should	have	similar	to	or	more	of	overexpressed	WT-SERCA	phenotype	in	sequestering	Ca2+	from	cytosol.	Fig.	32A	shows	AAV-293	cells	expressing	Cer-SERCA	(blue)	and	YFP-PLB	(yellow),	while	the	cytosolic	Ca2+	is	labeled	with	Ca2+	indicator	X-Rhod-1	(red),	and	white	arrows	are	indicating	untransfected	(UT)	cells	in	the	same	field.	I	triggered	inositol	1,4,5-trisphosphate	receptors-mediated	Ca2+	release	from	ER	by	activation	of	inositol	1,4,5-trisphosphate	receptors	on	ER	membrane	via	stimulation	of	purinergic	receptor	with	extracellular	ATP	(Dubyak	and	el-Moatassim,	1993).	Ca2+	accumulation	in	the	cytosol	was	detected	by	an	increase	in	X-Rhod-1	fluorescence	(Fig.	32B).	I	detected	endogenous	SERCA	activity	(Fig.	32B,	black)	as	a	decrease	in	cytosolic	Ca2+	fluorescence.	Subsequent	application	of	SERCA	
	
Figure	30.	SERCA	structural	conformers	as	determined	by	FRET	in	microsomes	from	
AAV-293	cells	expressing	2-color	SERCA	with	or	without	PLB.	Data	represent	mean	±S.E.M	of	at	least	3	ns.	(A)	SERCA	showed	an	increase	in	FRET	with	Ca2+	concentration	by	itself	(black)	and	in	complex	with	phosphomimetic	PLB-Ser16Glu	(orange),	or	non-phosphorylatable	PLB-Ser16Ala	(blue).	(B)	KCa	remained	unchanged	upon	PLB	binding.	(C)	FRET	of	2-color	SERCA	stabilized	in	key	enzymatic	states.			
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inhibitor	TG	was	designed	to	determine	Ca2+	store	remaining	in	ER	and	resulted	in	a	rise	in	Ca2+	signaling	as	I	detected	an	increase	in	X-Rhod-1	fluorescence.	Cells	co-transfected	with	SERCA	and	WT-PLB	(Fig.	32B,	red)	displayed	similar	to	exogenous	SERCA	response	to	ATP	and	Ca2+	transport,	as	was	expected,	considering	that	PLB	inhibits	SERCA	function.	Nevertheless,	ER	Ca2+	storage	was	larger	than	for	UT	cells,	which	suggests	that	SERCA	inhibited	by	PLB	has	greater	than	endogenous	SERCA	capabilities	to	sequester	Ca2+.	This	observation	is	contradictory	to	published	reports,	where	SERCA	in	complex	with	PLB	has	been	shown	to	have	similar	to	exogenous	SERCA	Ca2+	transport	activity	(Bidwell	et	al.,	2011).	Even	more	surprising	was	Ca2+	transient	observed	for	SERCA	in	complex	with	phosphomimetic	PLB-Ser16Glu/Thr17Glu	(Fig.	32B,	blue).	Instead	of	expected	smaller	than	UT	response	to	ATP	and	larger	Ca2+	release	from	ER	stores	upon	TG	treatment,	I	observed	responses	similar	to	SERCA	in	complex	with	WT-PLB,	which	suggests	that	phosphorylation	of	PLB	has	no	effect	on	SERCA	activity	in	this	experimental	set-up.	Since	I	performed	Ca2+	measurements	in	live	cells,	it	is	possible	that	overexpressed	WT-PLB	gets	phosphorylated	in	response	to	increased	cytosolic	Ca2+	by	the	cells’	endogenous	PKA.	To	
	
Figure	32.	Ca2+	uptake	in	live	cells	
(A)	Representative	wide-field	fluorescence	images	of	AAV-293	cells	transfected	with	Cer-SERCA	(blue)	and	YFP-PLB	(yellow),	loaded	with	Ca2+	indicator	X-Rhod-1	(red).	This	field	contains	examples	of	untransfected	(UT)	cells	labeled	with	white	arrows.	(B)	Ca2+	transi-ents	were	observed	after	the	addition	of	extracellular	ATP.	TG	was	used	to	determine	ER	Ca2+	load.	Data	represent	the	average	of	13-19	cells;	error	bars	are	SEM.	
	
Figure	31.	FRET	values	for	SERCA	E1	and	E2	states.		Intramolecular	FRET	was	measured	in	ER	microsomes	from	AAV-293	cells	expressing	2-color	SERCA	without	PLB	or	with	non-phosphorylatable	PLB-Ser16Ala	or	phosphomimetic	PLB-Ser16Glu.	Yellow	highlights	E1	states,	while	green	highlights	E3	states.	Data	represent	the	mean	±	S.E.	of	at	least	3	independent	experiments.		
E1/E2 states no PLBMean FRET (%) S.E.
PLB-Ser16Ala
Mean FRET (%) S.E.
PLB-Ser16Glu
Mean FRET (%) S.E.
TG 10.8 1.1 15.4 1.3 18.2 1.4
H+ 12.1 1.3 16.3 2.3 18.6 2.4
ATP 17.7 2.6 20.8 3.2 23.9 3.4
2Ca 16.6 1.4 20.0 1.3 23.2 2.3
2Ca+ATP 16.9 0.8 19.7 1.0 23.0 2.1
Vi 9.9 0.8 13.5 2.4 16.5 3
AlF4- 9.2 3.4 13.1 3.1 18.24 1.4
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optimize	this	experiment,	I	would	need	to	repeat	measurements	with	a	non-phosphorylated	version	of	PLB-Ser16Ala,	as	well	as	determine	the	true	ratio	of	PLB.	Another	aspect	for	optimization	would	be	determination	of	the	in-cell	SERCA:	PLB	ratio	to	determine	that	enough	PLB	is	expressed	to	overcome	PLB	pentamers	formation	and	allow	association	with	SERCA	(I	have	used	up	to	1	nM	SERCA	to	20	nM	PLB	ratio	of	constructs’	expression	for	FRET	measurements).	Overall,	PLB	seems	to	inhibit	overexpressed	SERCA	activity,	and	ER	Ca2+	stores	are	increased	for	overexpressed	SERCA	in	complex	with	PLB.		Our	FRET	structural	data	indicate	that	PLB	binding	to	SERCA	leads	to	SERCA	cytosolic	domain	compact	conformation,	which	is	further	enhanced	by	PLB	Ser16	phosphorylation	(Fig.	30A).	Based	on	the	substrate-stabilized	SERCA	intermediates	of	enzymatic	cycle	experiment,	PLB	binding	and	phosphorylation	induce	compact	conformation	in	all	transitional	states	of	Ca2+	transport	(Fig.	30C),	which	suggests	that	SERCA	compact	conformation	may	be	of	a	regulatory	significance.	To	elucidate	the	details	of	structural	aspects	of	SERCA	regulation	by	PLB,	further	investigations	are	necessary.	In	particular	Ca2+	handling	in	live	cells	in	the	presence	of	PLB	variants	are	of	great	interest,	as	well	as	extended	MD	simulation	of	SERCA-PLB	complex	spontaneous	dynamics.
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CHAPTER	FIVE	APPLICATION	OF	2-COLOR	FRET	BIOSENSORS	IN	IDENTIFICATION	OF	REGULATORY	INTERACTIONS	Our	lab	has	generated	the	2-color	SERCA	FRET	sensor	(Hou	et	al.,	2012)	which	was	used	in	this	work,	as	well	as	in	multiple	assays	aimed	to	determine	SERCA	structural	dynamics	(Blackwell	et	al.,	2016;	Hou	et	al.,	2012;	Pallikkuth	et	al.,	2013)	and	potential	substrates	(Cornea	et	al.,	2013;	Gruber	et	al.,	2014).	Additionally,	my	lab	has	demonstrated	that	the	technique	to	generate	2-color	FRET	biosensor	can	be	applied	to	other	molecules.	For	example,	2-color	MRP-1,	another	transporter	ATPase,	was	generated	and	used	in	FRET	high-throughput	screening	for	identification	of	novel	substrates	(Iram	et	al.,	2015).	For	both	SERCA	and	MRP-1	transporters,	the	most	mobile	domains	were	labeled	with	donor	and	acceptor	fluorescent	proteins	to	monitor	structural	changes	upon	interaction	with	potential	modulators.	The	identified	substrates	were	further	tested	to	determine	their	functional	effect.	Thus,	my	lab	has	developed	a	general	technique	of	2-color	FRET	biosensor	generation	which	can	be	applied	to	a	wide	variety	of	molecules.	In	support	to	this	statement,	I	will	next	describe	several	examples	of	the	2-color	FRET	biosensors	use	for	detections	and	investigations	of	regulatory	interactions.			
SERCA	and	Hax-1	Direct	Interactions	as	Assessed	by	FRET	Hax-1	has	been	shown	to	interact	with	SERCA	in	vitro	(Vafiadaki	et	al.,	2009).	Nevertheless,	the	direct	interaction	of	HAX-1	and	SERCA	in	vivo	has	not	been	observed	and	is	highly
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debated	(Vandecaetsbeek	et	al.,	2011).	To	observe	the	potential	interaction	in	cells,	I	tested	to	determine	if	Hax-1	has	an	effect	on	SERCA	intramolecular	FRET	in	AAV-293	cells	expressing	unlabeled	Hax-1	and	2-color	SERCA	(Cer	fluorophore	on	N-terminus	and	YFP	before	residue	509	within	N-domain).	I	detected	an	apparent	decrease	in	intramolecular	FRET	for	2-color	SERCA	in	the	presence	of	Hax-1	using	the	acceptor	sensitization	technique,	but	not	the	acceptor	photobleaching	method	(Fig.	33A-B).	Even	though	the	2-color	SERCA	by	itself	showed	FRET	values	similar	to	those	reported	previously	(Hou	et	al.,	2012),	the	main	concern	about	2-color	SERCA	FRET	in	the	presence	of	Hax-1	is	the	possibility	that	the	YFP	fusion	site	on	the	SERCA	N-domain	before	residue	509	can	be	too	close	to	the	proposed	Hax-1	binding	site	(Fig.	32C,	loop	consisting	of	residues	E575-V594,	red)	(Vafiadaki	et	al.,	2009;	Vandecaetsbeek	et	al.,	2011).	Binding	of	Hax-1	to	this	highly	accessible	N-domain	loop	would	result	in	Hax-1	being	physically	in	the	way	of	measuring		
	
Figure	33.	2CS	FRET	in	the	presence	of	Hax-1.		2CS	intramolecular	FRET	measured	by	(A)	the	acceptor	photobleaching	method	(n=3,	#p≤0.0001)	and	(B)	the	acceptor	sensitizing	method	(n=5,	*p=0.008	and	#p≤0.0001).	Only	the	acceptor	sensitization	assay	showed	a	significant	decrease	in	SERCA	intramolecular	FRET	in	the	presence	of	HAX1	(*).	HAX1	has	no	additive	effect	on	FRET	decrease	by	TG	(#).	
(C)	2CS	structure	shows	Cer	fluorophore	(cyan)	attached	to	A-domain	(blue),	YFP	fluorophore	(orange)	attached	to	N-domain	(yellow),	and	proposed	cytoplasmic	Hax-1	binding	sites	in	red.	
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Nevertheless,	the	detection	of	a	FRET	decrease	in	the	presence	of	HAX-1	(Fig.	33A-B)	indicates	direct	binding	of	HAX-1	to	SERCA,	and	that	this	interaction	indeed	occurs	in	live	cells.	Following	investigations	are	needed	to	determine	how	stable	this	interaction	is	and	if	there	is	a	functional	aspect	to	this	direct	association	of	HAX-1	with	SERCA.			
Analysis	of	SERCA	Association	with	DWORF	Recently	identified	by	Dr.	Eric	Olson	group	micropeptide	encoded	by	lncRNA	DWORF	has	been	proposed	to	bind	to	SERCA	in	the	same	binding	site	as	SERCA	inhibitor	PLB	as	presented	in	Fig.	34A-B,	thus	relieving	SERCA	inhibition	by	displacement	of	PLB	(Nelson	et	al.,	2016).	Nevertheless,	the	details	of	SERCA-DWORF	association	have	not	been	investigated	due	to	the	fact	that	discovery	of	DWORF	micropeptide	is	relatively	recent.	I	used	progressive	acceptor	photobleaching	FRET	measurements	to	investigate	DWORF	interaction	with	SERCA	and/or	PLB,	as	well	as	DWORF	ability	to	form	homo-dimers.	Fig.	34C	shows	that	DWORF-SERCA	complex	has	lower	FRET	compared	to	PLB-SERCA	complex	(Fig.	34D).	The	lower	FRET	can	be	explained	by	shorter	topology	of	DWORF	(Fig.	34A)	compared	to	PLB	(Fig.	34B).	PLB	truncated	all	the	way	to	TM-domain	has	been	shown	to	have	decreased	FRET	compared	to	full	length	PLB	(data	by	previous	lab	member	Phil	Bidwell,	not	published).	Plotting	Cer	vs.	YFP	resulted	in	a	linear	relationship	of	donor	and	acceptor	fluorophores	(Fig.	34E)	consistent	with	1:1	stoichiometry.	This	result	means	that	DWORF	binds	to	SERCA	as	a	monomer	to	form	a	heterodimer	(one	Cer	for	one	YFP	detected),	the	same	way	as	PLB	(Blackwell	et	al.,	2016;	Kelly	et	al.,	2008).	I	detected	no	FRET	between	DWORF-DWORF	(Fig.	34F),	consistent	with	the	suggestion	that	DWORF	is	monomeric	(Nelson	et	al.,	2016).	Additionally,	I	did	not	detect	FRET	between	DWORF-PLB	(Fig.	34G),	indicating	that	DWORF	does	not	form	hetero-oligomers	with	PLB.	Overall,	these	
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data	confirmed	DWORF	association	with	SERCA	in	1:1	stoichiometry	and	showed	that	DWORF	most	likely	exists	as	a	monomer	and	does	not	form	homo-	or	heterodimers.		 When	using	the	acceptor	sensitization	FRET	method,	DWORF-SERCA	FRET	was	also	decreased	compared	to	PLB-SERCA	FRET	(Fig	35A-B).	I	observed	smaller	Kd	of	DWORF	compared	to	PLB	(Fig.	35C),	which	indicates	that	DWORF	has	higher	apparent	affinity	for	SERCA	than	PLB.	This	observation	indicates	that	targeting	PLB	displacement	with	DWORF	overexpression	can	become	a	novel	approach	to	enhance	SERCA	activity	in	cardiac	dysfunctions.	
	
Figure	34.	Analysis	of	DWORF	homo-oligomerization	and	association	with	SERCA,	
PLB	and	itself	by	acceptor	photobleaching	FRET.	
(A)	SERCA-DWORF	complex	shows	DWORF	bound	to	the	same	groove	as	PLB	as	in	(B)	SERCA-PLB	complex.	For	(C-D,	F-H)	photobleaching	starts	at	the	black	arrow.	(C)	FRET	detected	between	Cer-SERCA	and	YFP-PLB.	(D)	FRET	detected	between	Cer-SERCA	and	YFP-DWORF.	(E)	Plotting	Cer	fluorescence	as	a	function	of	YFP	reveals	that	both	the	FRET	complexes,	SERCA-PLB	and	SERCA-DWORF,	are	heterodimers.	(F-G)	No	FRET	detected	between	Cer-DWORF	and	YFP-DWORF	(F)	or	YFP-PLB	(G).	(H)	FRET	detected	between	Cer-PLB	and	YFP-PLB	represents	PLB	homo-oligomerization.	Error	bars	represent	SD,	n=6-16.		
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To	investigate	if	DWORF	competes	with	PLB	for	association	with	SERCA,	I	performed	competition	experiments.	Specifically,	I	measured	FRET	between	Cer-SERCA	and	YFP-PLB	in	the	presence	of	increasing	DWORF	expression.	The	maximal	SERCA-to-PLB	FRET	was	progressively	decreased	by	increased	co-expression	of	DWORF	(Fig.	35D-E),	which	indicated	that	DWORF	indeed	competes	with	PLB	for	the	same	binding	site.	Since	I	have	shown	that	DWORF	does	not	oligomerize	with	PLB	(Fig.	34G),	this	decrease	is	not	due	to	PLB	being	sequestered	away	from	SERCA	into	DWORF-PLB	hetero-oligomeric	complexes.	Additionally,	I	saw	a	progressive	decrease	in	the	apparent	PLB-to-SERCA	Kd	
	
Figure	35.	Analysis	of	DWORF	association	with	SERCA	by	acceptor	sensitizing	FRET.	
(A)	Representative	data	for	FRET	detected	between	Cer-SERCA	and	YFP-DWORF	or	YFP-PLB.	(B)	Quantification	of	relative	maximal	FRET	in	(A).	(C)	Quantification	of	Kd	FRET	in	(A).	(D)	Representative	data	set	for	competing	PLB	off	with	DWORF.	Ratios	represent	molar	ratio	of	PLB	to	DWORF	DNA	constructs	used	for	transient	transfection	of	AAV-293.	
(E)	Quantification	of	relative	maximal	FRET	in	(D).	(F)	Quantification	of	Kd	in	(D).	Error	bars	present	SD,	n=3.			
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parameter	(Fig.	35F).	This	result	indicates	that	PLB’s	apparent	affinity	to	SERCA	increases	in	the	presence	of	DWORF.	This	is	exactly	what	I	would	expect	if	PLB	is	competed	away-	a	positive	correlation	between	an	increased	number	of	free	PLB	molecules	and	their	affinity	for	SERCA.	With	the	present	FRET	measurements,	I	still	cannot	exclude	the	possibility	that	DWORF	binds	to	SERCA	at	different	from	the	PLB	binding	site(s)	and	alters	SERCA-PLB	complex	structure	which	results	in	a	FRET	decrease.	Further	investigations	are	needed	to	determine	the	details	of	structural	regulations	of	SERCA	activity	by	DWORF.	Overall,	I	confirmed	that	DWORF	binds	to	SERCA	with	higher	affinity	than	PLB	(Fig.	35C)	most	likely	at	the	same	binding	site	(Fig.	35D-E)	in	one	to	one	ratio	(one	DWORF	molecule	per	one	SERCA)	(Fig.	34E).	I	showed	that	primarily	DWORF	exists	as	a	monomer	and	does	not	form	oligomers	with	itself	or	PLB.	Since	DWORF	positively	regulates	SERCA	activity	(Nelson	et	al.,	2016)	and	has	a	higher	affinity	to	SERCA	than	PLB	(Fig.	35C),	DWORF	is	very	likely	to	become	a	high	significance	novel	therapeutic	target	to	enhance	cardiac	function.		
Quantification	of	DOX	Uptake	by	AAV-293	Cells	to	Assess	MRP-1	Transport	Activity	2-color	SERCA	pump	has	been	successfully	used	to	identify	modulators	in	a	high-throughput	screen	of	a	library	of	biologically	active	compounds	(Gruber	et	al.,	2014).	My	lab	had	applied	the	same	labeling	technique	to	generate	2-color	multi-drug	resistance	protein-1	(MRP-1)	biosensor	with	GFP	and	TagRFP	fluorophores	attached	to	the	two	most	dynamic	cytosolic	nucleotide-binding	domains,	which	were	predicted	to	undergo	transition	from	open-to-closed	conformation	during	extrusion	of	substrates	from	the	cytosol	(Aller	et	al.,	2009).	2-color	MRP-1	FRET	measurements	were	performed	to	screen	for	and	identify	
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prospective	transporter	modulators	(Iram	et	al.,	2015).	As	a	result,	several	MRP-1	substrates	were	detected:	MK571	(known	MRP1	inhibitor),	epigallocatechin	gallate	(antioxidant),	mesalamine	(anti-inflammatory),	calcipotriol	(analog	of	vitamin	D),	and	meropenem	(antibiotic).	To	define	these	substrates’	functions,	I	tested	to	determine	if	these	compounds	are	able	to	alter	MRP-1	activity.	I	used	doxorubicin	(DOX),	one	of	the	MRP-1	substrates,	to	perform	assessment	of	MRP-1	function	in	the	presence	of	the	identified	substrates.	When	DOX	is	not	transported	out	of	the	cell,	it	accumulates	in	the	nuclei	as	detected	by	the	presence	of	red	florescence	(Fig.	36B-C,	UT).	Overexpressed	MRP-1	prevents	DOX	accumulation	in	the	nuclei	and	I	saw	great	reduction	of	red	signal	in	cells	nuclei	(Fig.	36B-C,	MRP-1).	Treatment	of	cells	with	
	
Figure	36.	DOX	uptake	in	the	nucleus	of	AAV-293	cells	in	the	presence	of	candidate	
modulators.	
(A)	Schematic	representation	of	MRP-1	structure.	Top	panel	represents	high	affinity	for	ligands	conformation	with	globular	nucleotide-binding	domains	apart,	while	bottom	panel	pictures	low	ligand-affinity	conformation.		(B)	Representative	images	of	cells	treated	with	DOX	in	the	presence	of	candidate	compound.	On	Ctrl	image	several	untransfected	(UT)	cells	are	marked	with	white	arrows,	while	several	MRP-1	expressing	cells	are	marked	with	green	arrows.	(C)	Quantification	of	red	fluorescence	intensities	was	used	as	an	index	of	nuclei	DOX	accumulation.	Values	are	±	S.E.M,	normalized	to	UT	cells	in	the	same	microscopic	field.	*P	<	0.0001	versus	UT;	#P<	0.0001	versus	“Ctrl”	MRP-1	alone.	All	error	bars	represent	±	S.E.M.			
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known	MRP-1	inhibitor	MK571,	one	of	the	high-throughput	screening	hits,	resulted	in	DOX	accumulation	in	cells’	nuclei	as	would	be	expected	for	a	transporter	inhibitor.	Calcipotriol	inhibited	MRP-1	transport	comparable	to	MK571	with	similar	DOX	levels	detected	in	cells’	nuclei	(Fig.	36B-C,	calcipotriol).	Since	calcipotriol	is	a	vitamin	D	analog,	this	result	explains	the	fact	that	vitamin	D	has	been	demonstrated	to	potentiate	the	effect	of	chemotherapeutic	agents	(Ma	et	al.,	2010).	Epigallocatechin	gallate	and	meropenem	exhibited	no	effect	on	MRP-1	transport	activity,	even	though	they	induced	structural	changes	to	MRP-1	organization	in	preceding	high-throughput	screening.	Mesalamine	interfered	with	DOX	redistribution	in	UT	cells,	and	was	not	used	to	evaluate	MRP-1	function	(Fig.	36B-C,	mesalamine).	Overall,	I	was	able	to	confirm	two	hit	compounds	as	MRP-1	inhibitors,	MK571	and	calcipotriol,	which	demonstrated	the	potential	of	utilizing	2-color	FRET	sensors	in	combination	of	high-throughput	screening	analysis	with	functional	assay	in	order	to	identify	novel	modulators	of	protein	of	interest.	This	technique	has	a	potential	to	become	a	powerful	tool	in	clinical	drug	discovery.
		
85		
CHAPTER	SIX	DISCUSSION	While	SERCA	is	one	of	the	major	regulators	of	Ca2+	handling	in	the	heart,	and	thus	the	ideal	target	to	improve	cardiac	function	(Hayward	et	al.,	2015;	Inesi	et	al.,	2008),	at	the	moment,	no	successful	therapeutic	approaches	have	been	developed	to	increase	SERCA	activity.	The	promising	gene	therapy	clinical	trials	designed	to	increase	SERCA	expression	in	patients’	failing	hearts	have	not	yet	achieved	success	in	improving	patients’	cardiac	function	(Zsebo	et	al.,	2014)	and	highlighted	the	apparent	lack	of	understanding	of	SERCA	structure	and	function.	One	of	the	goals	of	this	work	was	to	contribute	to	understanding	of	SERCA	function	via	thorough	investigation	of	SERCA	structural	dynamics	during	Ca2+	transport.	The	strength	of	the	current	study	was	in	a	combination	of	in	silico,	in	vitro,	and	ex	vivo	assays	that	resulted	in	a	detailed	evaluation	of	SERCA	structural	and	regulatory	dynamics.		
Structural	Dynamics	of	WT-SERCA	During	Ca2+	Transport	SERCA	FRET	measurements	in	a	substrates-stabilized	environment	allowed	identification	of	SERCA	headpiece	structural	conformers	for	several	intermediate	states	during	Ca2+	transport	(Fig.	15).	I	modified	a	Post-Alberts	reaction	cycle	by	adding	my	FRET	data	and	emphasizing	states	with	similar	intramolecular	FRET	efficiencies	in	blue	boxes:	SERCA	high-calcium	affinity	E1	states	(yellow)	are	presented	by	compact	conformers	(~15%	FRET),	while	SERCA	low-calcium	affinity	E2	states	(green)	have	more	open	headpiece	conformation	(~8%	and	~10%	FRET)	during	specific	cycle	steps	(Fig.	16).
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Figure	16	presents	SERCA	ground	protonated	state	E2	and	biochemically	equivalent	TG-bound	state	(E2-TG)	(Satoh	et	al.,	2011;	Toyoshima	et	al.,	2000),	both	of	which	displayed	low	FRET	states	(~10%)	suggesting	SERCA	open	conformers.	These	in	vitro	results	were	confirmed	by	ex	vivo	measurements	of	SERCA	structural	conformation	in	cells,	where	TG	also	sequestered	SERCA	population	into	low	FRET	state	(Fig.	17B).	Thus,	both	measurements	consistently	resulted	in	detection	of	low	FRET.	On	the	other	hand,	SERCA	biochemically-stabilized	intermediate	states	of	enzymatic	cycle	representing	physiological	Ca2+	bound	states	E1-2Ca-ATP	and	E1P-2Ca,	as	well	as	non-physiological	state	E1-2Ca,	all	displayed	high	FRET	states	(~15%)	characterizing	SERCA	closed	conformers.	I	also	detected	high	2-color	SERCA	FRET	in	AAV-293	cells	treated	with	Iono	(Fig.	17C,	black).	However,	I	observed	low	FRET	during	spontaneous	Ca2+	release	events	(Fig.	18B).	Here,	I	will	elaborate	on	these	apparently	inconsistent	observations,	which	are	actually	the	major	findings	of	this	work.	To	resolve	the	deceptive	discrepancies	of	the	detected	FRET	changes	in	response	to	intracellular	Ca2+	oscillations	in	cells,	I	treated	cells	with	Iono	after	detection	of	the	spontaneous	anti-correlated	FRET	and	cytosolic	Ca2+	fluctuations	(Fig.	19A).	Figure	37,	left	panels,	shows	a	schematic	representation	of	one	spontaneous	anti-correlated	FRET/Ca2+	change	and	FRET	biphasic	response	to	Iono	treatment.	High-starting	SERCA	FRET	(Fig.	37A,	blue	arrows)	was	observed	in	live	cells,	which	are	characterized	by	low	basal	Ca2+	(up	to	200	nM)	and	high	ATP	(up	to	5mM).	Thus,	SERCA	is	saturated	with	ATP	but	not	Ca2+	(Fig.	37A,	E1-ATP),	the	same	conditions	as	in	non-muscle	cells	and	in	relaxed	muscle	cells.	I	observed	high	SERCA	FRET	in	microsomal	preparations	when	both	ATP	and	Ca2+	were	high	(Fig.	15B	and	Fig.	16,	E1-2CA-ATP).	However,	in	the	cells	during	intracellular	
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Ca2+	oscillations,	I	observed	low	FRET	upon	cytosolic	Ca2+	increase	(Fig	18B).	Numerous	reports	suggested	that	exposure	to	low	Ca2+	shifts	ATP-bound	SERCA	(E1-ATP)	into	high-affinity	conformer	primed	for	efficient	Ca2+	binding	and	transport	upon	major	Ca2+	influx	(Inesi	et	al.,	2006;	Jensen	et	al.,	2006;	Mintz	et	al.,	1995).	Thus,	SERCA	in	resting	E1-ATP	state	is	readily	activated	upon	influx	of	cytosolic	Ca2+.	In	support	to	this	statement	and	in	contrast	to	biochemically	‘fixed’	SERCA	intermediates,	in	live	cells,	where	ATP	levels	are	high,	SERCA	starts	cycling	immediately	upon	Ca2+	release	event.	However,	because	of	the	
	
Figure	37.	WT-SERCA	population	accumulates	in	states	prior	to	slow	steps	during	
transient	Ca2+	increase.	Schematic	representation	of	simultaneous	FRET	and	cytosolic	Ca2+	fluctuations	as	detected	in	Fig.	19A	is	on	the	left,	while	corresponding	transitional	steps	are	highlighted	by	blue	arrows	on	the	Post-Albers	cycle	(left	panels).	(A)	In	basal	Ca2+,	SERCA	population	is	at	resting	E1-ATP	state	(high	FRET-	open	conformers)	(B)	During	transient	Ca2+	increase,	SERCA	population	accumulates	in	E2P	prior	to	slow	Pi	release	step	(low	FRET-	open	conformers).	I	propose	the	existence	of	SERCA	Ca2+-bound	low	FRET	state	(open	conformers)	just	before	Ca2+	release	event,	another	slow	step	of	enzymatic	cycle.		
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slow	steps	in	SERCA	enzymatic	cycle,	like	during	release	of	Pi	group	(Champeil	et	al.,	1986;	Hanel	and	Jencks,	1990;	Petithory	and	Jencks,	1986),	SERCA	population	accumulates	in	E2	low	FRET	state	(open	conformers)	(Fig.	37B,	E2P).	These	conditions	occur	during	contractions	of	cardiac	or	skeletal	muscle	cells	and	in	non-muscle	cells	during	intracellular	Ca2+	waves.	Ca2+	release	was	also	identified	as	one	of	the	slow	steps	of	SERCA	enzymatic	cycle	(Fernandez-Belda	et	al.,	1984).	Based	on	this	statement	and	the	fact	that	I	detected	accumulation	of	majority	of	pumps	in	low	FRET	state,	I	propose	the	existence	of	Ca2+-bound	state,	which	is	most	likely	short-lived	and	exists	right	before	Ca2+	ions	are	released	into	ER	lumen	(Fig.	37B,	‘?’).	After	each	spontaneous	Ca2+	release	event,	probably	due	to	SERCA	function	and	temporary	inactivation	of	RyR,	cytosolic	Ca2+	concentration	drops	and	SERCA	population	returns	to	low	Ca2+/high	ATP	conformation	of	high	FRET	state	(Fig.	37A,	E1-ATP).	In	contrast	to	transient	intracellular	Ca2+	increases,	during	sustained	Ca2+	elevation	upon	Iono	treatment,	even	though	SERCA	population	originally	accumulates	in	high	Ca2+/high	ATP	low	FRET	state	(open	conformers),	the	majority	of	SERCA	pumps	gradually	shifts	into	high	FRET	state	(compact	conformers)	(Fig.	17B	and	19A).	The	immediate	decrease	in	phase	1	FRET	upon	the	addition	of	Iono	matches	the	prediction	that	the	transition	of	pumps	to	E2	conformation	(Fig.	38A)	is	the	slowest	step	of	the	Ca2+	catalytic	cycle,	and	the	majority	of	SERCA	pumps	accumulates	in	E2P	(or	anticipated	low	FRET	Ca2+-bound)	state(s).		Less	clear	was	an	increase	in	phase	2	FRET	change	observed	in	Iono-treated	cells	(Fig.	17C).	In	this	experiment	the	cytosolic	Ca2+	remained	high	while	FRET	gradually	
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increased	over	a	period	of	several	minutes.	This	observation	was	surprising	as	I	only	expected	to	detect	phase	1	low	FRET	of	SERCA	population	accumulated	in	the	slow	step	of	Ca2+	release	(Fig.	38A,	E2P).	I	confirmed	my	observation	in	a	muscle	reconstituted	setup	when	Iono	was	applied	to	cells	after	detection	of	anti-correlated	FRET/Ca2+	changes	and	caused	both	the	initial	low	FRET	phase	1	and	the	following	high	FRET	phase	2	(Fig.	19A).	I	propose	several	possible	explanations	for	the	phase	2	FRET	change	in	Iono-treated	cells.	
	
Figure	38.	WT-SERCA	population	accumulates	in	states	prior	to	slow	steps	during	
sustained	Ca2+	increase.	Schematic	representation	of	simultaneous	FRET	and	cytosolic	Ca2+	fluctuations	as	detected	in	Fig.	19A	is	on	the	left,	while	corresponding	transitional	steps	are	highlighted	by	blue	arrows	on	the	Post-Albers	cycle	(left	panels).	(A)	Upon	Iono	treatment,	phase	1	FRET	decrease	(open	conformers)	are	observed	due	to	accumulation	of	WT-SERCA	in	E2P	step	of	enzymatic	cycle.		(B)	Phase	2	FRET	increase	(closed	conformers)	of	WT-SERCA	during	sustained	Ca2+	increase	are	observed	due	to	accumulation	of	WT-SERCA	in	E1-2Ca-ADP	bound	step	of	enzymatic	cycle.		
90		
	 	
First,	Iono	application	as	low	as	2	μM	has	been	shown	to	activate	Ca2+/H+	exchangers	and	increase	intracellular	pH	due	to	Ca2+	influx	(Yamada	et	al.,	1996).	Fluorescent	proteins	are	known	to	be	highly	sensitive	to	pH	outside	of	cellular	levels	range	(Schmitt	et	al.,	2014).	Therefore,	an	increase	in	intracellular	pH	(alkalinization)	could	affect	fluorescent	proteins	and	result	in	non-relevant	FRET	change.	Nevertheless,	the	experiment	with	Cer-SERCA	and	YFP-SERCA	(Fig.	20C)	did	not	detect	intermolecular	FRET	change	upon	addition	of	Iono.	This,	it	is	unlikely	that	cell	alkalinization	was	the	direct	cause	of	observed	phase	2	FRET	change.	Second,	luminal	Ca2+	accumulation	have	been	shown	to	inhibit	SERCA	in	a	non-active	state	(Inesi	and	de	Meis,	1989).	Nevertheless,	I	detected	slow	accumulation	of	Ca2+	in	ER	lumen	after	Iono	treatment,	much	slower	than	phase	2	FRET	change	(Fig.	21A).	Therefore,	I	do	not	believe	that	the	luminal	Ca2+	may	inhibit	SERCA	in	non-active	state.	Third,	I	cannot	exclude	inhibition	of	SERCA	cycling	by	the	ADP	build-up	(Inesi	and	de	Meis,	1989)	as	ADP	to	ATP	ratio	was	shown	to	be	dramatically	increased	upon	cells	perturbation	(up	to	100	times)	due	to	distortion	of	the	mitochondrial	membrane	(Tantama	et	al.,	2013).	Therefore,	SERCA	activation	may	gradually	deplete	ATP	and	increase	ADP	levels	in	Iono-treated	cells,	which	would	shift	SERCA	population	into	non-physiological	high	Ca2+/ADP	bound	state	(Fig.	38B,	E1-2Ca-ADP)	which	is	consistent	with	observed	high	FRET	(~15%)	in	ligand-stabilized	conformations	E1-2Ca-ADP-AlF4−	(Fig.	15B	and	16).	To	summarize,	in	the	cells	with	low	basal	Ca2+	and	high	ATP	levels,	SERCA	accumulates	in	E1-ATP	high	FRET	state	(compact	conformation).	During	temporary	cytosolic	Ca2+	elevation,	SERCA	population	progresses	through	E1-2Ca-ATP	and	phosphoenzyme	E1P-2Ca	states	and	accumulates	in	the	slow	E2P	low	FRET	states	(open	
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conformers),	which	is	the	main	and	novel	funding	of	current	project.	Thus,	in	physiological	conditions	during	contractions	of	cardiac	or	skeletal	muscle	cells,	majority	of	the	actively	cycling	SERCA	population	has	an	open	headpiece	conformation.		
Structural	Dynamics	of	AAA-SERCA,	the	Nβ5-β6	Loop	Mutant,	During	Ca2+	Transport	The	experiments	with	AAA-SERCA,	which	has	key	residues	of	the	Nβ5-β6	loop	mutated,	allowed	the	understanding	of	the	SERCA	conformers’	redistribution	during	Ca2+	cycling	in	the	presence	of	a	defective	headpiece	closure	mechanism.	Even	though,	I	observed	AAA-SERCA	phase	1	FRET	decrease	after	Iono	application	similar	to	WT,	the	subsequent	recovery	and	accumulation	of	SERCA	in	high	FRET	state	was	not	achieved	(Fig	17C	and	19C).	These	data	indicate	that	AAA-SERCA	population	was	accumulating	in	a	specific	for	AAA-SERCA	slow	step,	E2	low	FRET	states	(open	conformers),	and	was	not	able	to	progress	to	E1	high	FRET	states	(compact	conformers)	due	to	decreased	kinetics	of	structural	transition	from	open	to	closed	headpiece	conformations	(Fig.	39).		 Based	on	these	results,	I	was	surprised	to	observe	AAA-SERCA	FRET	change	kinetics	similar	to	WT	during	spontaneous	Ca2+	release	events	(Fig.	18D).	I	speculate	that	while	overexpressed	AAA-SERCA	has	a	deficit	in	obtaining	closed	conformation,	endogenous	SERCA	sequesters	Ca2+	back	into	ER	lumen	while	Na2+/Ca2+	exchangers	and	plasma	membrane	Ca2+	ATPases	remove	Ca2+	from	the	cell,	which	results	in	cytosolic	Ca2+	levels	decrease.	Thus,	when	intracellular	Ca2+	levels	return	to	basal	level,	AAA-SERCA	population	redistributes	back	to	the	resting	E1-ATP	high	FRET	state	(Fig.	16,	E1-ATP).	This	statement	is	supported	by	the	observed	AAA-SERCA	FRET	decease	in	response	to	transient	elevations	of	Ca2+	upon	RyR	inhibitor	Caf	treatment,	and	following	the	increase	in	FRET	as	Ca2+	gets	
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exported	from	the	cell,	supposedly	via	Na2+/Ca2+	exchangers	and	plasma	membrane	Ca2+	ATPases	(Fig.	19D).	To	summarize,	when	AAA-SERCA	is	exposed	to	persistent	elevation	of	Ca2+,	like	upon	Iono	treatment,	the	defective	in	opened-to-closed	transition	pumps	accumulate	in	a	new	and	AAA-SERCA	specific	slow	step,	E2	low	FRET	states	(open	conformers).	As	a	consequence,	phase	2	FRET	recovery	is	not	observed	(Fig.	17C	and	17C).		
The	Nβ5-β6	Loop	as	a	Determinant	of	SERCA	Structural	Dynamics	and	Function	Previously,	Dr.	Nikolai	Smolin	had	predicted	that	the	SERCA	Nβ5-β6	loop	plays	an	important	role	in	SERCA	headpiece	transition	from	open-to-closed	conformation	(Smolin	and	Robia,	2015a).	Specifically,	salt	bridges/H-bonds	between	the	Nβ5-β6	loop	acidic/negative	residues	(Asp426,	Glu429,	and	Glu435)	and	basic/positive	residues	of	the	A-domain	(residues133-139)	were	predicted	to	initiate	the	contact	between	N-	and	A-
	
Figure	39.	AAA-SERCA	population	accumulates	in	a	new	state	prior	to	slow	step	
during	sustained	Ca2+	increase.	Schematic	representation	of	simultaneous	FRET	and	cytosolic	Ca2+	fluctuations	as	detected	in	Fig.	19C	is	on	the	left,	while	corresponding	transitional	steps	are	highlighted	by	blue	arrows	on	the	Post-Albers	cycle	(left	panels).	Upon	Iono	treatment,	AAA-SERCA	population	accumulates	in	E2	low	FRET	state	(open	conformers)	due	to	AAA-SERCA	structural	deficit	in	headpiece	closure,	a	new	slow	step	of	enzymatic	cycle.		
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domains	and	subsequent	closure	of	the	headpiece.	The	current	study	was	designed	to	investigate	a	role	of	the	Nβ5-β6	loop	in	the	SERCA	dynamics	during	Ca2+	transport	and	transporter	function.	To	prevent	the	formation	of	the	salt	bridges/H-bonds	between	Nβ5-
β6	loop	and	the	A-domain,	I	designed	triple	Alanine	mutant	of	these	three	negatively	charged	residues	(AAA)	or	point	mutants	(Asp426Ala,	Glu429Ala,	and	Glu435Ala).	Generated	SERCA	constructs	were	used	to	analyzed	SERCA	structure	and	function	during	Ca2+	transport.	The	all-atoms	MD	simulations	showed	that	even	though	AAA-SERCA	had	conserved	overall	structural	integrity	(Fig.	8-9),	it	was	deficient	in	headpiece	closure	(Fig.	10)	and	had	reduced	structural	dynamics	(Fig.	11).	Interestingly,	mutation	of	just	one	of	the	Nβ5-β6	loop	residues	was	not	sufficient	to	induce	these	detrimental	changes;	although,	Glu429	may	have	a	more	prominent	role	in	A-	and	N-domains	closure	than	other	two	residues	(Fig.	10D).	Overall,	my	MD	simulations	indicated	that	the	Nβ5-β6	loop	facilitate	SERCA	structural	transition	to	compact	headpiece	conformation	and	regulate	transporter	structural	dynamics.	The	in	silico	results	were	confirmed	by	ex	vivo	measurements	of	SERCA	structural	dynamics	by	FRET,	which	detected	a	deficit	in	SERCA	triple	loop	mutant	transition	from	open-to-closed	conformation	(Fig.	17C).	Again,	the	point	loop	mutants	showed	similar	to	WT-SERCA	kinetics	during	transition	from	open-to-closed	conformation	(Fig.	17D).	Since	I	detected	AAA-SERCA	population	in	a	low	FRET	state	with	application	of	TG	similar	to	WT(Fig.	17B),	I	excluded	global	defects	in	transporter	structure	upon	Nβ5-β6	loop	mutations	and	attributed	AAA-SERCA	deficiency	in	headpiece	closure	to	a	specific	role	of	the	Nβ5-β6	loop	negative	residues.	
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I	revealed	functional	significance	of	the	SERCA	Nβ5-β6	loop	in	ATPase	assay	by	detecting	a	63%	reduction	in	SERCA	maximal	ATPase	activity	for	AAA-SERCA	compared	to	WT	transporter	(Fig.	15A,	C).	Detected	decline	of	SERCA	function	was	not	attributed	to	the	reduction	in	Ca2+	affinity	as	mutated	transporter	binds	Ca2+	with	similar	to	WT	apparent	affinity	(Fig.	15B).	I	propose	that	detected	functional	deficit	in	SERCA	ATPase	activity	is	a	direct	consequences	of	AAA	mutant	deficit	in	structural	transition	from	opened	to	closed	headpiece	conformation.	Overall,	I	identified	the	SERCA	Nβ5-β6	loop	as	a	determinant	of	SERCA	structural	dynamics	and	function	by	presenting	evidence	that	the	Nβ5-β6	loop	facilitates	closure	of	SERCA	headpiece	and	regulates	ATPase	activity.		
Structural	Dynamics	of	SERCA-PLB	Complex	Previous	MD	simulation	by	my	lab	predicted	that	the	SERCA	Nβ5-β6	loop	can	interact	with	PLB	cytoplasmic	domain.	(Smolin	and	Robia,	2015a).	Here	I	performed	additional	MD	simulations	to	confirm	that	interaction	between	the	SERCA	Nβ5-β6	loop	and	PLB	was	stabilized	throughout	the	MD	trajectories	and	independent	of	loop	mutations	(Fig.	22F)	or	PLB	phosphorylation	(Fig.	24A-B).	Additionally,	the	SERCA	structure	was	stabilized	by	association	with	PLB	as	detected	by	reduction	in	RMSF	N-domain	(Fig.	8D	vs.	23B)	and	in	
vitro	(Fig.	30),	which	indicates	that	PLB	induces	more	compact	SERCA	conformation	as	proposed	by	my	lab	previously	(Bidwell	et	al.,	2011).	I	speculate	that	the	induction	of	more	ordered	SERCA	headpiece	conformation	may	be	a	result	of	overall	structural	stabilization	by	PLB.	In	support	to	this	statement,	I	observed	positive	correlation	between	motions	of	the	PLB	cytosolic	domain	and	the	SERCA	headpiece	domains	(Fig.	25),	as	well	as	increase	in	SERCA	intramolecular	motions	as	represented	by	predominantly	red	color	(positive	
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correlation)	of	SERCA-PLB	covariance	matrixes	(Fig,	25)	versus	white	color	(no	correlation)	of	SERCA	alone	(Fig.	9).	Even	though	I	did	not	detect	a	particular	effect	of	Ser16	phosphorylation	on	SERCA	headpiece	structural	dynamics	(Fig.	23	and	24G-H),	I	resolved	structural	rearrangements	within	the	SERCA	TM-domain	upon	phosphorylation.	Ser16	phosphorylation	induced	a	slight	shift	of	PLB	from	the	SERCA	TM-helix	M2	toward	helix	M9	(Fig.	26A-B)	at	the	same	time	as	the	Ca2+	transport	site	II	was	increased	by	displacement	of	gating	residue	Glu309	by	0.7	Å,	which	may	be	a	substantial	structural	rearrangements	to	accommodate	passage	of	1.14	Å	Ca2+	ion.	This	observation	supports	SERCA	relief-of-inhibition	subunit	model,	which	states	that	upon	phosphorylation	PLB	shifts	to	a	new	position	on	the	SERCA	TM-domain	(Bidwell	et	al.,	2011;	Negash	et	al.,	2000).	Additionally,	I	demonstrated	that	like	sarcolipin	(Autry	et	al.,	2016),	PLB	can	induce		structural	rearrangements	in	the	Ca2+	transport	site	II	by	displacement	of	gating	residue	Glu309,	possibly	for	accommodation	of	Ca2+	ion	passage.	Overall,	these	data	demonstrate	that	phosphorylation	of	the	cytosolic	PLB	domain	induces	SERCA	compact	conformation	and	structural	rearrangements	within	the	SERCA	TM-domain,	which	most	likely	has	functional	significance	for	efficient	Ca2+	transport.	When	I	examined	changes	within	PLB	itself,	I	detected	that	PLB	phosphorylation	introduced	a	kink	in	the	area	of	the	phosphorylation	site	Ser16	(Fig.	27),	increased	separation	of	the	PLB	TM-	and	cytosolic	domains	(Fig.	27	D-G),	and	oriented	PLB	more	upward	(Fig.	28F-H).	At	the	same	time	Ser16	phosphorylation	resulted	in	an	increase	of	PLB	overall	structural	organization	(Fig.	28).	I	propose	that	these	specific	changes	in	PLB	structure	are	the	preceding	cause	of	changes	in	SERCA	TM-domain.	This	statement	is	
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supported	by	the	report	that	PLB	phosphorylation	alters	structure	of	the	SERCA-PLB	regulatory	complex	(Hou	et	al.,	2008).	In	summary,	I	propose	that	SERCA	overall	structure	is	stabilized	by	association	with	PLB,	and	structural	reorganization	of	PLB	upon	Ser16	phosphorylation	results	in	PLB	displacement	from	SERCA	M2-	toward	M9-helix.	As	a	consequence,	SERCA	TM-domain	Ca2+	transport	site	II	is	able	to	accommodate	Ca2+	passage,	leading	to	SERCA	activation.		 	
2-color	ATPases	as	Biosensors	for	Identification	of	Regulatory	Interactions	SERCA	targeting	in	cardiac	dysfunctions	is	aimed	at	increasing	SERCA	activity	which	is	predicted	to	improve	cardiac	function	(Hayward	et	al.,	2015;	Inesi	et	al.,	2008).	Thus,	it	is	important	to	identify	and	characterize	SERCA	direct	regulators.		My	lab	has	successfully	used	the	2-color	SERCA	pump	to	investigate	transporter	structural	dynamics,	function,	and	regulatory	interactions	(Blackwell	et	al.,	2016;	Gruber	et	al.,	2014;	Hou	et	al.,	2012).	I	utilized	2-color	SERCA	as	a	tool	to	investigate	SERCA	interactions	with	proposed	direct	regulators	of	SERCA	activity:	HAX-1	and	DWORF.		 HAX-1	has	been	shown	to	directly	interact	with	SERCA	in	vitro	(Vafiadaki	et	al.,	2009),	but	no	evidence	has	been	reported	for	this	interaction	in	vivo.	My	measurements	with	acceptor-sensitized	and	acceptor	photobleaching	FRET	in	live	cells	detected	a	decrease	in	FRET	values	in	the	presence	of	HAX-1	(Fig.	33),	confirming	HAX-1	direct	binding	to	SERCA.	It	is	worthwhile	to	indicate	that	for	the	2-color	SERCA,	the	YFP	fusion	site	on	the	SERCA	N-domain	before	residue	509	is	too	close	to	the	proposed	Hax-1	binding	site	(residues	E575-V594)	(Vafiadaki	et	al.,	2009;	Vandecaetsbeek	et	al.,	2011).	Thus,	binding	of	Hax-1	to	this	site	on	the	N-domain	could	result	in	Hax-1	being	physically	in	the	
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way	of	measuring	true	FRET	values.	Nevertheless,	this	detail	does	not	disprove	the	demonstrated	direct	interaction	of	HAX-1	and	SERCA.			 Another	SERCA	proposed	regulator	is	DWORF,	a	recently	identified	micropeptide	encoded	by	lncRNA.	It	has	been	proposed	that	DWORF	binds	to	SERCA	in	the	same	binding	groove	as	SERCA	inhibitor	PLB	and	relieves	SERCA	inhibition	by	displacement	of	PLB	(Nelson	et	al.,	2016).	I	investigated	the	details	of	SERCA-DWORF	regulatory	interaction	by	utilizing	2-color	SERCA	in	live	cell	FRET	measurements.	I	confirmed	direct	DWORF	interaction	with	SERCA	(Fig.	34D)	and	detected	a	higher	DWORF	apparent	affinity	to	SERCA	compared	to	PLB	(Fig.	35C).	The	competition	FRET	experiments	indicated	that	DWORF	competes	with	PLB	for	SERCA	binding	(Fig.	35A).	Since	I	did	not	detect	DWORF-PLB	oligomerization	(Fig.	34G),	I	can	exclude	the	possibility	that	PLB	is	sequestered	into	heterodimers	and	the	observed	decrease	in	FRET	between	SERCA-PLB	is	due	to	true	competition	with	DWORF	for	a	binding	site.	These	results	make	DWORF	a	promising	target	for	gene	therapy	to	enhance	SERCA	activity	and	thus	improve	cardiac	function.	I	noted	that	it	was	hard	to	compete	PLB	off	with	increasing	DWORF	levels	(the	decrease	in	maximal	FRET	was	not	proportional	to	an	increase	in	DWORF	construct	expressed)	(Fig.	35D-E).	This	observation	suggests	that	when	PLB	gets	competed	away	from	SERCA	and	its	free	concentration	increases,	it	attains	higher	affinity	for	SERCA	(Fig.	35F),	which	should	be	taken	into	consideration	if	DWORF	is	to	be	used	in	gene	therapy.		 Utilization	of	2-color	SERCA	FRET	sensor	in	this	work	and	multiple	other	studies	is	aimed	to	determine	SERCA	structural	dynamics	(Blackwell	et	al.,	2016;	Hou	et	al.,	2012;	Pallikkuth	et	al.,	2013)	and	potential	substrates	(Cornea	et	al.,	2013;	Gruber	et	al.,	2014).	It	has	been	shown	that	the	technique	to	generate	2-color	FRET	biosensor	can	be	applied	to	
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other	molecules.	For	example,	2-color	MRP-1,	another	transporter	ATPase,	was	generated	and	used	in	high-throughput	screening	to	identify	potential	substrates	(Iram	et	al.,	2015).	Here,	I	confirmed	that	several	of	the	compounds	identified	as	hits	were	MRP-1	modulators,	among	which	I	recognized	a	novel	MRP-1	inhibitor,	the	vitamin	D	analog-	calcipotriol	(Fig.	36).	This	discovery	can	potentially	explain	the	mechanism	of	action	by	which	vitamin	D	has	been	demonstrated	to	potentiate	the	effect	of	chemotherapeutic	agents	(Ma	et	al.,	2010).	In	summary,	2-color	FRET	sensors	have	proved	to	be	an	effective	tool	in	investigation	of	various	transporters	structural	dynamics,	regulatory	interaction,	identification	of	novel	substrates,	and	analysis	of	ATPase	function.	Utilization	of	2-color	FRET	biosensors	is	a	promising	tool	for	the	high-throughput	screening	assays	that	are	important	in	the	drug	discovery	field	(Cornea	et	al.,	2013;	Gruber	et	al.,	2014;	Iram	et	al.,	2015).			
Clinical	Implications	SERCA	regulates	Ca2+	handling	in	cardiac	cells	by	sequestering	Ca2+	from	cytosol	into	SR	lumen,	which	allows	heart	relaxation	and	also	restores	SR	Ca2+	load	and	determines	heart	contractile	force	(Fig.	1)	(Bers,	2006;	Gwathmey	et	al.,	1987).	SERCA	is	an	attractive	target	for	improving	cardiac	function	in	heart	failure	patients	(Roe	et	al.,	2015).	In	heart	failure	a	deficiency	in	SERCA	levels	and	function	has	been	reported	(Hasenfuss	and	Pieske,	2002;	Hasenfuss	et	al.,	1994).	Restoration	of	SERCA	levels	in	various	models	of	heart	failure	has	been	shown	to	improve	cardiac	performance	of	failing	cardiomyocytes	and	hearts	(Kho	et	al.,	2012).	Nevertheless,	latest	human	clinical	studies	failed	to	significantly	improve	clinical	outcome	of	heart	failure	patients,	presumably	due	to	the	viral	delivery	failure	(Greenberg	et	al.,	2016;	Hayward	et	al.,	2015).	The	alternative	
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reason	for	gene	therapy	failure	could	be	that	solely	an	increase	in	SERCA	levels	is	not	enough	to	override	the	regulatory	processes	of	failing	heart.	Instead,	enhancing	SERCA	function	and	positive	regulation	are	alternative	strategies	for	improving	cardiac	output	in	heart	failure	patients.	Thus,	it	is	extremely	important	to	understand	details	of	SERCA	function	and	regulation.	SERCA	function	and	regulation	have	been	under	investigation	for	decades.	Nevertheless,	only	few	SERCA	specific	activators	have	been	identified	so	far	(Cornea	et	al.,	2013;	Dahl,	2017;	Kang	et	al.,	2016).	Small	molecular	allosteric	activators	of	SERCA	have	been	shown	to	increase	SERCA	Ca2+	transport	to	relive	ER	stress	and	attenuate	apoptosis	and	mitochondrial	dysfunction	(Dahl,	2017;	Kang	et	al.,	2016).	However,	the	mechanisms	of	action	for	SERCA	pharmacological	activators	are	still	not	described.	Based	on	the	FRET	method	used	for	initial	high-throughput	screening	in	identification	of	these	compounds	(Cornea	et	al.,	2013;	Gruber	et	al.,	2014),	I	reason	that	binding	of	small-molecule	activators	results	in	SERCA	cytosolic	headpiece	structural	rearrangement.	Thus,	understanding	of	the	SERCA	structural	dynamics	upon	binding	of	pharmacological	activators	is	important	for	the	rational	design	of	SERCA	novel	activators.	This	study	provided	ample	details	of	SERCA	structural	dynamics	during	Ca2+	transport	cycle	to	enhance	scientific	understanding	of	SERCA	function.	Specifically,	I	described	SERCA	structural	dynamics	in	regard	to	slow	steps	of	Ca2+	transport.		Ultimately,	designing	small-molecules	which	facilitate	SERCA	‘fast’	transition	through	these	relatively	slow	steps	that	I	described	can	enhance	SERCA	function	and	become	beneficial	for	improving	cardiac	function.	
100		
	 	
Additionally,	I	have	identified	and	investigated	one	of	SERCA	functional	determinant,	the	Nβ5-β6	loop.	The	Nβ5-β6	loop	facilitates	SERCA	structural	transition	from	opened	to	closed	conformations,	which	is	one	of	the	fundamental	steps	of	SERCA	enzymatic	cycle.	I	predict	that	enhancing	SERCA	cycling	‘speed’	would	allow	boosted	Ca2+	transport	and	result	in	improved	cardiac	function.	Since	I	showed	that	the	Nβ5-β6	loop	facilitate	A-	and	N-domains	closure,	I	propose	that	a	small	pharmacological	molecule	that	is	designed	to	interact	with	this	loop	and	simultaneously	serve	as	an	extension	of	this	structure	even	further	toward	A-domain,	could	allow	more	efficient	cytosolic	headpiece	closure	and	enhanced	cycling.	Overall,	this	project	provided	insights	into	SERCA	structural	transitions	through	catalytic	cycle,	including	identification	of	the	SERCA	novel	structural	and	functional	determinant,	the	Nβ5-β6	loop.	These	insights	contribute	to	understanding	of	SERCA	function	and	provide	novel	justifications	for	design	of	SERCA	small	molecular	activators.		
Limitations	of	Current	Study	In	present	work	I	utilized	a	variety	of	techniques,	including	in	silico,	in	vitro,	and	ex	
vivo	measurements.	There	are	several	limitations	in	each	of	these	techniques	that	I	had	encountered.	For	example,	I	performed	MD	simulations	for	SERCA	spontaneous	motions	for	WT	and	mutants	up	to	100	ns	due	to	limited	resources	of	computer	time	available	to	perform	MD	runs.	This	short	timescale	excludes	a	variety	of	structural	changes	that	are	happening	on	a	much	longer	timeline.	Recently,	MD	studies	of	SERCA	structural	dynamics	as	long	as	1	µs	were	conducted	(Espinoza-Fonseca	et	al.,	2015b;	Espinoza-Fonseca	and	Ramirez-Salinas,	2015;	Fernandez-de	Gortari	and	Espinoza-Fonseca,	2017)	and	MD	
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simulations	at	1	µs	timescale	are	much	anticipated	in	scientific	publications.	Nevertheless,	I	was	able	to	resolve	specific	differences	induced	by	loop	mutations	for	all	SERCA	structures	in	a	short	100	ns	timeline.	However,	I	had	a	setback	in	investigation	of	SERCA-PLB	complex	structural	dynamics	upon	PLB	Ser16	phosphorylation	due	to	limitation	of	computer	time	resources.	Specifically,	the	differences	detected	between	Ser16	and	the	A-domain	number	of	contacts	for	SERCA-PLB	and	SERCApS16	complexes	at	100	ns	MD	simulation	runs	(Fig.	22E)	became	opposing	at	200	ns	(Fig.	24C).	This	is	not	surprising,	considering	that	in	physiological	conditions	structural	changes	such	as	SERCA	headpiece	closure	or	Ca2+	ion	transport	are	predicted	to	take	place	on	a	µs-scale.	Thus,	my	studies	are	limiting	to	the	detection	of	short-lived	events	and	do	not	include	the	full	spectrum	of	spontaneous	structural	changes.	Due	to	this	limitation,	I	decided	to	supplement,	and	in	this	way	strengthen,	my	MD	simulations	data	with	physical	experiments.	The	basis	for	FRET	technique	have	been	established	70	years	ago	(Förster,	1948)	and	up-to-date	this	assay	plays	a	major	role	in	detection	and	characterization	of	proteins’	inter-	and	intramolecular	structural	changes.	The	structural	dynamics	of	2-color	SERCA	captured	by	acceptor	photobleaching	and	acceptor-sensitized	emission	FRET	measurements	have	been	well	characterized	(Bidwell	et	al.,	2011;	Hou	et	al.,	2012;	Smolin	and	Robia,	2015b).	Nevertheless,	such	measurements	only	capture	average	FRET,	which	represents	average	conformation	of	SERCA	population.	Most	likely,	SERCA	conformers	exist	in	a	significant	structural	heterogeneity	which	is	not	detected	with	these	methods.	For	example,	x-ray	crystallography	and	electron	microscopy	identified	only	one	structural	state	of	SERCA	stabilized	by	TG	(Takahashi	et	al.,	2007;	Toyoshima	et	al.,	2000;	Young	et	al.,	2001),	while	time-resolved	fluorescence	measurements	showed	that	SERCA	bound	to	TG	
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exists	in	at	least	two	conformations	(Pallikkuth	et	al.,	2013).	Thus,	my	FRET	results	do	not	report	all	the	variety	of	SERCA	conformers	which	presumably	exists.	In	this	study	I	used	muscle-like	HEK-293	cell	model	which	was	initially	developed	for	monitoring	intracellular	Ca2+	oscillations	(Bovo	et	al.,	2016).	This	model	was	supplemented	with	2-color	SERCA	and	adapted	for	simultaneous	detection	of	SERCA	FRET	and	spontaneous	Ca2+	release	events.	I	obtained	clear	traces	of	the	FRET	ratio	and	intracellular	Ca2+	oscillations	for	cells	expressing	WT-SERCA	(Fig.	18B-C.	19A-B).	Nevertheless,	cells	transfected	with	AAA-SERCA	and	exhibiting	simultaneous	FRET	change	/Ca2+	release	events	were	harder	to	find.	Additionally,	the	Ca2+	fluctuations	were	much	rare,	while	traces	were	noisier	compared	to	those	of	the	cells	expressing	WT-SERCA	(Fig.	18D,	19C-D).	This	difficulty	of	finding	‘firing’	cells	limited	my	AAA-SERCA	analysis	by	the	number	of	cells	evaluated	compared	to	WT-SERCA.	On	the	other	hand,	the	inability	to	detect	number	of	cells	with	simultaneous	FRET	and	Ca2+	fluctuations	similar	to	WT	indicates	the	deficiency	of	AAA-SERCA	to	store	Ca2+	in	the	ER	for	the	release	event,	which	I	believe	to	be	the	direct	consequence	of	AAA-SERCA	deficiency	in	structural	transitions	from	open-to-closed	conformation.	In	my	DWORF	acceptor-sensitized	FRET	detection	experiment	I	observed	a	higher	DWORF’s	apparent	affinity	to	SERCA	than	PLB	(Fig.	35C).	Nevertheless,	in	my	competition	experiments,	when	I	increased	DWORF	levels	to	outcompete	PLB	from	SERCA,	non-linear	SERCA-PLB	FRET	and	Kd	decreases	were	observed,	suggesting	that	PLB	has	higher	affinity	to	SERCA	in	the	presence	of	DWORF	(Fig.	35E-F).	This	observation	may	seems	as	contradictory	to	my	previous	observation	that	DWORF	binds	to	SERCA	better	than	PLB	(Fig.	35C).	I	believe	that	the	increased	apparent	affinity	of	PLB	to	SERCA	was	due	to	the	
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increase	of	PLB	monomers	as	a	result	of	competition	with	DWORF.	Availability	of	PLB	monomers	enhanced	PLB	ability	to	bind	to	SERCA	and	in	this	way	increased	PLB	apparent	affinity.	Ideally,	I	need	to	perform	the	competition	experiments	when	instead	of	outcompeting	PLB	with	DWORF	from	SERCA	binding	site,	I	compete	DWORF	from	SERCA	with	gradually	increasing	co-expression	of	PLB.	In	reality,	this	experiments	required	a	large	amount	of	PLB	DNA	construct	transfection,	and	cells,	overwhelmed	with	DNA	load,	became	unhealthy,	which	resulted	in	inconstant	measurements	between	experiments.	Therefore,	optimization	of	the	expression	system	is	required	to	overcome	this	limitation	for	successful	execution	of	the	PLB-DWORF	competition	experiments.	One	of	possible	strategy	could	be	the	use	of	smaller	DNA	vectors.		Another	difficulty	that	I	encountered	was	the	struggle	to	produce	functional	microsomes.	As	presented	in	Figure	15,	I	measured	WT-SERCA	FRET	in	microsomal	membrane	preparations	from	AAV-293	cells	transiently	transfected	with	SERCA	DNA	constructs.	The	FRET	increase	curve	over	increasing	Ca2+	levels	(Fig.	15A)	was	regarded	as	a	control	experiment	in	determination	if	the	microsomal	preparations	are	suitable	for	
	
	
Figure	40.	AAA-SERCA	structural	dynamics	measured	by	FRET	in	microsomes.	
(A)	AAA	2-color	SERCA	showed	steady	FRET	levels	with	Ca2+	increase.	(B)	FRET	of	AAA	2-color	SERCA	stabilized	in	key	enzymatic	states.	
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substrate-stabilized	structural	FRET	measurements	(Fig.	15B).	However,	for	AAA-SERCA	microsomal	preparations	I	constantly	observed	no	significant	FRET	response	to	increasing	Ca2+	levels	(Fig.	39A)	or	in	substrate-stabilized	structural	measurements	(Fig.	39B).	Since	I	prepared	several	batches	all	of	which	showed	this	result,	I	am	unsure	if	AAA-SERCA	headpiece	was	not	responsive	to	substrates	tested,	or	microsomal	samples	were	compromised.	Based	on	the	ATPase	curves,	AAA-SERCA	has	similar	to	WT	pump	Ca2+affinity	(Fi.	14B).	Thus,	I	believe	that	Ca2+	binds	to	mutated	transporter	and	should	induce	a	structural	response	similar	to	WT.	However,	since	AAA-SERCA	has	a	deficit	in	progression	from	open	to	closed	conformer,	I	may	only	detect	this	specific	to	AAA-SERCA	slow	step	of	enzymatic	cycle.	Thus,	the	interpretation	of	this	experiment	is	ambiguous	and	for	that	reason	it	was	not	included	in	the	main	chapter.	Overall,	I	believe	that	I	was	able	to	provide	a	complex	review	of	the	SERCA	structural	dynamics	during	Ca2+	transport	and	identified	the	Nβ5-β6	loop	as	SERCA	structural	and	functional	determinant	by	combining	in	silico,	in	vitro,	and	ex	vivo	experiments,	which	were	aimed	at	complementing	and	strengthening	each	other.		
Overall	Conclusion	The	novel	insights	and	substantial	details	of	SERCA	transient	conformations	during	Ca2+	transport	revealed	in	this	study	extend	the	scientific	understanding	of	SERCA	structural	dynamics	and	redistribution	of	SERCA	conformers	in	response	to	intracellular	Ca2+	fluctuations.	The	SERCA	Nβ5-β6	loop,	identified	as	a	structural	determinant	of	transporter	headpiece	closure	with	a	functional	implication	in	SERCA	ATPase	activity	and	Ca2+	transport,	can	become	a	promising	target	of	a	novel	small-molecule	therapeutics	aimed	to	enhance	cardiac	output	in	heart	failure	patients.	
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